GLUTAMINE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2004 by ICON Group International, Inc. Copyright ©2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Glutamine: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84439-9 1. Glutamine-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on glutamine. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON GLUTAMINE .............................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Glutamine ..................................................................................... 4 E-Journals: PubMed Central ....................................................................................................... 60 The National Library of Medicine: PubMed ................................................................................ 79 CHAPTER 2. NUTRITION AND GLUTAMINE .................................................................................. 127 Overview.................................................................................................................................... 127 Finding Nutrition Studies on Glutamine .................................................................................. 127 Federal Resources on Nutrition ................................................................................................. 132 Additional Web Resources ......................................................................................................... 132 CHAPTER 3. ALTERNATIVE MEDICINE AND GLUTAMINE ............................................................ 135 Overview.................................................................................................................................... 135 National Center for Complementary and Alternative Medicine................................................ 135 Additional Web Resources ......................................................................................................... 163 General References ..................................................................................................................... 168 CHAPTER 4. DISSERTATIONS ON GLUTAMINE .............................................................................. 169 Overview.................................................................................................................................... 169 Dissertations on Glutamine ....................................................................................................... 169 Keeping Current ........................................................................................................................ 170 CHAPTER 5. CLINICAL TRIALS AND GLUTAMINE......................................................................... 171 Overview.................................................................................................................................... 171 Recent Trials on Glutamine ....................................................................................................... 171 Keeping Current on Clinical Trials ........................................................................................... 171 CHAPTER 6. PATENTS ON GLUTAMINE ......................................................................................... 173 Overview.................................................................................................................................... 173 Patents on Glutamine ................................................................................................................ 173 Patent Applications on Glutamine ............................................................................................ 202 Keeping Current ........................................................................................................................ 244 CHAPTER 7. BOOKS ON GLUTAMINE ............................................................................................ 245 Overview.................................................................................................................................... 245 Book Summaries: Federal Agencies............................................................................................ 245 Book Summaries: Online Booksellers......................................................................................... 246 Chapters on Glutamine .............................................................................................................. 247 CHAPTER 8. PERIODICALS AND NEWS ON GLUTAMINE............................................................... 249 Overview.................................................................................................................................... 249 News Services and Press Releases.............................................................................................. 249 Newsletter Articles .................................................................................................................... 251 Academic Periodicals covering Glutamine................................................................................. 251 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 253 Overview.................................................................................................................................... 253 U.S. Pharmacopeia..................................................................................................................... 253 Commercial Databases ............................................................................................................... 254 Researching Orphan Drugs ....................................................................................................... 254 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 259 Overview.................................................................................................................................... 259 NIH Guidelines.......................................................................................................................... 259 NIH Databases........................................................................................................................... 261 Other Commercial Databases..................................................................................................... 263 The Genome Project and Glutamine .......................................................................................... 263
viii Contents
APPENDIX B. PATIENT RESOURCES ............................................................................................... 269 Overview.................................................................................................................................... 269 Patient Guideline Sources.......................................................................................................... 269 Finding Associations.................................................................................................................. 271 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 273 Overview.................................................................................................................................... 273 Preparation................................................................................................................................. 273 Finding a Local Medical Library................................................................................................ 273 Medical Libraries in the U.S. and Canada ................................................................................. 273 ONLINE GLOSSARIES................................................................................................................ 279 Online Dictionary Directories ................................................................................................... 279 GLUTAMINE DICTIONARY...................................................................................................... 281 INDEX .............................................................................................................................................. 385
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with glutamine is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about glutamine, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to glutamine, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on glutamine. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to glutamine, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on glutamine. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON GLUTAMINE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on glutamine.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and glutamine, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “glutamine” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Effect of Growth Hormone, Glutamine, and Diet on Adaptation in Short-Bowel Syndrome: A Randomized, Controlled Study Source: Gastroenterology. 113(4): 1074-1081. October 1997. Summary: The effects of parenteral growth hormone, glutamine supplementation, and a high carbohydrate, low fat (HCLF) diet on gut adaptation in short bowel syndrome are unclear. This article reports on a study undertaken to compare effects of this treatment regimen and placebo in patients with short bowel syndrome. The randomized, 6 week, double blind crossover study investigated eight patients with short bowel syndrome (average small bowel length, 71 cm; mean duration, 12.9 years). Active treatment was growth hormone, oral glutamine, and the HCLF diet for 21 days. The weight, basal metabolic rate, nutrient and electrolyte balance, serum insulin-like growth factor 1 levels, D-xylose absorption, morphology and DNA proliferation of small intestinal
4
Glutamine
mucosa, and gastrointestinal transit were evaluated. Active treatment transiently increased body weight, significantly but modestly increased the absorption of sodium and potassium, and decreased gastric emptying. The assimilation of macronutrients, stool volumes, and morphometry of small bowel mucosa were not statistically different in the two treatment arms. 4 figures. 1 table. 43 references. (AA-M). •
Role of Glutamine in TPN Source: Nutrition and the M.D. 17(3): 1, 3. March 1991. Summary: This article briefly explores the role of glutamine in total parenteral nutrition (TPN). Glutamine is the most abundant free amino acid in plasma, intracellular pools, and skeletal muscle, and is a key energy source for the small intestinal mucosa. Under normal conditions, the gut utilizes glutamine and glucose and releases alanine and ammonia. The article reviews some current research into the role of glutamine and how it can be successfully incorporated into a TPN regimen. The article concludes that, in certain conditions, glutamine may be an essential nutrient, and in these situations, intravenous glutamine-dipeptides may be an effective way to provide glutamine.
Federally Funded Research on Glutamine The U.S. Government supports a variety of research studies relating to glutamine. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to glutamine. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore glutamine. The following is typical of the type of information found when searching the CRISP database for glutamine: •
Project Title: ADJUVANT NUTRITION FOR CRITICALLY III TRAUMA PATIENTS Principal Investigator & Institution: Rathmacher, John A.; Metabolic Technologies, Inc. 2625 N Loop Dr, Ste 2150 Ames, Ia 50010 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2004 Summary: (provided by applicant): Of the four million cases of trauma cases each year that will require hospitalization, 200,000 will be classified as severe trauma. During the hospital stay, malnutrition is a major complication in about 50% of the patient population. The result is muscle wasting which is a major risk factor for increased morbidity and mortality. In the study proposal presented we postulate that supplementation with Beta-hydroxy-Beta-methylbutyrate (HMB), arginine and
2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
5
glutamine (HMB/Arg/Gln) to these severely traumatized patients can stem the loss of muscle tissue and whole body nitrogen and in turn decrease morbidity and mortality. This hypothesis is based on two recent studies showing the same nutritional mixture of HMB/Arg/Gln can reverse the muscle wasting associated with AIDS and Cancer. The hypermetabolic state seen in AIDS and cancer have a similar multilifactorial etiology seen in trauma. There is an increase in the mobilization of fat and muscle, increased or normal metabolic rate, increased protein breakdown, and an increased or normal glucose turnover. In addition, HMB alone has been shown to reduce nitrogen loss, decrease muscle proteolysis and muscle damage within the first 48 hours to three week after initiating supplementation. Male and female patients (n=100) will be recruited at the time of admittance to the Trauma ICU with an ISS of greater than 18 Patients who meet the inclusion/exclusion will be randomized to receive either 1) standard tube feed plus HMB/Arg/Gln, standard tube feed plus HMB alone, or standard tube feed (control) in a blinded fashion. Clinical outcomes measures will be assessed through out the hospital stay and on a outpatient basis on week 4 and week 12. Muscle proteolysis and nitrogen economy will be evaluated on daily basis while in the hospital and after 4 weeks on an out patient basis. If as expected, Phase I results confirm the effectiveness of the nutrient mixture in trauma patients. Expanded multicenter studies will be proposed in Phase II. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AMINO ACID TRANSPORT AFTER SMALL BOWEL RESECTION Principal Investigator & Institution: Sax, Harry Charles.; Professor of Surgery; Surgery; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2002; Project Start 30-SEP-1994; Project End 31-MAR-2005 Summary: Short bowel syndrome is a devastating clinical condition which leads to dehydration, muscle wasting, debilitation and death. Although the residual bowel has the capacity to adapt to its reduced surface area, this process is often inadequate and may require lifetime total parenteral nutrition, a modality with serious metabolic and economic consequences. Growth factors can improve adaptation in part by increasing the enterocyte's ability to transport luminal nutrients. A major nutrient glutamine (GLN) is the primary oxidative fuel for the enterocyte. The parenteral administration of epidermal growth factor (EGF) and/or human growth hormone (GH) increases sodiumdependent glutamine transport after 70% enterectomy in rabbits. The specific timing, route of administration, mechanisms of action, and potential synergistic effects of these two compounds remain to be elucidated. EGF binding activates the EGF receptor (EGFR). In cell suspensions derived from both human jejunum and C2BBE1cell line, EGF increases glutamine transport, upregulation is blocked by tyrosine kinase inhibitors which implicates a role for EGFR signaling transduction pathways. GH independently may also act through EGFR. It is hypothesized that the combination of EGF and GH upregulate sodium-dependent glutamine transport through EGFR signal transduction pathways. The specific aims of the proposal are to 1) optimize glutamine transport mediated by EGF/GH through EGFR in rabbits after massive enterectomy; 2) determine the involvement of EGFR signal transduction pathways in altering glutamine transport by EGF/GH exposure in C2BBE1cell line; 3) to investigate the effects of EGF/GH via EGFR in upregulating glutamine transport in human small bowel. The investigators plan to use three models of small bowel function: 70% enterectomy in the rabbit, the human cell line C2BBE1 in Transwells and human small bowel as an enterocyte suspension or as a neurovascularly intact loop. It is hypothesized that a better understanding of mechanisms involved in growth factor induced upregulation of
6
Glutamine
nutrient transport will have significant clinical implications in developing safe and innovative strategies to treat patients with short bowel syndrome and other malabsorptive states. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METABOLISM
ANTISENSE
INHIBITION
OF
RETINAL
GLUTAMATE
Principal Investigator & Institution: Danias, Ioannis J.; Ophthalmology; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2002; Project Start 01-AUG-1999; Project End 31-JUL-2004 Summary: The objective of this K08 project is to test one of the two major current hypotheses about the role of glutamate in glaucomatous retinal ganglion cell (RGC) death. According to this hypothesis one result of elevated IOP is a derangement of the glutamate metabolic cycle in RGCs. This derangement results in glutamate excitotoxicity that has a primary role in the pathogenesis of glaucoma. Aim 1 and 2 of this project test the second component of this hypothesis; aim 3 tests the first component. Aim 1 is to determine the effects of a deranged glutamate metabolic cycle in the retina on the RGC function and survival. Antisense oligonucleotides to the glutamate metabolizing enzymes, glutamate dehydrogenase (GDH) and glutamine synthetase (GS) and to glutamate transporters (GLAST) will be used to inhibit glutamate metabolism and uptake in RGCs. Their effects will be determined in tissue culture and then following intra-vitreal administration rats to assess RGC survival, activities and amounts of GDH. GS and GLAST, intra-vitreal glutamate concentrations, and visual function by electroretinography. Aim 2 tests whether glutamate antagonists and anti-apoptosis agents can reverse the effects of a deranged glutamate cycle in the retina caused by the antisense oligonucleotides. Aim 3 is to determine whether changes in the glutamate metabolic cycle similar to those induced by the use of antisense oligonucleotides to GDH, GS and GLAST are present in a chronically elevated IOP model of glaucoma in rats. The K08 candidate has recently completed a clinical fellowship in the field of glaucoma and has begun a tenure track academic career in Mt. Sinai School of Medicine. While he does have some prior fundamental research experience, in order to embark upon the proposed studies he must first strengthen his skills in the areas of antisense design and pharmacokinetics and in some specific methods that will be used in testing the animals and assessing the outcomes. Mentoring will be provided by senior scientists, experts in these areas. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BASES OF CIRRHOSIS IN ALCOHOLIC LIVER DISEASE Principal Investigator & Institution: Zern, Mark A.; Director, Div. Gastroenterology; Internal Medicine; University of California Davis Sponsored Programs, 118 Everson Hall Davis, Ca 95616 Timing: Fiscal Year 2002; Project Start 01-SEP-1988; Project End 31-MAR-2006 Summary: This proposal is a continuation of our studies which attempt to elucidate the molecular bases of cirrhosis in alcoholic liver disease. Hepatic fibrogenes caused by alcohol abuse or other etiologies is a complex process that involves a balance between liver cell proliferation and cell death, as well as the increased deposition and modeling of extracellular matrix (ECM) proteins. Our recent studies provide evidence for the significance of one factor, tissue transglutaminase (tTG), in many of these interactions. This ubiquitous enzyme has characteristics that may induce either apoptosis or cell
Studies
7
proliferation, and it appears to contribute to the fibrotic process in a number of ways. This proposal is an attempt to elucidate the mechanisms by which tTG affects the process of hepatic mitogenesis or apoptosis, especially as it pertains to ethanol administration. Specific Aims: 1) To determine the pathways and functional significance of alpha-1 adrenergic signaling in hepatocytes; 2) To investigate the downstream effects of alpha-1 adrenergic signaling on hepatocyte mitogenesis; and 3) To delineate the mechanisms by which tTGase cross-linking activity inhibits proliferation and enhances apoptosis in hepatocytes. These studies will entail determining whether phenylephrineinduced hepatocyte mitogenesis acts through alpha-1B adrenergic receptor binding coupled to the tTGase G-protein subunit, Galphah, whether this activates the MAPK pathway, and by what mechanism this activation may be occurring. In addition, the mechanism by which tTGase cross-linking activity may affect upstream events in the apoptosis cascade will also be explored. Health Relatedness: It is hoped that by better understanding the molecular mechanisms by which ethanol affects fibrogenesis, hepatic mitogenesis, and apoptosis, more effective and rational therapeutic intervention may be developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOLOGY OF IL-4 RECEPTOR ALLELIC VARIANTS Principal Investigator & Institution: Khurana Hershey, Gurjit K.; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2002; Project Start 30-SEP-2000; Project End 31-MAY-2005 Summary: This is the first revision of a proposal by a New Investigator to look at potential genetic abnormalities that may predispose individuals to asthma. The cytokine IL-4 has been shown to be important in the development of many asthmatic lesions. IL-4 binds to the IL-4 receptor alpha (IL-4Ra). This group previously has described a novel allele of IL-4Ra in which Arg replaces glutamine at position 576. This allele, named the R576 IL-4Ra allele, correlates with a ninefold increase in atopy risk, and is also associated with increased IL-4 responsiveness. There are now at least five additional polymorphic variants of IL-4Ra, and the purpose of this application is to determine the effects of each of the IL-4Ra variants, alone and in combination, on IL-4 responsiveness and the asthmatic phenotype in humans. The applicants propose to introduce missense mutations for each of the IL-4Ra alleles into the human IL-4Ra cDNA, and to transfect them into murine B cells. They then will analyze the transfectants with respect to IL-4 sensitivity and temporal responsiveness to IL-4, specifically related to activation of STAT6 and expression of CD23. They then wish to genotype a cohort of wellcharacterized asthmatic patients and to identify the specific IL-4Ra alleles as markers of asthma risk or severity. Finally, they wish to look at STAT6 activation and CD23 expression in A202.1 murine B cells, as used in the first aim, after cotransfection with combinations of the different allelic variants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BIOLOGY OF SINGLE ACTIVITY PGH SYNTHASES Principal Investigator & Institution: Funk, Colin D.; Professor; Pharmacology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: adapted from applicant's abstract): Prostaglandin H synthase-1 (PGHS-1) is the key enzyme in the biosynthesis of prostaglandins, homeostatic lipid mediators in the cardiovascular, gastrointestinal, renal and other organ systems. PGHS-2, on the other
8
Glutamine
hand, is a separate gene product, is highly regulated, inducible and is regarded as the form involved in cancer and inflammation. While the simplistic viewpoint of "housekeeping" PGHS-l vs "inducible, pro-inflammatory" PGHS-2 is practical, data is emerging that is not entirely consistent with this hypothesis. PGHS isozymes are bifunctional, with a cyclooxygenase (COX) activity and a functionally linked peroxidase (POX) activity. Non-steroidal antiinflammatory drugs (NSAIDs) act by inhibition of the COX activity, leaving POX activity intact. Substantial data, primarily from in vitro model systems, has implicated the POX component of PGHS in the metabolic activation of xenobiotics and other non-prostaglandin related activities. The main objective of this proposal is to delineate the distinct functions of the COX and POX activities of the PGHS isozymes in carcinogenesis and inflammation using mice with induced mutations created by gene targeting in embryonic stem cells. In Aim 1, COX gene-disrupted mice will be generated by mutation of the aspirin-binding site (serine 530 to asparagine or glutamine), while POX gene-disrupted mice will be created via mutation of the proximal heme ligand (histidine 388 to tyrosine) in Aim 3. The involvement of PGHS POX in the metabolic activation of the nitrofuran compound FANFT, a potent urinary bladder carcinogen, will be analyzed by examination of tumor formation in the mutant mice. Also, the effects of separate COX and POX ablation on skin carcinogenesis using the two-stage DMBA/phorbol ester initiation/promotion protocol and models of inflammation will be assessed in Aims 2 and 4. The COX-disrupted mice, in essence, are perfect in vivo models for complete and selective PGHS-1 arid PGHS-2 inhibition and will be invaluable for studying non-PGHS dependent actions of NSAIDs. Results obtained from this proposal should have broad implications for understanding mechanisms of human cancer and inflammatory disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BLOOD-BRAIN BARRIER TRANSPORT AND ISCHEMIC BRAIN INJURY Principal Investigator & Institution: Keep, Richard F.; Associate Professor; Neurosurgery; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 25-JUL-1996; Project End 31-MAY-2003 Summary: (adapted from applicant's abstract) Because of its juxtaposition to blood, the cerebral endothelium (which forms the blood-brain barrier, BBB) has been thought to be relatively resistant to the effects of cerebral ischemia. However, examination of taurine, glutamine and myo-inositol influx into brain (all Na+-dependent processes) indicate a marked early (<1 hour) reduction in transport during focal cerebral ischemia suggesting that endothelial cell injury could play a role in primary, rather than secondary, ischemic brain damage. This may be particularly the case if efflux from as well as influx into brain are affected since those efflux systems are involved in controlling the concentration of potentially toxic factors in the brain extracelluar space. This proposal, therefore, has two major goals: to determine whether energy-dependent efflux from brain to blood is inhibited during cerebral ischemia (Specific Aims 1 and 2) and to examine whether changes in influx and efflux transport mechanisms at the blood-brain barrier contribute to ischemic brain damage (Specific Aim 3). The cerebral volume of distribution reached by [3H] vinblastine (a P-glycoprotein substrate) and p-[3H] aminohippuric acid (PAH, an organic acid transporter substrate) will be determined following middle cerebral artery occlusion in rat and mouse (Specific Aim 1). Whether an increased volume of distribution with ischemia reflects a change in influx or an alteration in efflux at the blood-brain barrier will then be determined, the latter by examining the effect of
Studies
9
cerebral ischemia in the absence of BBB P-glycoprotein (the mdr la knock out mouse) or during probenecid-induced inhibition of organic acid transport. Specific Aim 2 will examine the mechanism by which ischemia inhibits efflux, by examining PAH, Lglutamate and methyl aminosobutyric acid efflux (an A-system amino acid transporter substrate) uptake into choroid plexus using ventriculo-cisternal perfusion. Specific Aim 3 will determine the effect of altering specific transporters at the BBB on ischemic brain injury and will examine whether drugs known to ameliorate the effect of reperfusion on blood-brain barrier disruption actually have their effects by altering transport during ischemia. Determining whether early BBB dysfunction should be an alternate therapeutic target early during cerebral ischemia, the finding that there is an inhibition of energy-dependent efflux at the BBB during ischemia has major implications for drug delivery to the injured brain. P-glycoprotein and the organic acid transporter both play a major role in limiting the access of some drugs to the brain. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHANGES IN THE CORNIFIED CELL ENVELOPE IN HPV INFECTION Principal Investigator & Institution: Brown, Darron R.; Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): The mechanism of HPV transmission at the cellular level is poorly understood. Keratinocytes are the target cells for HPV infection. These cells normally exit the cell cycle and undergo the process of differentiation, including expression of proteins that become components of the cornified cell envelope (CCE). Loricrin, involucrin, small proline rich proteins (SPRs), cytokeratins, and other proteins are covalently cross-linked to make up the CCE. The endpoint of differentiation is a layer of flattened, durable, enucleated CCEs that provides the host with barrier protection. HPV infection does not induce cell lysis, and the mechanism of virion escape from infected keratinocytes is not known. The CCE in its normal, durable state would likely hinder virion release. We theorized that a defective CCE would facilitate release of virions. Our studies support this hypothesis. We have shown that HPV 11 infection induces abnormalities of CCEs, and that desquamated, cornified cells from HPV 11 infected tissue are effective transmitters of infection. We have also shown that the HPV 11 El^E4 protein is associated in vivo with the CCE. Our studies of the effects of HPV 11 infection on the CCE demonstrate a markedly reduced amount of Ioricrin and an abundance of SPR3 in HPV 11-infected epithelium. Our studies, performed on fully differentiated epithelium, suggest that HPV 11 gene products cause the defects in the CCE. In addition, our recent studies show that HPV 11 infection reduces Ioricrin transcription. The combined effects of HPV gene products on the CCE may facilitate the escape of virions, and thus increase the efficiency of HPV transmission. In the current proposal, we will test the hypothesis that HPV 11 induces defects of the CCE, and that these defects can be attributed to the effects of the El^E4 and E2 proteins. To test the hypothesis, we will 1) determine if the El^E4 protein is a TGase substrate or an inhibitor of these enzymes; 2) analyze the effects of El^E4 proteins on the composition and biophysical characteristics of CCEs, and 3) examine of the effects of the E2 on expression of the CCE proteins Ioricrin and small proline rich protein 3. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
10
•
Glutamine
Project Title: CHEMICAL MODELS OF PROTEIN BETA SHEET INTERACTIONS Principal Investigator & Institution: Nowick, James S.; Professor; Chemistry; University of California Irvine Irvine, Ca 926977600 Timing: Fiscal Year 2002; Project Start 01-APR-1994; Project End 31-MAR-2004 Summary: beta-Sheet interactions between proteins play a critical role in many biological processes associated with diseases and with normal function. Examples including the binding of Ras and Rap by the serine/threonine kinase Raf in cell signaling and oncogene expression, the dimerization of HIV protease, and the interaction between the CD4 receptor and the HIV viral protein gp120. beta-Sheet formation is also involved in the aggregation of peptides and proteins to form insoluble beta-sheet structures that are associated with a variety of devastating neurological disorders, including Alzheimer's disease, Creutzfeld-Jacob disease and other prion diseases, and Huntington's disease. This proposal seeks to mimic and to disrupt betasheet interactions by using chemical model systems called "artificial beta-sheets." The broad, long-term objectives of this research encompass both the development of drugs for diseases involving beta-sheet formation between proteins (e.g., cancer, Huntington's disease, and Alzheimer's disease) and the development for general strategies for creating compounds that disrupt beta-sheet interactions. The specific aims are as follows: (1) Artificial beta-sheet structures based upon the beta-sheet at the interface of the two halves of the met repressor dimer will be synthesized dimer will be synthesized, and their structures will be studied by NMR and CD spectroscopy. (2) An artificial betasheet designed to mimic the protein G binding region of the Fab portion of the immunoglobulin G will be synthesized, and its interaction with domain III of protein G will be studied by NMR spectroscopy. (3) An artificial beta sheet designed to mimic the beta-sheet interface between Ras proteins and the c-Rafl kinase (Raf) and artificial betasheets that mimic the binding regions of Ras and Raf will be synthesized. Their structures and interactions will be studied by CD and NMR spectroscopy, and the latter two compounds will be evaluated for anti-cancer activity by the NCI using an in vitro 60 human tumor cell line screen. (4) Artificial beta-sheets designed to mimic polyglutamine beta-sheet aggregates, which are involved in Huntington's disease and other genetic neurodegenerative diseases will be synthesized. Their structures will be studied by CD and NMR spectroscopy, and their ability to block polyglutamine beta-sheet aggregation will be determined using an in vitro assay. (5) Artificial beta-sheets designed to block beta-amyloid aggregation will be synthesized, and their abilities to block its aggregation and deposition will be studied using in vitro assays. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CONTROL OF RENAL GLUTAMINASE INDUCTION DURING ACIDOSIS Principal Investigator & Institution: Curthoys, Norman P.; Professor and Chairman; Biochem and Molecular Biology; Colorado State University Fort Collins, Co 80523 Timing: Fiscal Year 2002; Project Start 01-OCT-1989; Project End 31-MAR-2006 Summary: During chronic metabolic acidosis, increased renal ammoniagenesis and gluconeogenesis from glutamine are sustained, in part, by a cell specific increase in expression of the mitochondrial glutaminase (GA) that results from the selective stabilization of the GA mRNA. Previous experiments identified an 8-base AU- sequence within the 3'- non-translated region of the GA mRNA that functions as a pH-response element (pHRE) when introduced into a chimeric reporter mRNA. This sequence was used as an affinity ligand to purify and identify zeta-crystallin/NADPH; quinone
Studies
11
reductase as the pHRE-binding protein. The functional characterization of the pHRE was carried out in LLC-PK1-FBPase+ cells, a porcine proximal tubule-like cell line that expresses multiple forms of GA mRNAs. The corresponding porcine GA cDNAs were cloned and sequenced. Only the 4.5-kb GA mRNA contains pHREs that are identical to the sequence identified in the rat GA mRNA and only this form of GA mRNA is stabilized and increased by incubating the cells in acidic medium (Ph=6.9, 10 mM HCO3). Thus this cell lines provides a system to further characterized the molecular mechanism of GA mRNA stabilization and the associated signal transduction pathway. Finally, the 4.50kb GA mRNA is the ortholog of a newly identified isoform of the human kidney-type GA that is generated by alternative splicing of exons within the GA gene. This isoform contains a unique C-terminal domain of unknown function. The specific aims of the proposed research are: to express and characterize the isoforms of the kidney-type GA; to characterize the mechanism of GA mRNA turnover; to characterize the role of zeta-crystallin/NADPH; quinone reductase in the stabilization of the GA mRNA; and to identify the signal transduction pathway that leads to enhanced binding of zeta-crystallin/NADPH; quinone reductase to the pHRE. The results of the proposed experiments should significantly increase the understanding of the molecular mechanism that regulates this essential adaptive response and may provide insight to improve the clinical treatment of chronic acidosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NETWORK
COOPERATIVE
MULTICENTER
NEONATAL
RESEARCH
Principal Investigator & Institution: Lemons, James A.; Pediatrics; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 01-APR-1991; Project End 31-MAR-2006 Summary: Indiana University Medical Center has been an active member of the Neonatal Research Network since 1991. Particular strengths of the Indiana Center include a large patient population, design of new randomized trials for the Network, effective enrollment of subjects in Network protocols, eighteen neonatology faculty with extensive experience and expertise in basic and clinical research, an established newborn follow-up program, excellent infrastructure and support staff, and important collaborative research programs with other departments and university centers. Since 1995 (starting year of the second competitive renewal of the Network grant) the faculty within the Section of Neonatal-Perinatal Medicine has had 20 NIH grants and 49 other extramural awards, and has published over 200 manuscripts during that period. Indiana University School of Medicine is the only medical school and the site of the only comprehensive children's hospital in Indiana. The Medical Center serves as the principal referral center for pediatric subspecialty care for the entire state, which has a population of 5.9 million and 87,000 births annually. Further, the Indiana Center expanded in 1997 when Methodist Hospital (a large community hospital with a high risk obstetric service and NICU) merged with the Medical Center. Indiana has a strong record of participation in and contribution to the Neonatal Research Network. During the past four years Indiana enrolled an average of 334 VLBW infants yearly in the generic data base, and 390 infants in 1999 (the largest of any center). Indiana has participated in 12 trials since 1995, contributing 34/235 subjects to the Neonatal Inhaled Nitric Oxide Study 45/170 and 24/115 infants to the two Erythropoietin trials, 3/16 infants to date in the Hypothermia and Hypoxic Ischemic Encephalopathy study, and 65 of 300 to date in the Glutamine Trial. Indiana faculty chaired and developed the Newborn Follow-up Program, the Glutamine Trial, the Magnesium Sulfate Subcommittee and the Protocol
12
Glutamine
Review Subcommittee, chaired the GDB Subcommittee, and served on nine other subcommittees. The clinical and basic research of the neonatology faculty is focused on molecular immunology, developmental hematopoiesis, and fetal/neonatal nutrition and metabolism. These research programs lend themselves to ancillary studies of the Neonatal Network; one currently active and six other ancillary studies were designed and initiated by Indiana faculty. Collaborative support has been provided by other investigators, departments and centers when additional expertise and/or resources could benefit Network protocols. Indiana University brings to the Neonatal Network a large patient population, a uniquely balanced program of clinical service and research, and a strong record of participation and accomplishment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CREB BINDING PROTEIN AND GENE REGULATION Principal Investigator & Institution: Ludlam, William H.; None; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2002; Project Start 01-JUN-1999; Project End 31-MAR-2004 Summary: The cAMP mediated second messenger pathway is a well established model of gene regulation. Within a given cell, many transcription factors are known to interact with and work through the protein kinase A/CREB pathway making integration of multiple signals through common regulatory factors an exceedingly complex phenomenon. The mechanism by which CBP (a CREB co-activator) influences gene regulation is not fully understood, but it is likely that this factor contributes to transcriptional signal integration. There is increasing evidence that this activity may be, in part, due to histone acetylation (HAT) of chromatin that exposes DNA for transcription. The main thrust of this project is to characterize the intrinsic HAT activity of CBP/p300. Four Specific Aims are proposed: (1) CBP/p300 proteins mutated in the putative intrinsic HAT domain (between the bromodomain and the glutamine-rich region of CBP/p300) will be developed to determine and test whether they retain their intrinsic HAT activity. This will also be helpful in mapping the HAT domain. (2) To test whether the intrinsic HAT activity of CBP/p300 for nucleosomes and polynucleosomes is blocked by E1A, since the mechanism by which adenovirus 12S E1A blocks the CBP/p300 co-activator is unknown. (3) To determine whether mutants lose their ability to activate reconstituted chromatin (DNA bound to histones), yet maintain their ability to activate transcription in DNA not bound to histones. (4) To study CBP HAT mutants in developing flies. This lab has previously shown that dCBP rescues CBP-null flies. The inability of CBP HAT mutants to rescue CBP-null flies would be strong evidence that intrinsic HAT activity of CBP (and p300) is critical for in vivo function, and that histone acetylation plays a central role in their gene regulatory function. Gaining insight to the mechanisms of gene activation and silencing has far reaching relevance in the treatment of many diseases including cancers and endocrinopathies. Through a mentored career development plan, the Principal Investigator will gain an enhanced capacity to be productive in the field of molecular biology with a focus on gene regulation. This will be accomplished by conducting the above described research, attending and presenting at local and national seminars and meetings, and participating in courses teaching molecular biology techniques. The proposed mentoring laboratory and institution are rich in intellectual and physical facility resources that provide an excellent environment for the Principal Investigator to transition to independence in the design and implementation of research in the field of gene regulation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
13
Project Title: CRYSTALLIZATION OF ATAXIN-3 Principal Investigator & Institution: Loll, Patrick J.; Biochemistry; Drexel University 3201 Arch Street Philadelphia, Pa 19104 Timing: Fiscal Year 2004; Project Start 01-FEB-2004; Project End 31-JAN-2006 Summary: (provided by applicant): The polyglutamine diseases are incurable neurodegenerative disorders affecting hundreds of thousands of people worldwide; they are caused by the expansion of normally occurring polyglutamine tracts in proteins. Patients suffer a steady deterioration in motor and cognitive abilities, followed by death. The Aim of this research is to investigate the structural basis of polyglutamine disease, focusing specifically on the ataxin-3 protein. The lengths of polyglutamine tracts in proteins vary within the normal population, but never exceed 35- 40 consecutive glutamines in healthy individuals. Mutations that expand the number of these residues to greater than 40 cause disease. Proteins with expanded polyglutamine regions misfold and aggregate into amyloid fibrils; the aggregation and fibril formation are inextricably linked with cellular dysfunction and death. Expanded glutamine repeats disrupt native protein structure and favor the formation of misfolded states, which can assemble into toxic aggregates. An understanding of this aberrant folding process requires a thorough structural knowledge of both the native and pathological states of the protein. Advances have been made in the characterization of fibril architecture, but no three-dimensional structure is currently available for any polyglutamine protein. This lack of structural information drastically hinders progress toward understanding the molecular basis of polyglutamine disease and developing rational therapies. Ataxin-3 is the causative agent of Machado-Joseph disease, the most common polyglutamine disease. The P. I.'s laboratory is developing ataxin-3 as a model system for studying the misfolding and aggregation of polyglutamine proteins. The structural aspects of this work require crystals of ataxin-3 suitable for X-ray diffraction studies. We therefore have developed a systematic and comprehensive approach to obtaining crystals of full-length and truncated forms of ataxin-3. Three Specific Aims are proposed, namely the identification and crystallization of isolated domains of ataxin-3, the use of rational mutagenesis to improve our ability to grow diffraction-quality crystals, and the use of antibody fragments to prepare Fab-ataxin-3 cocrystals. The molecular understanding of ataxin-3 that will be obtained from this work is a prerequisite for any rational design of therapeutics that will interfere with the protein's aberrant folding and aggregation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DERMATITIS HERPETIFORMIS AND THE MUCOSAL IMMUNE RESPONSE Principal Investigator & Institution: Hall, Russell P.; Professor and Chair; Medicine; Duke University Durham, Nc 27706 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (Verbatim) Dermatitis herpetiformis (DH) is a blistering skin disease characterized by the presence of cutaneous IgA deposits and an associated, almost always asymptomatic, gluten sensitive enteropathy (GSE). The critical role of the mucosal immune response (MIR) in DH has been demonstrated by the observation that, despite the lack of clinical symptoms of GSE in the majority of DH patients, the cutaneous manifestations of DH can be controlled by a gluten free diet. The mechanisms that allow for the development of cutaneous IgA deposits and skin disease yet that prevent the development of symptoms of GSE are not known. The purpose of this project is to characterize the MIR in patients with DH in order to determine the factors
14
Glutamine
that prevent the development of clinical signs of gastrointestinal disease yet result in cutaneous deposits of IgA and the development of the cutaneous manifestations of DH. In addition, this project will provide new information regarding factors that may modify and regulate the mucosal immune response to dietary proteins in man and how mucosal inflammation results in inflammatory disease in the skin, joints and other organs. The specific aims of this project are: 1. Determine the antigenic patients with DH and isolated GSE and control subjects using organ culture of specificity and dose response of the T cells in small bowel biopsies from isolated GSE. 2. Characterization of the circulating neutrophils in patient with small bowel biopsies and gliadin peptides, some of which induce disease in DH on gluten containing diets and of the level of cytokine(IL1/TNFa)/chemokine(IL-8) expression in the skin. Skin biopsies from patients with DH from areas predisposed to develop skin lesions (extensor, surfaces) and those areas which normally do not develop skin lesions (upper inner arm) will be analyzed for IL1a, TNF-a, IL-8, and other cyto/chemokine expression during periods of control of the skin disease and no skin lesions and during disease activity. Neutrophils will be analyzed during periods when skin lesions are present and not present to assess the level of activation and expression of cell surface molecules which play a role in neutrophil migration 3. Characterization of the CDR3 region of the T cell Vb families expressed in the small bowel biopsies of patients with DH and of patients with isolated symptomatic and asymptomatic GSE. cDNA from the small bowel of patients with DH, patients with isolated symptomatic GSE and patients with isolated, asymptomatic (treated) GSE and patients with non-gluten sensitive intestinal disease will be analyzed by RT-PCR for the evidence of clonality of the T cells in the gut using CDR3 spectrotype analysis and single strand conformational polymorphisms. These studies will provide insights into the pathogenesis of DH and isolated GSE, the relationship between the MIR and the skin and factors important in controlling the mucosal immune response in man. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DYNAMIC MRI AND MRS STUDIES OF FOCAL NEURAL ACTIVATION Principal Investigator & Institution: Gruetter, Rolf; Associate Professor; Radiology; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 10-APR-2000; Project End 31-MAR-2003 Summary: (Adapted from applicant's abstract): Many functional imaging techniques are based on measuring changes in cerebral blood flow (CBF), either directly (such as radiotracer methods or perfusion MRI) or indirectly, such as blood-oxygen level dependent (BOLD) functional MRI. These changes in CBF are thought to reflect changes in cerebral metabolic activity, specifically cerebral glucose consumption, CMRglc, which in turn is thought to reflect neuronal activity. The hypotheses of this project are: A) That glutamate-glutamine cycling measured from glutamine labeling reflects neurotransmission, which is increased in focal activation (neuronal spike activity). B) That changes in neurotransmission are matched by changes in metabolic rates, such as flux through (neuronal) pyruvate dehydrogenase (CMRO2), glycolysis and malateaspartate shuttle and that these changes are consistent with BOLD fMRI and perfusion MRI providing a coherent depiction of neurotransmission and its metabolic/hemodynamic correlates. C) Those enzymatic pathways of cerebral glycogen synthesis and breakdown are simultaneously active, such that brain glycogen concentration and cerebral activity levels modulate metabolism. With the following specific aims: 1. To simultaneously measure label incorporation into several distinct
Studies
15
carbon positions in cerebral glutamate, glutamine and aspartate during 13C labeled glucose infusions with concomitant measurement of tissue glucose and lactate concentrations and combined with perfusion and BOLD fMRI. 2 To develop 13C NMR detection of brain glycogen concentration and metabolism. Significant phosphorylase and synthase activity as reported for brain tissue is expected to lead to label transfer from plasma glucose to brain glycogen when infusing labeled 13C glucose and thus to an observable 13C NMR signal. These aims will be achieved in rat brain using localized 1H and 13C NMR spectroscopy in conjunction with 1H fMRI of BOLD and perfusion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENTERAL PRECURSORS FOR UREA SYNTHESIS IN HUMANS Principal Investigator & Institution: Gaskins, H R.; Professor; Animal Sciences; University of Illinois Urbana-Champaign Henry Administration Bldg Champaign, Il 61820 Timing: Fiscal Year 2002; Project Start 30-SEP-1998; Project End 31-JUL-2003 Summary: (provided by applicant): The long term goal of the research is to further understand the regulation of nitrogen flow to urea synthesis in humans. A specific focus is on patients with genetic disorders of the urea cycle (UCDs). Currently funded research has shown that inviduals who are heterozygotic for ornithine transcarbamylase and arginino succinic acid synthase deficiency appear to have a partial block in their ability to use glutamine as a nitrogen source for urea synthesis, and that they rely on the hepatic clearance of ammonia generated in the gut to maintain their post prandial N homeostasis. Preliminary results suggest that the administration of sodium phenyl butyrate, a common treatment for UCDs, disrupts branched chain amino acid metabolism. We argue therefore that because of the importance of leucine to protein metabolic regulation, treatment with phenyl butyrate not only diverts N away from urea synthesis, but compromises the regulation of body protein turnover. We hypothesize: Hypothesis 1: Phenyl butyrate, given at therapeutic levels, specifically diverts branched chain amino nitrogen towards glutamine production and away from net tissue protein synthesis. Hypothesis 2: Phenyl butyrate treatment thus inhibits the ability of the body to maintain nitrogen equilibrium, particularly at the restricted protein intakes used in the treatment of UCDs and other metabolic diseases; Hypothesis 3: Patients with UCDs, who are concurrently treated with phenylbutyrate and a low protein diet, will benefit from dietary supplements of branched chain amino acids.To test these hypotheses, we will use stable isotopic tracers of leucine, glutamine, phenylalanine and urea metabolism in studies in normal subjects and individuals with partial or complete defects in urea synthesis. The specific aims will be: Specific aim 1: Determine, in control subjects and heterozygotic carriers of UCDs, the effect of phenyl butyrate on urea, glutamine and branched chain amino acid metabolism. Quantify its effects on body protein turnover. Specific aim 2: Quantify whole body protein turnover and balance in patents with null urea cycle activity who are receiving the conventional regime of phenyl butyrate and a low protein diet. Specific aim 3: Determine the effect of oral branched chain-amino acid supplements on protein, leucine and glutamine metabolism in urea-cycle patients and controls who are receiving phenyl butyrate.The main objective therefore is to use the new clinically oriented information on the regulation of human nitrogen homeostasis, to develop novel nutritional approaches to the treatment of UCDs and other metabolic diseases. In addition it is anticipated that the results will benef it other individuals who have compromised protein metabolism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
16
•
Glutamine
Project Title: ENTERAL VS IV FEEDING: EFFECT ON MUCOSAL IMMUNITY Principal Investigator & Institution: Kudsk, Kenneth A.; Surgery; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2002; Project Start 01-FEB-1998; Project End 31-MAR-2006 Summary: Hospital acquired pneumonia costs up to 2 billion dollars per year in the United States, and any inexpensive therapy which reduces this septic complication could greatly impact health care costs. Enteral feeding significantly reduces the complications of pneumonia compared with intravenous (IV-TPN) feedings by 60-70 percent in trauma patients. Our experimental and clinical work implicates previously unrecognized defects in mucosal immunity which develop when the intestinal tract is not stimulated with enteral feeding or when surrogates of enteral feeding are not provided. The principal specific immunologic defense at mucosal surfaces is secretory IgA produced by the mucosal-associated lymphoid tissue (MALT). The principal anatomic site for immunologic sensitization of Peyer's patches within the small intestine. Adhesion molecules direct unsensitized immunocytes through the Peyer's patches where these lymphocytes are sensitized and change their own surface integrins. They are then directed to both intestinal and extraintestinal sites, such as the respiratory tract, where they produce IgA against those antigens. The antibody binds to bacteria, preventing their attachment and their ability to infect. This proposal focuses on how route and type of nutrition affects the expression of the specific adhesion molecules, modified MAdCAM-1, unmodified MAdCAM-1, and ICAM-1 which are important in directing unsensitized immunocytes into Peyer's patches. The proposal tests the hypothesis that interaction between these adhesion molecules and their ligands on naive T and B cells are critical in maintaining mucosal immunity in both intestinal and extraintestinal sites. The proposal is designed to test the hypothesis that inhibition of these interactions recreates the defects in in vivo mucosal defenses that are induced when enteral feeding is not provided. It also focuses on previous observations that a specific immunocyte fuel, glutamine, and the enteric nervous system neuropeptide, bombesin, can act as surrogates for enteral feeding and exert beneficial effects upon the MALT in IV-TPN-fed animals by upregulating MAdCAM-1 and ICAM- 1 expression. The experiments are designed to confirm that IgA is a critical element of specific immunity and respiratory defenses against pneumonia with in vivo experiments. These experiments use a monoclonal antibody produced by a hybridoma cell line which is specific for polysaccharide antigen(s) found on a high percentage of clinical isolates of Pseudomonas aeruginosa. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FACTOR XLLL ACTIVATION AND SUBSTRATE SPECIFICITY Principal Investigator & Institution: Maurer, Muriel C.; Associate Professor; Chemistry; University of Louisville University of Louisville Louisville, Ky 40292 Timing: Fiscal Year 2002; Project Start 08-JUL-2002; Project End 31-MAY-2006 Summary: In blood coagulation, the enzyme thrombin cleaves fibrinogen, sites for fibrin polymerization are revealed, and fibrin clot formation begins. Activated Factor XIII, a transglutaminase, is responsible for catalyzing the formation of covalent crosslinks between fibrin molecules and in fibrin-enzyme complexes. Thrombin activates Factor XIII by cleaving a peptide sequence that lies across the Factor XIII catalytic site. The thrust of this research project will be to examine in solution the structural features that govern the activation and substrate specificity of Factor XIII. The specific aims are designed to prove the following hypotheses: 1) There is no obvious consensus sequence
Studies
17
for defining the substrate specificity of Factor XIII for glutamine donating groups. The glutamine containing substrates are hypothesized to interact with the Factor XIII enzyme surface using similar bound conformations with defined flexible and/or solvent exposed regions. Peptides based on natural and synthetic substrates will be examined. 2) The Factor XIII activation peptide segment has components that resemble the fibrinogen Aalpha chain, the thrombin receptor, and PPACK, all of which interact with thrombin. The Factor XIII activation peptide segment is hypothesized to adopt a bound conformation that allows for the most effective interactions with the thrombin surface. An understanding of how unique amino acid positions within this segment participate in binding may lead to the design of Factor XIII enzymes whose degree of activation and optimal target site can be controlled. A model system for these studies is Factor XIII V34L, a common polymorphism that has been correlated with protection against myocardial infarction and is more susceptible to thrombin cleavage than the native sequence. To address these specific aims, a combination of kinetic studies, hydrogen/deuterium exchange followed by MALDI-TOF mass spectrometry, 1D proton line broadening NMR, 2D TOCSY, 2D transferred NOESY, and molecular modeling will be used. Understanding the molecular details of how Factor XIII is activated and how its substrate specificity is regulated is critical considering the role this enzyme plays in increasing the risk of heart disease, stroke, and arteriosclerosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FACTORS THAT MODIFY INSULIN ACTION Principal Investigator & Institution: Buse, Maria G.; Professor; Medicine; Medical University of South Carolina 171 Ashley Ave Charleston, Sc 29425 Timing: Fiscal Year 2002; Project Start 01-MAY-1978; Project End 31-MAR-2003 Summary: "Glucose toxicity" accounts for insulin resistance in uncontrolled Type I diabetes (IDDM) and contributes to insulin resistance in Type II diabetes (NIDDM). Sustained hyperglycemia or hyperinsulinemia cause insulin resistance; glucose and insulin act synergistically in down- regulating insulin-stimulated glucose transport. A hypothesis to be tested in 3T3-Ll adipocytes is that glucose/insulin induced glucose transport desensitization reflects altered subcellular trafficking of the glucose transporter, GLUT4, which may involve impaired GLUT4 translocation and inappropriate association of GLUT4 containing vesicles (GCV) with the plasma membrane. Products of the hexosamine synthesis pathway (HNSP) have been implicated in glucose-induced insulin resistance; glutamine-fructose-6-P amidotransferase (GFAT) is the rate limiting enzyme and UDP-N-acetyl glucosamine (UDP-GlcNAc) the major product. The role of HNSP will be tested by examining whether conditions which increase or decrease flux via HNSP augment or mitigate, respectively, glucose induced insulin resistance. O-GlcNAcylation is a reversible process, involving O-glycosylation of proteins on Ser/Thr residues with monosaccharide GlcNAc. It usually involves phosphorylation sites and may be regulatory. Based on preliminary data in muscles of a mouse model of insulin resistance, over-expressing GLUTI in muscle, the hypothesis will be tested that increased flux via HNSP promotes O-GlcNAcylation of critical proteins involved in insulin- stimulated glucose transport. These may include GSV-associated proteins, possibly GLUT4 itself and/or proteins associated with GSV docking and fusion. Since adaptive regulation usually involves multiple sites, we will test the hypothesis that glucose-induced insulin resistance represents in part down-regulation of the insulin receptor (IR) signaling cascade, attempt to identify the major regulatory sites and critically assess the possible contribution of HNSP to the glucose effect. If warranted, the involvement of modulators
18
Glutamine
of IR signal transduction, I.E. protein kinase C (PKC) isoforms, and candidate protein tyrosine phosphatases (PTP-ases: PTP-1B, SH-PTP2 and LAR) will be examined. GFAT activity is allosterically regulated by UDP-GlcNAc, and is modulated in vivo in muscle by the hormonal and metabolic milieu. The pre- and post-translational regulation of GFAT expression will be studied in muscles of rodent models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTION OF GENES AND PROTEINS IN LEARNING AND MEMORY Principal Investigator & Institution: Eskin, Arnold; Professor and Chair; Biology and Biochemistry; University of Houston 4800 Calhoun Rd Houston, Tx 77004 Timing: Fiscal Year 2002; Project Start 01-JAN-1991; Project End 31-MAR-2004 Summary: The long-term goal of this research is to understand how changes in properties of neurons lead to the formation of memory and subsequent changes in behavior. The behavioral framework of our research is long-term sensitization of the defensive tail, siphon withdrawal reflex of Aplysia. Glutamatergic sensory neurons are key components of the reflex. Long-term presynaptic facilitation (LTF) at the sensorymotor synapse is mainly responsible for sensitization. We hypothesize that a number of properties of a sensory neuron must change in a coordinated fashion to produce LTF and store memory. Thus, we predict that the increase in transmitter release that occurs during LTF should be coordinated with an increase in uptake and synthesis of glutamate. In testing this hypothesis, we found that sensitization training leads to a substantial long-term increase in the Vmax of the high affinity neuronal glutamate transporter. In addition, we found that glutamine uptake was increased suggesting that glutamate synthesis was also increased. These findings provide the basis for molecular and biochemical studies on newly-discovered plastic properties of the sensory neuron. In particular, we will study molecular correlates of memory storage and expression in Aplysia and will extend these findings to research on long-term potentiation in the hippocampus of rats. The proposed research has 4 Specific Aims: Aim 1 is to determine the relationship between increases in glutamate uptake, glutamate synthesis, and behavioral sensitization. Aim 2 is to determine the cellular mechanisms that mediate coordinate regulation of glutamate uptake, synthesis, and long-term facilitation. Aim 3 is to determine whether the mechanisms responsible for the long-term increase in glutamate uptake involve synthesis of transporters and then transport through the ERGolgi-vesicle transport pathway. Aim 4 is to determine the generality of regulation of uptake by studying glutamate uptake during long-term potentiation in the CA1 region of the hippocampus. Deficiencies in glutamate uptake have been implicated in a number of diseases (e.g., ALS, Hodgkin's, Alzheimer's). Glutamate appears to be a remarkably potent and rapidly-acting neurotoxin. This underlines the important role of glutamate uptake in the normal functioning of brains. Our research will help elucidate possible causes for decreased glutamate uptake in these diseases by identifying mechanisms responsible for long-term regulation of glutamate transporters. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FUNCTIONAL TRANSPORTERS
CHARACTERIZATION
OF
LEISHMANIA
Principal Investigator & Institution: Landfear, Scott M.; Professor; Molecular Microbiology and Immunology; Oregon Health & Science University Portland, or 972393098
Studies
19
Timing: Fiscal Year 2002; Project Start 01-SEP-1991; Project End 31-MAY-2006 Summary: (provided by applicant): The objective of this proposal is to characterize at the molecular level several transporters from Leishmania and trypanosomes that mediate the uptake of important nutrients from the hosts. These nutrients include glucose which is an major source of metabolic energy in the insect stage of the life cycle, purines which are essential nutrients that the parasites cannot synthesize de novo, and amino acids which are both catabolized to generate energy and utilized in anabolic pathways such as protein synthesis. In the first aim, the physiological functions of the LdGT1 and LdGT2 glucose transporter isoforms of L. donovani will be probed by generating null mutants and analyzing their phenotypes. These studies may elucidate the functional differences between the flagellar membrane LdGT1 and the pellicular plasma membrane LdGT2. In the second aim, the permeation pathway of the L. donovani adenosine/pyrimidine nucleoside transporter LdNT1.1 will be probed by a combination of cysteine-scanning mutagenesis and sulfhydryl group chemical modification. These studies have been guided by the detection of two distinct point mutations that inactivate LdNT1.1, possibly by altering amino acids that line the permeation pathway. The TbNT8 transporter from Trypanosoma brucei, whose mRNA is expressed exclusively in insect stage parasites, is closely related in sequence to other well characterized nucleoside transporters, but it's function remains to be defined. This third aim will characterize a strongly developmentally regulated nucleoside transporter and allow its comparison to other bloodstream-specific nucleoside transporters. The final aim will functionally characterize a novel amino acid transporter from L. major that is related in sequence to mamrnalian N-type amino acid permeases that mediate the uptake of glutamine, and histidine, essential amino acids for growth of Leishmania parasites. These studies will initiate the molecular analysis of amino acid transporters in Leishmania. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GAMMA-CRYSTALLIN MODIFICATIONS /MECHANISMS OF LENS OPACI Principal Investigator & Institution: Pande, Jayanti; Research Associate; Physics; Massachusetts Institute of Technology Room E19-750 Cambridge, Ma 02139 Timing: Fiscal Year 2003; Project Start 01-JUN-1994; Project End 31-MAY-2008 Summary: (provided by applicant): Our long-term objectives are to understand how specific post-translational chemical modifications and genetic mutations of the gammacrystallin proteins lead to lens opacity. We hypothesize that not all protein modifications are deleterious - only those that lead to increased light scattering. Our strategy designed to test this hypothesis is as follows: We will model the cataractogenicity of a given modification or mutation of a gamma-crystallin in vitro, by introducing the required change into the protein and determining the effect on the formation of protein aggregates, liquid droplets containing protein-rich and protein-poor phases, and protein crystals (i.e., protein-derived condensed phases). Protein modifications that enhance the formation of such condensed phases (all of which lead to increased light scattering) will be potentially cataractogenic. We will compare the phase behavior (liquid-liquid and solid-liquid phase separation) of native and modified gamma-crystallins to evaluate if a given modification enhances or suppresses the formation of condensates. In parallel, we will also examine protein structure and conformation using biochemical and spectroscopic methods (chromatography, HPLC, gel electrophoresis, Raman spectroscopy, circular dichroism, fluorescence, and x-ray crystallography). We propose the following Specific Aims: (1) Evaluate which physiologically relevant chemical
20
Glutamine
modifications of the 7 crystallins found enhance the formation of condensed phases - (1 a) Examine the effect of modifications of cysteine residues (i.e., thiolations) with (i) glutathione (ii) cysteine (iii) cysteinylglycine and (iv) gamma-glutamyl cysteine, (1b) Examine the effect of deamidation of asparagine and glutamine residues, and (1c) Examine the effect of truncations of the 7 crystallin polypeptide chain (2) Evaluate which of the genetic variants of the gamma-crystallins enhance the formation of condensed phases - (2a) Determine the mechanisms of opacification due to mutant proteins expressed from gamma-crystallin genes associated (in the literature) with human or animal model cataracts, (2b) Determine what effect the mutant proteins expressed from gamma-crystallin gene variants due to single-nucleotide polymorphisms, have an effect on opacification. This work is designed to provide plausible mechanisms for lens opacification due to gamma-crystallin modifications and mutations. Understanding these mechanisms is an essential first step towards the development of reagents to delay the onset of opacities due to (a) the commonly encountered age-onset cataract and (b) the rare nuclear opacities of genetic origin seen in children and young adults. In view of the recent evidence in the literature that suggests that age-onset cataract may have a genetic component, the studies proposed here have the potential for predicting the susceptibility of individuals towards this disease due to normal variants of the gamma-crystallins in the general populations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC STUDIES OF GLUTAMINE SYNTHETASE IN BACTERIA Principal Investigator & Institution: Kustu, Sydney G.; Associate Professor; Plant and Microbial Biology; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2002; Project Start 15-SEP-1986; Project End 31-MAY-2007 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GI MUCOSAL BARRIER IN HEALTH AND SURGICAL DISEASE Principal Investigator & Institution: Hagen, Susan J.; Associate Professor; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2003; Project Start 01-JAN-1977; Project End 31-MAY-2008 Summary: (provided by applicant): The overall aim of the proposed work is to understand how Helicobacter pylori (HP) infection causes mucosal damage in the stomach, with special emphasis on the fundic region of the stomach. The investigators plan to study how HP infection impairs tight junction integrity and wound repair after injury (restitution) to result in increased mucosal permeability. HP-induced mucosal damage of the stomach is important because it is a major initiating factor in the pathogenesis of HP disease, including inflammation, atrophy of fundic epithelial cells including parietal and chief cells, metaplasia, and progression to gastric cancer. Because HP infection has far-reaching implications in terms of benign and malignant disease, mechanisms that underlie the initiation of mucosal damage, repair after damage, and protection against damage are important and timely. Three hypotheses will be tested. 1) HP infection increases mucosal permeability because either HP or inflammatory cells decrease tight junction integrity. This hypothesis will be tested by investigating how HP sonicates or cytokines secreted during a type 1 T-helper (Th1) response affect the phosphorylation and membrane association of proteins associated with the tight junction. 2) HP infection increases mucosal permeability because ammonia, a cytotoxin produced during HP infection, inhibits restitution. This hypothesis will be tested by
Studies
21
investigating the effects of ammonia on activity of the H+/lactate transporter, MCT1, and on basolateral K+-channel activity. 3) L-glutamine (Gln) supplementation decreases mucosal permeability by inhibiting the Th1 response and cytokine-induced decreases in tight junction integrity that occur during HP infection. This hypothesis will be tested by determining whether L-Gln supplementation inhibits the Th1 cytokine response to preserve tight junction integrity in a mouse model of disease. The proposed investigations follow a logical sequence from previous studies in this laboratory, which have provided a structural framework for our knowledge of mucosal injury, protection against injury, and rapid epithelial repair (restitution) as they relate to maintenance of the gastric mucosal barrier in health and surgical disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUCONEOGENESIS IN VERY LOW BIRTH WEIGHT INFANTS Principal Investigator & Institution: Sunehag, Agneta; Assistant Professor of Pediatrics; Pediatrics; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-FEB-2000; Project End 31-JAN-2005 Summary: Improvements in the management of premature infants have resulted in a dramatic increase in their survival. Previously, nutritional management was not of high priority in very low birth weight (VLBW) infants since most died early in life. As a result, our refinement of the nutritional management of these surviving infants has lagged behind the advancements in cardio-respiratory therapy. VLBW infants are susceptible to hypoglycemia; thus, to provide sufficient calories and to prevent hypoglycemia, glucose is routinely infused at high rates (approximately 60 mumol/kg min, twice that of measured glucose turnover rates in these infants) as part of standard total parenteral nutrition (TPN) which frequently results in hyperglycemia. Like hypoglycemia, hyperglycemia can have significant short and long term adverse impact on their outcomes. The specific focus of the present application is to determine the individual and collective roles of the substrates provided in standard total parenteral nutrition on glucose production from glycogenolysis and gluconeogenesis (GNG) and glucose utilization. These studies will determine: a. Whether VLBW infants receiving TPN who are normoglycemic suppress their glucose production completely and those who are hyperglycemic have incomplete suppression of glucose production and/or reduced glucose utilization; b. When VLBW infants are supplied glucose at a reduced rate (17 mumol/kg min): 1. Do i.v. lipids (IntralipidR) increase GNG and glucose production and if so is this the result of providing energy for GNG through betaoxidation or providing glycerol as a 3-carbon precursor; 2. Whether glycerol increases GNG and glucose production in a dose dependent fashion in VLBW infants; 3. Whether i.v. amino acid solution (TrophAmineR) and/or the gluconeogenic amino acids, glutamine and alanine, will increase GNG and glucose production; and 4. Whether glucagon will increase GNG and glucose production from endogenous and exogenous substrate sources. The ultimate aim will be to utilize this information in designing alternative mixtures of constituents (substrates and possibly hormones) which will decrease the risk of both hypo- and hyperglycemia in these infants, by utilizing the infants' gluconeogenic pathway, while providing sufficient substrate to sustain normal growth and development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GLUTAMINE AMIDOTRANSFERASES AND PARTNER ENZYMES Principal Investigator & Institution: Smith, Janet L.; Professor; Biological Sciences; Purdue University West Lafayette West Lafayette, in 479072040
22
Glutamine
Timing: Fiscal Year 2002; Project Start 01-FEB-1990; Project End 31-JAN-2003 Summary: Glutamine amidotransferases are "complex" enzymes with two different catalytic domains, each contributing to the catalysis of a single biochemical reaction. The family of sixteen enzymes catalyzes the transfer of amide nitrogen from glutamine (glutamine catalytic domain) to a variety of acceptor substrates (acceptor catalytic domain). Crystal structures have been determined for two amidotransferases of de novo purine biosynthesis. The structures of glutamine PRPP amidotransferase (GPATase) and GMP synthetase are prototypes for the two homologous families of glutamine catalytic domains, the Ntn and Triad families, respectively. The acceptor domains of both enzymes also represent homologous enzymes families, the phosphoribosyltransferases and the N-type ATP pyrophosphatases. Results from these first structures of amidotransferases have changed thinking about the enzyme family and led to new direction for future experiments. The most important new discovery of this work has been the means by which Ntn amidotransferases couple catalysis between glutamine and acceptor domains. The enzyme creates a channel for NH/3 between glutamine and acceptor active sites. Signal transduction between catalytic sites is triggered by substrate binding in the acceptor domain and involves formation of the NH/3 channel and activation of the glutamine domain. The proposed studies will investigate control and operation of the NH3 channel in GPATase and determine whether Triad amidotransferases also channel NH/3 between active sites. The product of GPATase is extremely unstable, and there is indirect evidence for channeling to GAP synthetase, the next enzyme of the purine biosynthetic pathway. This possibility will be investigated by structural studies of GAP synthetase and by mutagenesis experiments. The significant observations of the first two amidotransferases will be extended to other members of the enzyme family. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUTAMINE METABOLISM IN THE HUMAN NEWBORN Principal Investigator & Institution: Kalhan, Satish C.; Professor; Pediatrics; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2007 Summary: (provided by applicant): Glutamine, an endogenously synthesized amino acid, has been variously considered "essential" or "conditionally essential" during acute illness and in very low birth weight (VLBW) infants. Several investigators have proposed the use of supplemental glutamine in VLBW babies in order to accelerate adaptation to extrauterine environment and recovery from related neonatal illness. However, there are no data actually quantifying changes in glutamine metabolism in relation to ontogeny or acute illness in full term and prematurely born infants. The specific aims of these studies are to examine the systemic and splanchnic metabolism of glutamine, and its relation to whole body protein/nitrogen and urea kinetics in the neonate. Since glutamine is synthesized de novo via a cataplerotic reaction of the tricarboxylic acid cycle from alphaketoglutarate and glutamate, it is hypothesized that its metabolism will be closely linked with the anaplerotic flux of substrates such as glucose and amino acids into the tricarboxylic acid cycle. Glutamine also serves as an important respiratory fuel for the enterocytes and the lymphocytes. It is hypothesized that enterally administered glutamine will be utilized locally in the splanchnic compartment in growing infants when the enterocytes (and lymphocytes) are proliferating. Furthermore, during neonatal adaptation and during recovery from acute illness in the low birth weight baby, glutamine will not be locally metabolized and will bypass the splanchnic compartment. These hypotheses will be examined by quantifying
Studies
23
the kinetics of glutamine in zombination with measurements of the transamination of branched chain amino acids, protein turnover and urea synthesis. Stable isotopic tracers and gas chromatograph-mass spectrometric methods will be employed. These studies will systematically examine the interrelationship between the transamination of an essential amino acid, leucine, and the de novo synthesis of a dispensable amino acid, glutamine, during the critical period of ransition to extrauterine environment and during growth, and will provide a metabolic basis for nutritional management of low birth weight infants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUTAMINE:FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE FORNIDDM Principal Investigator & Institution: Teng, David H.; Deltagen Proteomics, Inc. 615 Arapeen Dr, Ste 300 Salt Lake City, Ut 84108 Timing: Fiscal Year 2002; Project Start 04-JUN-2002; Project End 31-MAY-2003 Summary: We have developed a transdominant genetic methodology for isolating peptide, protein or RNA factors (collectively called peturbagens) that modulate biochemical targets within a cell to alter its phenotype. Because it is genetic approach, it can be applied in both the classical forward mode (from phenotype to genotype) to reverse mode (from gene to function). The main goal of the proposed Phase I research is to validate human glutamine: fructose-6-phosphate amidotransferase (hsGFA1), the rate- limiting enzyme that catalyzes the first reaction in the hexosamine pathway, as a pharmacologic target for insulin resistance. This will be achieved by the following steps: (1) Isolating peptides that bindhsGFA1 using a modified yeast two hybrid assay. (2) Determine which peptides inhibit hsGFA1 activity by examining the conditional lethality of gfa1-/pGaI-hsGFA1+ yeast, that are viable despite to loss of the endogenous gfa1 gene due to rescue by galactose- regulated expression of hsGFA1. Inhibitors of hsGFA1 in these yeast cells will be cytotoxic. (3) Expressing the hsGFA1 peptide inhibitors in insulin-responsive cultured HepG2 hepatic cells and3T3-L1 adipocytes and ascertaining effects on GFA activity and the hexosamine pathway, as well as cellular glucose transport. The successful completion of Phase I will enable downstream studies of gsGFA1 inhibitors in mouse models of type 2 diabetes and obesity. PROPOSED COMMERCIAL APPLICATIONS: Perturbagen technology offers a novel way to probe and validate the function of a protein within a cell or animal. Proof that inhibition of hsGFA1 is capable of reversing insulin resistance in mammalian cells, or mouse models of diabetes and obesity, would open the flood gates for the search of chemical antagonists of the enzyme. If so, the peptide binders themselves may be useful in a highthroughput screen involving the displacement of the peptide binder from hsGFA1 by a small molecule. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GLUTAMINE'S ROLE IN CARDIOPROTECTION FROM CARDIAC BYPASS Principal Investigator & Institution: Wischmeyer, Paul E.; Anesthesiology; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The Principal Investigator, Dr. Wischmeyer has the long-term goal of pursuing independent clinical investigation in the field of nutritional pharmacology. Receipt of a Mentored Patient-Oriented Research Career Development
24
Glutamine
Award will facilitate the growth of Dr. Wischmeyer's investigative skills and experience by expanding his knowledge of clinical research design and the use of molecular and metabolic assay techniques in human research. The learning objectives set out in this proposal, combined with the support of his mentor, Dr. Robert Eckel and the critical environment within the Department of Anesthesiology, the Department of Surgery, and the Training Program in Clinical Sciences at the UC, will foster Dr. Wischmeyers's progression to independent lines of investigation into the clinical applications of nutrition to clinical states of tissue injury and critical illness. The specific aims of this proposal will extend previous pre-clinical research by Dr. Wischmeyer demonstrating a protective effect of the amino acid glutamine (GLN) on myocardial ischemia/reperfusion (I/R) injury. This proposal aims to evaluate in a randomized, controlled clinical trial the effect of pre-operatively administered, oral GLN on patients undergoing elective coronary artery bypass grafting (CABG) in which cardiopulmonary bypass is employed. Four immediate goals for the trial are defined: 1) Determine the effect of GLN on myocardial tissue injury. Comary effluent and plasma will be collected and analyzed for troponin, CKMB analysis. 2) Determine the effect of GLN on human atrial tissue heat shock protein content. Right atrial appendage tissue will be harvested from patients undergoing CABG surgery and analyzed for heat shock protein 72 and 27 content (Western analysis). 3) Determine the effect of GLN on enhancement of measures of metabolism in human atrial tissue. Right atrial appendage tissue will be harvested from patients undergoing CABG surgery and analyzed for tissue metabolism magnetic resonance spectroscopy (MRS). These measurements will include tissue ATP, ATP/ADP ratio, NAD/NADH content, lactate, glutamine, glutamate, and reduced glutathione content. 4) Determine the effect of GLN on post-operative cardiac function and overall patient outcomes. Data will be collected on cardiac function (cardiac output), occurrence of arrhythmias, need for vasopressor therapy, length of post-operative ventilation, ICU stay; and survival trends. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DENTICOLA
H2S
PRODUCTION
AND
VIRULENCE
OF
TREPONEMA
Principal Investigator & Institution: Chu, Lianrui; Research Associate Professor; Orthodontics; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2004; Project Start 01-SEP-2000; Project End 31-DEC-2007 Summary: This application is an extension of current research examining the association between H2S production and virulence of Treponema denticola. T. denticola has been identified as an important member of a consortium of microorganisms as etiologic in the initiation and progression of periodontal diseases. In addition, the existence of volatile sulfur compounds produced at destructive sites is a characteristic feature of periodontal diseases, with H2S as a major compound in this family. Nevertheless, the metabolic pathways used to produce H2S are not well understood. Previous studies suggest that glutathione present in host cells can be a substrate for H2S production. Recently, we have shown that T. denticola has the capacity to utilize glutathione as a substrate to produce high levels of H2S. We have identified three enzymes that are required for the successful metabolism of glutathione: gamma-glutamyltransferase (GGT), cysteinylglycinase (CGase), and cystalysin. GGT converts glutathione into Cys-Gly and glutamic acid; CGase catalyze Cys-Gly to Cys and glycine; and cystalysin digests Lcysteine into H2S, ammonia, and pyruvate. We have also demonstrated that the addition of cystalysin and L-cysteine resulted in apoptosis of HGF and PDL cells and
Studies
25
that glutathione was essential for lesion formation by T. denticola in an animal model. Based on these and other studies, three Specific Aims are proposed using biochemical, molecular genetic, and cell biologic studies to address the hypothesis that these three metabolic enzymes play a key role in T denticola pathogenesis. Specific Aim 1: To molecularly characterize the genes and proteins involved in converting glutathione to H2S. Specific Aim 2: To genetically characterize, by gene inactivation, the enzyme pathway of T. denticola that produces H2S from glutathione. Specific Aim 3: To measure the effects of the H2S/NH3 producing pathway on T. denticola virulence in vitro and in vivo. This application is designed to provide both seminal and critical information about the enzyme pathway of T. denticola to produce H2S from glutathione. The outcomes will elucidate the mechanisms of action that each member of the enzyme pathway plays in the virulence capacity of T. denticola. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEPATIC DRUG ELIMINATION IN PREGNANCY Principal Investigator & Institution: Vore, Mary E.; Professor and Director; Toxicology; University of Kentucky 109 Kinkead Hall Lexington, Ky 40506 Timing: Fiscal Year 2002; Project Start 30-SEP-1979; Project End 31-MAY-2006 Summary: (provided by applicant): This proposal focuses on the effects of estradiol and its metabolites on the function and expression of Mrp2 (ABCC2), the ABC transporter that mediates the biliary excretion of glucuronide and glutathione conjugates from the hepatocyte into bile. The proposal builds on our findings that 1) Mrp2-mediated transport of estradiol-17Beta-(Beta-D-glucuronide) (E217G) is essential for its cholestatic activity, 2) E217G causes endocytic retrieval of Mrp2 from the canalicular membrane that coincides with decreased bile flow, and 3) expression of Mrp2 protein, but not Mrp2 mRNA, is decreased in pregnancy. Aim 1 will test the hypothesis that transport of cholestatic E217G and the choleretic estradiol-3-glucuronide (E23G) by rat Mrp2 and human MRP2 is mediated by overlapping but non-identical substrate binding sites. We will use an Mrp2/MRP2 baculovirus expression system in Sf9 cells and probe the substrate binding sites of E217G vs E23G. We will also determine if women with intrahepatic cholestasis of pregnancy have polymorphisms in MRP2 that alter their transport of E217G vs E23G. Aim 2 will test the hypotheses that A) E217G causes endocytic retrieval of Mrp2 and other transporters critical to bile formation from the canalicular membrane leading to inhibition of flow, and B) agents that protect against cholestasis do so by either inhibiting Mrp2 transport of E217G or prevention of transporter retrieval. We will use confocal immunomicroscopy to monitor endocytic retrieval of transporters from and their exocytic insertion into the canalicular membrane. Aim 3 will characterize the changes in Mrp2 expression in pregnancy and test the hypotheses that A) estrogens mediate the decreased hepatic Mrp2 expression in pregnancy, B) Mrp2 is subject to transcript-specific translational control conferred by regulatory elements in the 5' or 3' untranslated regions of Mrp2 mRNA and C) pregnancy and estrogens increase the degradation of Mpr2 protein. We will use polysomal distribution analysis of Mrp2 mRNA, translation assays in HepG2 cells and determine the degradation half-life of Mrp2 protein in control, pregnant, and estrogentreated rats. Significance: Characterization of the mechanisms by which estrogens decrease Mrp2/MRP2 function and expression can lead to 1) improved drug therapy for women in pregnancy, 2) development of therapeutic measures to increase MRP2 function in cholestatic liver disease, and 3) methods to screen for cholestatic toxicity in drugs under development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26
•
Glutamine
Project Title: IL-8 IN CHONDROCALCINOSIS Principal Investigator & Institution: Bryan, Ru L.; Veterans Medical Research Fdn/San Diego Foundation of San Diego San Diego, Ca 92161 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2006 Summary: (provided by applicant): Calcification of the pericellular matrix in articular cartilage is highly prevalent in osteoarthritis (OA) and aging. The deposited crystals of calcium pyrophosphate dihydrate (CPPD) and/or hydroxyapatite (HA) can be released from the cartilage matrix and can trigger inflammation and promote the expression of connective tissue degrading enzymes, thereby contributing to further cartilage degradation. The expression of C-X-C chemokines including IL-8 and its receptors CXCR-1 and CXCR-2 has recently been demonstrated in chondrocytes, and these mediators all are up regulated in OA cartilage in vivo. Our preliminary studies demonstrated that IL-8 induces MMP-13, and promotes features of hypertrophic differentiation (type X collagen expression and transglutaminase activation) associated with heightened matrix calcification in vitro in articular chondrocytes. Base on our new data on IL-8 signaling and function in leukocytes and articular chondrocytes, we propose to advance understanding of how IL-8 signaling via CXCR1 and/or CXCR2 transduces hypertrophy and matrix calcification in articular chondrocytes. We will test the following hypothetical model: 1) Activation of p38 MAPK is essential for induction of the features of hypertrophic differentiation, matrix calcification and MMP-13 by IL-8 in articualr chondrocytes. 2) Pyk2 tyrosine kinase, associated with a Src family tyrosine kinase, plays a central role in activation of p38 MAPK in mediating such effects of IL-8 in articular chondrocytes. 3) CXCR1 and CXCR2 signal differentially to transduce the stimulatory effect of IL-8. 4) Phospholipase C (PLC) transduces CXCR1 and CXCR2 signaling to induce intracellular Ca2+ increase and protein kinase C (PKC) activation, which in turn, activate Pyk2 and alpha5beta1 integrin, respectively. 5) FAK, activated through alpha5-beta1 integrin, and Pyk2 differentially mediate CXCR1 and CXCR2 signaling to induce hypertrophic differentiation, matrix calcification and MMP-13 in articular chondrocytes. The completion of this study has the potential to provide a foundation for novel chemokine and signal transduction-based therapeutic strategies for treatment of chondrocalcinosis in OA and aging. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INHIBITION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN Principal Investigator & Institution: Berkman, Clifford E.; San Francisco State University 1600 Holloway Ave San Francisco, Ca 94132 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2006 Summary: Prostate cancer remains the most common male malignancy and the second most common cause of cancer-related mortality in most Western societies. The incidence of prostate cancer and corresponding mortality rates vary strikingly among ethnic, racial, and national groups with noteworthy high rates among African Americans. The identification of an upregulated and strongly expressed antigenic marker on prostate cancer cells, namely prostate specific membrane antigen (PSMA), has attracted a great deal of attention as a target for immunotherapy. More recently, it has been reported that PSMA possesses at least two specific enzymatic activities; the hydrolytic cleavage and liberation of glutamic acid from both gamma-glutamyl derivatives of folic acid and the neuropeptide NAAG (Nacetylaspartylglutamate). Although these enzymatic activities have been clearly identified, questions of medical interest remain to be answered for PSMA. Two such questions are: "What is the role of PSMA on the surface of prostate
Studies
27
cancer cells?" and "How would inhibiting PSMA affect the growth, proliferation, or regulation of prostate cancer cells?" Although the proposed research will not immediately address these questions, it is anticipated that the results of this work will provide the investigators with suitable tools to study these issues in future studies. Furthermore, it is likely that the enzymatic activity of PSMA could be exploited for chemotherapeutic strategies, one of which being the inhibition of its activity by small molecule inhibitors. The overall objective of the proposed work is to develop potent and selective inhibitors for PSMA. This will be accomplished by first conducting substrate studies to identify optimal structural frameworks for enzyme recognition. These frameworks will then be utilized in the design and development of a first generation of phosphonopeptide inhibitors of PSMA. The most promising and potent of these inhibitors will be then further elaborated with binding probes to identify and exploit auxiliary binding sites on the enzyme leading to enhanced inhibitory potency. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTEGRIN-TRANSGLUTAMINASE ASSOCIATED AND CELL ADHESION Principal Investigator & Institution: Belkin, Alexey M.; American National Red Cross Rockville, Md 20855 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2007 Summary: (provided by applicant): Interactions of cells with their neighbors and the surrounding extracellular matrix are critically important for normal physiological and pathological processes. The major goal of this project is to characterize the role of the newly identified integrin-binding adhesion coreceptor, tissue transglutaminase (tTG), in cell adhesion and adhesion-dependent cellular functions, including signaling and assembly of fibronectin (Fn) matrix. A number of deletion and point mutants, as well as chimeric constructs containing swaps with the a subunit of Factor XIII, a structural homologue of tTG which does not interact with integrins or Fn, will be employed to map the integrin- and Fn-binding sites on tTG. Dominant negative tTG mutants which retain integrin binding, but fail to interact with Fn, will be used in various assays designed to analyze the adhesive function of tTG. We will quantitate an increase in adhesion strength generated by integrin-associated surface tTG. A proposed bridging function of tTG in cell adhesion as a mediator of integrin-Fn interaction will be defined. We will test the ability of surface tTG to alter the overall pattern of cell-ECM recognition. The effects of tTG on integrin activation, clustering and cytoskeletal association will be studied. Since our initial data indicate the ability of tTG to alter activation of Rho and Rac GTPases, we will separate and define the roles of cell surface and cytoplasmic tTG in integrin-mediated and direct activation of Rho and Rac GTPases. Then, the contributions of Rho, Rac and their common downstream target, myosin II, to the unique phenotype of cells that express high levels of surface tTG, will be determined. We will also continue to analyze mechanisms of stimulation of Fn assembly by integrin-bound tTG. A hypothesis will be tested that binding of Fn to tTG or dual interaction of Fn with integrins and tTG exposes a cryptic self-assembly site in modules I9III1 of Fn, and thereby stimulates fibril formation. Finally, the effect of association with integrins on the ability of tTG to crosslink Fn will be examined. Together, the proposed experiments will provide novel insights into the role of tTG in cell adhesion, adhesion-mediated signaling and Fn matrix formation. Furthermore, our studies will define how adhesive and signaling functions of integrins are regulated by their association with tTG. Ultimately, this acquired knowledge will advance our understanding of basic mechanisms of cell-matrix interactions.
28
Glutamine
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INVESTIGATIONS ON GLUCONEOGENESIS Principal Investigator & Institution: Brunengraber, Henri; Professor and Chair; Nutrition; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2002; Project Start 01-JUL-2001; Project End 31-MAY-2004 Summary: (Scanned from the applicant's description) Gluconeogenesis plays a major role in the metabolic alterations, which threaten the health and the life of diabetic patients. We seek to expand our understanding of the dysregulation of gluconeogenesis in type I diabetics by a combination of clinical investigations, development of new techniques for measuring gluconeogenesis, and basic science studies in animals. Over the next three years, we plan to achieve the following specific aims: 1. To test the usefulness of measuring the hepatic flux ratio (pyruvate carboxylase)/(pyruvate dehydrogenase) as an index of liver insulinization in clinical investigations of type I diabetes. This ratio will be determined noninvasively via the 13C-labeling pattern of urinary phenylacetylglutamine. We plan to compare the gluconeogenic status of normal subjects and type I diabetics (kept in good control by an infusion of insulin, acutely deprived of infused insulin, and poorly controlled). The study will involve administering [3-13C]pyruvate, 2H2O [6,6-2H2]glucose, and phenylbutyrate, and assaying (i) the '3C-labeling pattern of urinary phenylacetylglutamine, (ii) fractional gluconeogenesis via the 2H enrichment ratio C5/C2 of plasma glucose, and (iii) the turnover of glucose. 2. To work out new procedures to determine fractional gluconeogenesis from the 2H enrichment ratio C5/C2 of plasma glucose in subjects ingesting 2H2O. The procedure will be applicable to small samples from children, and to glucose samples labeled with '3C in addition to 2H. 3. To characterize, in perfused livers from normal rats and diabetic BB rats, the involvement of ATP-citrate lyase in the gluconeogenic pathway, specifically in the transfer, from mitochondria to the cytosol, of oxaloacetate derived from lactate (which itself was formed during Con cycling and muscular exercise). We hypothesize that an active citrate cleavage pathway persists in the liver under non-lipogenic conditions such as starvation. This process contributes to the recycling of lactate to glucose and to the detoxification of xenobiotics via acetylation. We hope that the data of our investigations will help to devise new strategies for improving the treatment of type I diabetic patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: KETOGENIC DIET AND BRAIN AMINO ACID METABOLISM Principal Investigator & Institution: Yudkoff, Marc L.; Chief; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 01-JUN-1998; Project End 31-MAY-2004 Summary: (from applicant's abstract) The ketogenic diet is often used to control seizures in children who are resistant to antiepileptic drugs. The mode of action is totally unknown. The PI hypothesizes, based on their preliminary data, that one reason the ketone bodies (3-OH-butyrate and acetoacetate) are so effective in controlling seizures is that they increase the brain concentration of GABA (gamma amino butyric acid), a major inhibitory neurotransmitter, and lower the concentration of aspartate, an excitatory compound. Ketone bodies bring about these changes because they sharply reduce the rate of transamination of glutamate to aspartate. As a result, more glutamate becomes available for the synthesis of GABA. In astrocytes, more glutamate becomes available to the glutamine synthetase pathway. This results in increased synthesis of glutamine, a
Studies
29
highly effective precursor to GABA. They propose to test this hypothesis by developing a rat model of the ketogenic diet. The model involves the prolonged (from weeks to months) feeding of rat pups with either an artificial rat milk or an isocaloric amount of a high fat (ketogenic diet). They will use stable isotopes, e.g., 15N and 13C to measure rates of glutamate metabolism to GABA, aspartate and glutamine. Mass spectrometry is used as an analytical tool with which to measure stable isotopic abundance in amino acids and tricarboxylic acid cycle intermediates. The three specific aims are: (1) To test the above hypothesis; (2) To characterize the ketogenic diet: Is high fat feeding necessary, or could ketone bodies alone be fed? How rapidly do amino acid changes develop? How sustained are they? Are changes more pronounced in less mature animals?; and (3) To determine whether the ketogenic diet can ameliorate seizures in a standard rat model of epilepsy, and whether this therapeutic effect is associated with changes of amino acid levels that mimic those noted in control animals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LENS CATARACTOGENESIS
MEMBRANE
IN
RELATION
TO
HUMAN
Principal Investigator & Institution: Takemoto, Larry J.; Professor; Division of Biology; Kansas State University 2 Fairchild Hall Manhattan, Ks 665061103 Timing: Fiscal Year 2002; Project Start 01-JUN-1979; Project End 31-MAY-2007 Summary: (provided by applicant): Although posttranslational modifications of lens proteins play a causative role in biogenesis of human senile cataracts, surprisingly little is known concerning the identity of specific amino acids that are modified in these lenses. Nonenzymatic deamidation of asparagine and glutamine residues is probably the most prevalent modification occurring in the human lens, and studies from other tissues have suggested that resistance to deamidation is a general property of stable proteins. The central hypothesis of this proposal is that the aged human lens contains gamma/beta crystallins with very low rates of deamidation, and that if deamidation does occur, it could result in deleterious effects to the lens, such as the formation of high molecular weight aggregates, low molecular weight cleavage products, and eventual cataract. To identify and quantitate deamidation, we have developed a novel approach involving the use of synthetic peptide standards, HPLC, mass spectral analysis and Nterminal sequencing. This methodology will be used to identify and quantitate deamidation of specific residues from the high molecular weight aggregate and low molecular weight cleavage products, as well as total proteins from dissected nuclei of human cataractous and aged-matched normal lenses. Molecular modeling will be used to correlate known structural properties of crystallins, with their observed rates of deamidation. Finally, human gamma/beta crystallins containing specific residues found to be deamidated will be expressed in a recombinant system and characterized by various biochemical and biophysical methods. Together, this project will identify and quantitate deamidation of specific residues of gamma/beta crystallins in the aging normal and cataractous human lens, followed by determination of the consequences of these modifications upon the stability and structural properties of the expressed deamidated proteins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIFESPAN HYPOGLYCEMIA
NEURONAL/GLIAL
METABOLISM
DURING
Principal Investigator & Institution: Turner, Dennis A.; Professor; Surgery; Duke University Durham, Nc 27706
30
Glutamine
Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2004 Summary: (provided by applicant): The central hypothesis of this project focuses on protective strategies for enhancing neuronal metabolism during and after short-term hypoglycemia. Several related mechanisms will be studied using physiological and mitochondrial imaging techniques in acute hippocampal slices, following hypoglycemia. In particular, we will directly assess neuronal-glial metabolic inter-relationships by analyzing whether the "lactate shuttle" is altered as a function of age. We will also directly measure the presence or absence of mitochondrial permeability transition as a function of age. Because slice metabolism varies as a function of slice oxygenation, age of the tissue and slice conditions (i.e., interface versus submerged slice conditions), direct oxygen tension measurements will be performed in the tissue using a Clark-style oxygen microelectrode at the same depth as the electrical recordings. The oxygen tension monitoring will ensure that metabolic substrate provision is controlled appropriately within the slice. Neuronal-glial metabolic interactions will be analyzed using glial poisoning with fluoroacetate to estimate direct neuronal contribution to glycolysis and aerobic metabolism, by substituting lactate and pyruvate. Pyruvate will be assessed as a potential treatment for preventing hypoglycemic damage. Occurrence and prevention of mitochondrial permeability transition with these stresses will also be assessed, using cyclosporin A and newer analogs such as N-Me-VaI-CSA. Analysis of these mechanisms which lead to enhanced susceptibility to neuronal damage following hypoglycemia are likely to lead to enhanced treatment. Mechanisms of neuronal injury are expected to vary depending on the duration and severity of the hypoglycemia, and the age of the animal from which hippocampal slices were harvested. These in vitro slice models of hypoglycemia will contribute greatly to the understanding of neuronal metabolism, and particularly the metabolic interactions between neurons and glia as a function of lifespan. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LONG-TERM IMPACT AND INTERVENTION FOR DIARRHEA IN BRAZIL Principal Investigator & Institution: Guerrant, Richard L.; Professor; Internal Medicine; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2002; Project Start 01-MAY-1989; Project End 31-JUL-2004 Summary: Having defined the magnitude, major new etiologies, key novel mechanisms and short-term impact of persistent diarrheal illnesses and even certain "asymptomatic" enteric infections in a model collaboration and cohort of children born into active prospective surveillance in an urban shantytown in Northeast Brazil, we are now have a unique opportunity to define for the first time the long-term DALY (disability adjusted life years) impact of early childhood enteric infections on nutritional status defined by anthropometry, physical activity and fitness, and cognitive function over extended periods (even years later). We postulate, based on our short-term impact data, that the greatest long-term impact will occur in children with persistent diarrheal illnesses and in those with low height-for-age Z (HAZ) scores. Having also shown the potential shortterm benefits of a new glutamine-based oral rehydration and nutrition therapy (ORNT) and of vitamin A (with studies of zinc pending) on speeding the repair of damaged intestinal barrier function, we can now determine the potential long-term benefits of glutamine-based ORNT, with vitamin A and zinc therapy (targeting children with persistent diarrhea or reduced HAZ, as noted above). We shall also examine the intermediate (ie 1- 6 months) and long-term (greater than 6 months) effects of specific emerging enteric infections we have found to be important, enteroaggregative E. coli,
Studies
31
and Cryptosporidium parvum. Coupled with our new developments of stable glutamine derivatives, the above data on full long-term DALY impact of persistent diarrhea, enteric infections and malnutrition, and the data on benefits of glutaminebased ORNT with vitamin A and zinc will ultimately allow us to calculate a much more meaningful cost-effectiveness (in "dollars per DALY averted) of selected treatment of high risk children (ie any with a persistent diarrheal illness that extends greater than 14 days, or a height for age Z score of less than 0.5). This model, longstanding collaboration and prospective field cohort surveillance will also enable the use of molecular tools currently being developed to define the epidemiology and microbiology of such newly recognized major agents as enteroaggregative E. coli as well as opening new opportunities to train both US and international scientists in highly relevant bench and field investigation. This pioneering work builds on our unique opportunity to define for the first time the potentially huge (developmental and economic) burden of early childhood enteric infections, as well as holding promise for demonstrating a key intervention targeted at the most vulnerable subset of the population in greatest need. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT & INHIBITION Principal Investigator & Institution: Horwitz, Marcus A.; Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-APR-1998; Project End 31-MAR-2004 Summary: (Adapted from the applicant's abstract): Tuberculosis is the world's leading cause of death from a single infectious agent. The emergence of multidrug resistance tuberculosis poses a major new threat to the public health, giving new urgency to research aimed at combating this ancient scourge. The development of new strategies to prevent and treat tuberculosis requires more basic knowledge about the key molecules of the organism that allow it to infect the host. One such key molecule is glutamine synthetase. M. tuberculosis glutamine synthetase has three remarkable and very important characteristics, all discovered in the investigator's laboratory during the past three years. First, it is one of the major extracellular proteins and its export by the bacterium is highly correlated with pathogenicity, i.e., pathogenic mycobacteria secrete the enzyme but nonpathogenic mycobacteria do not. Second, its export, which does not involve a signal peptide, is determined by its amino acid sequence, making it an ideal model protein for studying signal peptide-independent protein export. Third, inhibition of its extracellular enzyme activity inhibits its growth both in broth and within human macrophages, making it an extraordinarily accessible and promising target for new antibiotic development. This project has two major goals. First, the investigators seek to use molecular biological approaches to map which amino acids govern the export of M. tuberculosis glutamine synthetase. Second, building upon their studies of a parent compound that inhibits the glutamine synthetase activity and growth of M. tuberculosis and upon their collaborative studies of the high resolution 3-dimensional structure of M. tuberculosis glutamine synthetase, they hope to develop more active entities than the parent compound and thereby to develop a new antibiotic against M. tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MCH MODULATION OF NEUROTRANSMISSION IN THE LH AREA Principal Investigator & Institution: Gao, Xiao-Bing; Child Study Center; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047
32
Glutamine
Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2006 Summary: (provided by applicant): In this proposal, the role and mechanism of melanin-concentrating hormone (MCH) in the regulation and function of the lateral hypothalamus (LH) at the cellular level will be addressed. In feeding regulation LH plays a key role and has been considered as a feeding center. The regulation of food intake is crucial in energy- balance homeostasis. Unbalanced energy accumulation leads to obesity. MCH is a cyclic 19-amino-acid peptide. A substantial body of evidence from systemic, morphological and molecular biological studies suggests that MCH is involved in feeding regulation. However, there is little evidence as to the physiological role of MCH in LH neurons at the cellular level. Also there is little evidence as to how MCH and other neuropeptides interact in LH neurons. Furthermore, there is little data about the cellular physiology as well as properties of neurons and neuronal organization in the LH area. In this proposal, electrophysiological methods (including extracellular recording, whole-cell voltage and current clamp recording), immunocytochemistry and digital calcium imaging will be employed in cultured neurons and acute hypothalamic slices from rats. The chief hypothesis to be tested is that MCH acts as an inhibitory neuropeptide to modulate neuronal activity in the LH. The following hypotheses will be examined: 1. MCH depresses the activity-dependent gene transcription. 2. MCH inhibits the function of voltage-dependent calcium channel subtypes via distinct signaling pathways. 3. MCH depresses glutamatergic and GABAergic synaptic transmission in the LH slices. 4. Characterization and organization of MCH responding neurons in LH slices will be documented. This proposal will begin to bridge the gap between molecular research and systemic studies on the regulation of feeding to benefit those suffering from obesity and obesity-related diseases. The applicant's previous work in characterizing the cellular physiology of the newly discovered neuropeptide hypocretin/orexin is the first step in his journey to pursue his long-term goal of understanding neurotransmission in the LH. The funding of this research proposal is important for the applicant to continue this course. A career development plan is also documented in this proposal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM CYTOTOXICITY
OF
ANDROGEN
RECEPTOR
INDUCED
Principal Investigator & Institution: Lafevre-Bernt, Michelle; Buck Institute for Age Research Novato, Ca 94945 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2005 Summary: (provided by applicant): Kennedy's disease, or spinal and bulbar muscular atrophy (SBMA) is caused by an expansion of CAG repeats (which encode for glutamine) in the 5' end of the coding region of the androgen receptor (AR) gene. It is one of nine polyglutamine repeat diseases that cause the selective loss of neurons in selective regions of the brain. Seven of the polyglutamine repeat proteins, including AR, are substrates for caspases. Therefore it is important to understand the role of caspase activation and proteolysis in polyglutamine repeat-mediated cell death. The specific aims of this proposal are: (1) To determine if the toxic fragments generated by caspasemediated proteolysis of AR interact with full-length AR and disrupts its function. (2) To determine which protein interaction domains are required for the caspase-7 and AR apoptosome-like complex. (3) To determine which initiator caspases are important in androgen receptor induced cell death. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: MENTORED DEVELOPMENT
PATIENT
ORIENTED
RESEARCH
33
CAREER
Principal Investigator & Institution: Escolar, Diana M.; Associate Professor of Neurology & Pedia; Children's Research Institute Washington, D.C., Dc 20010 Timing: Fiscal Year 2002; Project Start 10-AUG-2001; Project End 31-JUL-2006 Summary: (provided by applicant): The applicant is a neurologist and has extensive clinical experience in pediatric and adult neuromuscular diseases. This award will allow her to obtain the training and mentoring to become an independent clinical investigator focusing on neuromuscular disorders. The educational plan includes didactic courses covering epidemiology, statistics, clinical trial design and health policies. DMD is a relatively common fatal genetic disease in children, with equal incidence throughout the world. The goal of this research is to conduct therapeutic human clinical trials with chemicals shown to improve muscle strength in the mdx. The aims of the proposed research plan are: 1) to conduct a double-blind, placebo-controlled, three-arm clinical trial of creatine and L-glutamine in patients with DMD and to assess the effect of these compounds on muscle strength as measured by manual muscle testing (MMT), quantitative muscle testing (QMT) and other functional measurements. Aim 2 is to conduct a double-blind, placebo- controlled clinical trial of coenzyme Q10 (CoQ10) in patients with DMD to assess its effects on: a) muscle strength, measured by QMT, compound Medical Research Council (MRC) score and functional measures; b) exercise capacity, to be measured by a fatigability protocol; and c) quality of life, to be measures by the Child Health Questionnaire. Aim 3 is to validate the specificity of the pediatric QMT system measuring maximal voluntary isometric contraction sequentially in children with DMD. The studies will be conducted at Pediatric Clinical Research Center (PCRC) at the Children's National Medical Center (CNMC), satellite to Georgetown General Clinical Research Center (GCRC). Three cores of the PCRC will be involved: the Biostatistics Core, the Genetics Core Laboratory and the Bioanalytical Core Laboratory. In addition, to increase the statistical power of this study, the applicant has assembled an international collaborative group that will conduct identical protocols and submit the data to the study center at CNMC. Future studies will test several other drugs with potential to improve muscle strength in DMD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METABOLISM AND EXCITABILITY IN RODENT HIPPOCAMPUS Principal Investigator & Institution: Williamson, Anne D.; Assistant Professor; Neurosurgery; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-JAN-2007 Summary: (provided by applicant): Both excitatory and inhibitory synaptic transmission rely on the supply of glutamate. Glutamate is synthesized de novo from glucose and also recycled through the glutamate-glutamine cycle between neurons and astrocytes. GABA used for synaptic transmission is also dependent on neuronal-glial cycling as GABA is synthesized from glutamate which can enter interneurons either via uptake or through glutamine. The main goal of this proposal is to test the broad hypothesis that cellular excitability is intimately tied to the status of glutamate-glutamine-GABA cycling and specifically that GABAergic transmission is more sensitive than excitatory transmission to disruption in cycling during periods of sustained neuronal activity because of the added energy-dependent steps needed for the synthesis of GABA. In Specific Aim 1 we will interrupt cycling a several different levels including blockade of the synthetic enzymes of glutamine, glutamate and GABA as well as by blocking
34
Glutamine
glutamine uptake. The effect of these metabolic inhibitors on synaptic inhibition will be examined physiologically. In Specific Aim 2, we will use mass spectometry to measure the changes in the levels of glutamate, glutamine and GABA induced by alterations in neurotransmitter cycling in both the tissue and in the bathing medium to address the time-dependent changes in transmitter levels. In Specific Aim 3 will use 13C isomer spectroscopy to assess the effect of those compounds that cross the blood brain barrier (the GS inhibitor methionine sulfoximine and the glutamine transporter MeAIB) on glutamate-glutamine-GABA cycling in control animals. These experiments should provide important data on the regulation of normal synaptic transmission as well as an understanding of the pathology of a number of neurological disorders where changes in neural energetics have been seen including epilepsy, ALS and Huntington's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODELS OF SBMA MOTOR NEURON DEGENERATION Principal Investigator & Institution: La Spada, Albert R.; Assistant Professor; Laboratory Medicine; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-JUN-2001; Project End 31-MAY-2005 Summary: X-linked spinal and bulbar muscular atrophy (SBMA or Kennedy's disease) is a progressive neuromuscular disorder characterized pathologically by degeneration of lower motor neurons. In 1991, expansion of a CAG trinucleotide repeat was identified in the coding region of the androgen receptor (AR) gene of SBMA patients. In addition to SBMA, seven other neurodegenerative disorders are caused by CAG repeat expansions that encode elongated polyglutamine tracts. Molecular and genetic studies of the CAG/polyglutamine repeat diseases suggest that the polyglutamine tract expansion has a toxic gain-of- function effect, the basis of which remains unknown. The purpose of this grant proposal is to determine the molecular basis of neuronal cell death in SBMA. To achieve this goal, we have initiated studies aimed at recapitulating AR polyglutamine neurotoxicity in mice and in cell culture. For producing an in vivo model of SBMA, we have generated AR yeast artificial chromosomes (YACs) carrying 100 CAG repeats. These AR YACs have been introduced into the mouse germline by fusing yeast cells carrying the AR YACs with mouse embryonic stem (ES) cells. In addition to an in vivo model of SBMA, we are attempting to develop in vitro models of AR polyglutamine neurotoxicity. We have demonstrated cellular toxicity of mutant AR expression constructs in HEK-293T cells, a non-neuronal cell line. We are attempting to extend this finding to motor neuron-like cell lines, MN-1 and NSC-34, and are also establishing primary cultures of cortical, hippocampal, and spinal motor neurons. Once we have produced accurate in vivo and in vitro models of SBMA, we will examine the role of apoptotic pathways in SBMA pathogenesis by evaluating whether caspase activation and/or p53 participate in AR polyglutamine neurotoxicity. We will use our in vivo and in vitro models to determine what functions of the AR protein are required for SBMA disease pathogenesis. Animal and cell culture models of AR polyglutamine neurotoxicity will allow us to identify alterations in gene expression in diseased motor neurons and cell lines by performing microarray expression comparisons. As SBMA, amyotrophic lateral sclerosis and autosomal spinal muscular atrophy all show motor neuron cell death, any toxic factors or degenerative pathways that we identify in our studies may be relevant to these and other motor neuron diseases. In addition to allowing us to track the molecular events that lead to neuronal cell death, animal and cell culture models of SBMA will allow us to design novel treatments and test potential therapies for this motor neuron disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: ESOPHAGEAL CA
MOLECULAR
35
CORRELATES--OXALIPLATIN/5FU/XRT,
Principal Investigator & Institution: Pendyala, Lakshmi; Roswell Park Cancer Institute Corp Buffalo, Ny 14263 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: (Provided by applicant): There is a pressing need for new agents in the treatment of esophageal cancer and to identify intratumoral molecular markers predictive for tumor response to chemotherapy. Although cisplatin/5-fluorouracil (5FU) plus radiation (XRT) is considered standard therapy for patients with locally advanced esophageal cancer, distant tumor recurrence, representing chemotherapy failure, is the rule. Moreover, the toxicity profile for cisplatin may be disabling. Oxaliplatin (OXP) a diaminocyclohexane platinum complex has a more manageable toxicity profile. Clinical/pre-clinical data suggest OXP-5FU synergy; mechanisms behind the synergy are not understood. Prior studies have shown that response and survival after therapy with 5FU (colon cancer) or 5FU/cisplatin (gastric cancer) are inversely associated with thymidylate synthase (TS), dihydropyrmidine dehydrogenase (DPD) and the excision repair cross-complementing-1 (ERCC-1) gene expressions. Studies of OXP resistant cell lines indicate that resistance is multifactorial, as evidenced by lowered drug accumulation, increased glutathione and decreased DNA-Pt adducts. Resistant cells also had elevated expression of gamma-glutamyltranspeptidase (gamma-GT) and ERCC- 1 genes. Thus, the underlying hypotheses in this application are: A) molecular markers within a primary esophageal tumor will predict sensitivity or resistance to chemotherapy, B) oxaliplatin affects 5FU by lowering TS gene expression and C) pharmacokinetics (PK) of OXP will influence the changes in gene expression. The specific aims of this study are to determine: 1) the intra-tumoral mRNA expression of TS, DPD, gamma-glutamylcysteine synthetase (gamma-GCS), gamma-GT, multidrug resistance associated protein-2 (MRP-2), ERCC-1 and xeroderma pigmentosum A (XPA) at pretreatment, 1 week after OXP alone, and after 1 cycle (with 5FU/radiation), exploring the relationship between these expression levels and response/resistance to treatment; 2) the PK of ultrafilterable platinum on day 1 when OXP is given alone and again on day 15 a week after combination with 5FU + XRT and 3) the relation between PK and changes in intratumoral gene expression and 4) maximum tolerated dose (MTD), dose limiting toxicity (DLT), and the potential therapeutic responses to OXP when given with continuous infusion 5FU + XRT. The gene expression studies will be carried out using real time quantitative RT-PCR (Taqman( r )) assays in endoscopic biopsies. Preliminary results indicate that the regimen is tolerable, the proposed gene expression measurements can be carried out using endoscopic biopsies and changes in gene expression are being detected for some genes during therapy. The long term objectives are to identify a drug combination for better clinical outcome and to identify molecular parameters predictive for response or resistance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MRS STUDIES OF CORTICAL GABA IN DEPRESSION Principal Investigator & Institution: Sanacora, Gerard; Assistant Professor; Psychiatry; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-JUN-1999; Project End 31-MAY-2004 Summary: (adapted from applicant's abstract): I have been fortunate to work in stimulating environments that have afforded me substantial opportunities to engage in research training throughout my graduate (M.D., Ph.D.) and residency training. In July,
36
Glutamine
I will continue my training an additional year with the Daniel X. Freedman Clinical Neuroscience Fellowship at Yale University. However, without support from a K08 award, I would be required to assume substantial clinical responsibilities in order to support my salary when I join the Yale faculty in July, 1999. I have designed this K08 award to enable me to pursue a comprehensive five-year research-training Plan. This plan will provide me with the background and skills necessary to become an independent investigator-using novel magnetic resonance spectroscopy (MRS) techniques. I would like to apply these techniques to the study of GABA and glutamate neurotransmission related to the pathophysiology and treatment of affective disorders. Over the past two years I have developed basic skills in-proton-MRS (1H-MRS). We have produced exciting preliminary data describing reductions in cortical GABA associated with depression, and elevation of cortical GABA levels following electroconvulsive therapy (ECT). I propose to continue these investigations with two aims. 1) To fully characterize both GABAergic and glutamatergic systems in affective disorder disease states. (Years 1-3) and 2) To use pharmacological probes along with [13C]-MRS to examine possible pathophysiological mechanisms related to amino acid neurotransmitter regulation in depression. In order to advance the use of MRS applications in the study of affective disorders, I have identified several key areas where I will require additional training including: 1) nuclear magnetic resonance, 2)1 neurochemistry, kinetic modeling, and related neuroimaging technologies, 3) clinical and basic neuropharmacology applicable to affective disorders research; and 4) clinical trials methodologies. I believe my background in the basic sciences will enable me to complete the rigorous training plan outlined in this application. This training along with continued practical application of the technology under the co-mentorship of Drs. Rothman and Krystal should thoroughly prepare me for a career as an independent investigator using MRS technology to study brain neurochemistry. This novel line investigation will open previously inaccessible areas of research, with a broad range of future applications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF NEONATAL INTENSIVE CARE UNITS Principal Investigator & Institution: Tyson, Jon E.; Professor Pediatrics; Pediatrics; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, Tx 77225 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: The PI is Jon Tyson, MD, MPH, is the Michelle Bain Distinguished Professor of Medicine and Public Health, Director of the Center for Population Health and Evidence-Based Medicine, and a Professor of Pediatrics, Obstetrics, and Epidemiology at UT Houston. Th Co-PI is Kathleen Kennedy, MD who is an Associate Professor of Pediatrics and the Director of the Perinatal Epidemiology Program UT Houston was added to the Network in 1998 when the PI and Co-PI moved from UT Southwestern. UT Houston provides: A. A large and growing patient population. A total of 9,000 total births and 350 VLBW infants are projected this year for our 2 teaching hospitals: Memorial Hermann Hospital (a private hospital with an expanding referral base including 9 hospitals in the Memorial Hermann system [3 staffed by our Ob. Faculty]) and Lyndon Baines Johnson Hospital (a large county hospital with an increasing population). UT Houston's enrollment in the Glutamine Trial exceeds that for all but 2 of the other 13 Network centers. B. Strong, and highly supportive leadership at UT Houston. The Dean (Max Buja, MD) recruited Dr. Tyson to promote clinical research. The Ob. Chairman (Larry Gilstrap) is a perinatal investigator and Network consultant.
Studies
37
The Pediatrics Chairman (John Sparks, MD) is a neonatologist and Network advocate. The Neonatology Director (Fernando Moya, MD) is Hermann Physician of the Year and skilled in conducting clinical research, eliciting hospital support, and augmenting enthusiasm for Network studies. C. An experienced and highly committed PI and Co-PI. Dr Tyson has been a PI for 13 years; Dr. Kennedy, Co-PI for 9 years and acting PI for 1 year. In the past 4 years, they have been an author on 16 Network publications, 3 as 1st author; 3 as 2nd author, and 1 as 3rd author. (4 of these were published in New England Journal or JAMA.) In moving to Houston, Dr. Tyson petitioned NICHD to include both UT Southwestern and UT Houston (rather than UT Houston only) in the Network and has served as PI for both. He has helped the Co-PI at UT Southwestern to apply as PI there for the next funding cycle. Dr. Tyson has involved multiple other faculty and fellows in the Network including Robert Lasky, PhD a developmental psychologist with expertise in neural processing; Terri Major-Kincade, MD,MPH, 1st recipient of the Network Specialized Clinical Investigator Development Award; and Martin Blakely, MD a pediatric surgeon whose K23 proposal (Dr. Tyson as mentor) is focused on Network studies. D. Methodological and multidisciplinary expertise. The Network can further advance the methods of clinical research and enrich the evaluation of important neonatal issues. Dr. Tyson is an epidemiologist and neonatologist, the PI for the NIHfunded Clinical Research Curriculum, and Director of the Master's Degree Program in Clinical Research to start here. The Center for Population Health and Evidence- Based Medicine that he directs includes 9 faculty with expertise in clinical or population-based epidemiology, biostatistics, developmental psychology, health care economics, and/or bioethics; 3 of these faculty are now involved in Network studies. John C. Sinclair, MD, an eminent neonatologist, clinical epidemiologist, and Network advisor, will join the Center Jan. 2001. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NMR STUDIES OF GABA METABOLISM AND REGULATION IN VIVO Principal Investigator & Institution: Behar, Kevin L.; Professor; Neurology; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 22-JUL-1996; Project End 31-JUL-2005 Summary: (Verbatim from the Applicant's Abstract) For the last 10-15 years our laboratory has had a major role in the development and use of new spectroscopy and imaging techniques in vivo to study the regulation of pathways of brain glucose metabolism. Over the last 4 years of this grant we reported a number of important findings which indicate that release of glutamate and GABA from neurons and their cycling between neurons and glia has a major influence on brain energy metabolism and that the isoforms of a key enzyme of GABA synthesis, glutamic acid decarboxylase (GAD) mediate different proportions of total GABA synthesis. Our central hypothesis is that specific GAD isoforms and supply routes of glutamate carbon play key roles in regulating GABA synthesis and GABA neurotransmitter cycling. We propose the following specific aims: 1a) Determine the relationship between the rates of GABA synthesis, GABA neurotrasmitter cycling, and glutamate/glutamine cycle over a wide range of cortical metabolic activity. 1b) Assess the role of cofactor interaction and phosphorylation of the GAD isoforms in the regulation of GABA synthesis and GABA/glutamine cycling flux. 2) Investigate the role of GAD isoforms in regulation of GABA cycling flux through the two glutamate precursor pathways using GABAtransaminase inhibition and GABA elevation to selectively alter GAD isoform composition. 3) Quantitate the key metabolic pathway fluxes that supply glutamate
38
Glutamine
precursors for GABA synthesis and GABA/glutamine cycling. 4) Determine the relationship between vesicular and non-vesicular GABA, precursor glutamate pathways, and GAD isoforms using diffusion-sensitized MRS in vivo. Using Magnetic Resonance spectroscopy (MRS) and 13C-labeled isotopes in vivo, and enzymatic assays in vitro with pharmacological and molecular biological interventions, we will examine the role of GAD isoforms and glutamate precursors in GABA synthesis and GABA neurotransmitter cycling The uniqueness of this project derives from i) the combination of the these techniques, ii) the track record of the investigator in addressing such questions using MRS, and iii) it complements ongoing clinical investigations of GABA and glutamate metabolism in epilepsy and neuropsychiatric disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NONVESICULAR GABA RELEASE VIA GABA TRANSPORTER REVERSAL Principal Investigator & Institution: Richerson, George B.; Associate Professor; Neurology; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2006 Summary: As one of the most common neurological diseases in this country, epilepsy affects approximately 2.5 million Americans. Drugs used to treat epilepsy often target neurotransmission, and their design and use would be advanced by a better understanding of the mechanisms of neurotransmission. It is commonly assumed that neurotransmitters are only released by synaptic vesicle fusion. However, our recent studies suggest that GABA transporters reverse during seizures, resulting in GABA efflux. This "nonvesicular" GABA release inhibits neurons, and is also the target of a new class of anticonvulsants, including gabapentin and vigabatrin. The current proposal extends this work by using rat neurons to address the following unanswered questions. What is the source of nonvesicular GABA release: neurons or glia? This will be examined using neuronal vs. glial specific GABA transporter antagonists in pure neuron, pure glia or mixed cultures. How do changes in cytosolic [GABA] affect vesicular GABA release? The effect on vesicular and nonvesicular GABA release of increasing or decreasing cytosolic [GABA] will be compared. How commonly is nonvesicular GABA release modulated by anticonvulsants? The effects on nonvesicular GABA release of pregabalin, topiramate, levetiracetam, and tiagabine will be studied. How ubiquitous is nonvesicular GABA release? The role of nonvesicular GABA release will be studied in brain slices from the hippocampus, neocortex, striatum, cerebellum and medulla. Does the glutamate transporter reverse as easily as the GABA transporter? The threshold for nonvesicular glutamate release will be determined. We propose that the GABA transporter reverses as part of a fail-safe negative feedback system. If the glutamate transporter reversed so easily, it would lead to runaway excitotoxicity. The proposed experiments are designed to answer fundamental questions about the newly recognized role of the GABA transporter in inhibition of seizures, and the mechanism of action of anticonvulsants. A complete description of GABA transporter function should help define the pathophysiology of epilepsy, and lead to a better understanding of how and when the new anticonvulsants should be used. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PHOSPHOLIPASE DIFFERENTIATION
C-GAMMA-1
IN
MEDIATING
Principal Investigator & Institution: Bikle, Daniel D.; Professor; Northern California Institute Res & Educ 4150 Clement Street (151-Nc) San Francisco, Ca 941211545
Studies
39
Timing: Fiscal Year 2003; Project Start 20-SEP-2003; Project End 31-JUL-2008 Summary: Phospholipase C-gamma1 (PLC-gamma1) plays a critical role in calcium induced differentiation in part because of its ability to maintain high levels of intracellular calcium (Cai) through the provision of two important second messengers, inositol tris phosphate (IP3) and diacyl glycerol (DG). IP3 stimulates the release of calcium from intracellular stores by activating its receptor IP3R, a calcium channel in the endoplasmic reticulum and Golgi, whereas DG activates the classic and novel protein kinases C. Preliminary findings from our laboratory have demonstrated two pathways mediating calcium-induced activation of PLC-gamma1 in normal keratinocytes: one via src kinases and the other via phosphatidylinositol 3 kinases (PI3K). Furthermore, in normal keratinocytes much of the PLC-gamma1 colocalizes in the cell with other members of the calcium-signaling pathway including the calcium receptor (CaR), the IP3 receptor (IP3R), and the Golgi calcium pump (ATP2C1) suggesting an intimate interaction between PLC-gamma1 and the molecular regulators of intracellular calcium levels. Accordingly we propose the following hypothesis: PLC-gamma1 plays a central role in the mechanism by which calcium induces keratinocyte differentiation. Calcium activates PLC-gamma1 through src kinases and PI3K and promotes its interaction with regulators of Cai stores such as the IP3R and Golgi calcium pump (ATP2C1) that provide for the sustained increase in Cai essential for differentiation. To test this hypothesis we propose 4 specific aims. In the first two aims, we will explore the mechanisms by which calcium activates PLC-gamma1 in normal cells. In the third aim we will examine whether PLC-gamma1 activation by src kinases and PI3K is required for its interaction with IP3R and ATP2C1. In these aims we will compare the effects of calcium to those of EGF, which also activates PLC-gamma1 but stimulates proliferation rather than differentiation, with the expectation of finding differences between the two with respect to the mechanism of PLC-gamma1 activation. Because differentiation in vitro does not achieve the final product, namely the formation of a competent permeability barrier, in the fourth aim we will develop an in vivo model to analyze the impact of selectively deleting PLC-gamma1 expression with respect to the program of differentiation leading up to the development and regulation of the permeability barrier. Calcium signaling and calcium induced differentiation in the keratinocytes from these animals will also be studied in vitro to evaluate the comparability with earlier studies of human keratinocytes in which the PLC-gamma1 gene was knocked out by antisense techniques. These studies will increase our understanding of keratinocyte differentiation and may provide therapeutic targets for diseases in which epidermal differentiation is abnormal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT--BIOCHEMISTRY AND FUNCTION OF A NOVEL SECRETED KERATINOCYTE PROTEIN Principal Investigator & Institution: Ariizumi, Kiyoshi; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2006 Summary: The barrier function of skin against noxious environmental agents is provided primarily by the cornified cell envelop (CE) in the outer portion of the epidermis. The CE is a protein complex tightly assembled by transglutaminase (TGasemediated cross-linking of several structural proteins (e.g., involucrin). Using a signal sequence trap method, we have identified a novel secreted protein, KCS-1, that contains a leucine- zipper-like structure which is known to be responsible for dimer- formation of some transcription factors. KCS-1 is expressed specifically by keratinocytes (KC) of
40
Glutamine
epithelial tissues, localized to the CE in normal human epidermis. It is up-regulated in the skin of psoriatic patients with inflammation and microbial infection, and displays anti-proteinase activity. These findings suggest that KC secrete some KCS-1 proteins (as a dimer form) into the epidermal extracellular space, some of which are trapped into the CE by TGase and some remain as free dimers inside cells. Environmental stress and tissue damage induce abundant expression of proteinase in the epidermis that is likely to be a major mediator to delivery danger (or stress) signals to KC. We thus hypothesize that KCS-1 expression is inducible by environmental stresses and it functions as a intraand extracellular proteinase inhibitor to quench the potentially damaging effects of these harmful proteinases. Having characterized the biochemical and structural properties of KCS-1 in the previous one year funding period, we now propose to better illustrate functional properties of KCS-1, a new secreted inhibitor, in the proposed second year of funding. Functional characterization of KCS-1 will lead us to a better understanding of KC mechanisms that protect the skin and internal organs from environmental stresses and tissue damage. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT--REGULATION OF RENAL PYRUVATE DEHYDROGENASE DURING ACIDOSIS Principal Investigator & Institution: Harris, Robert A.; Professor of Pharmacology; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: The objective of this work is to establish the importance of regulation of the pyruvate dehydrogenase (PDH) complex in the kidney in maintenance of acid-base balance. Activity of the pyruvate dehydrogenase complex is regulated by covalent modification. Phosphorylation and inactivation of the complex is catalyzed by four pyruvate dehydrogenase kinase (PDK) isoenzymes; dephosphorylation by two pyruvate dehydrogenase phosphatase (PDP) isoenzymes. Unique regulatory properties of these isoenzymes and differences in their levels of expression in different cell types provide tissue specific control of the activity of the pyruvate dehydrogenase complex. The basis for this proposed work is our preliminary data indicating that two of the PDK isoenzymes, PDK2 and PDK4, are increased in the kidney by metabolic acidosis. We propose therefore that increased expression of these PDKs results in inactivation of pyruvate dehydrogenase complex, which promotes generation of new bicarbonate by the kidney. Our working hypothesis is that alterations in the expression of the PDK2 and PDK4 isoenzymes cause hyperphosphorylation and therefore inactivation of pyruvate dehydrogenase complex in kidney during metabolic acidosis. The hypothesis will be tested by: (a) determining the effects of acute and chronic metabolic acidosis and alkalosis on activity state of the PDH complex and the expression levels of its kinases and phosphatases in rat kidney; (b) determining whether the compensatory mechanism for metabolic acidosis is abnormal in the kidney of the PDK4 null mouse; and (c) establish factors and mechanisms that regulate expression of PDK2, PDK4, and PDP2 in the kidney. The findings are expected to provide new insight with respect to an important compensatory mechanism for life threatening metabolic acidosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: PILOT--SYSTEM NEUROTRANSMISSION
A
TRANSPORTERS
IN
41
GLUTAMINERGIC
Principal Investigator & Institution: Varoqui, Helene; Louisiana State Univ Hsc New Orleans New Orleans, La 70112 Timing: Fiscal Year 2002; Project Start 23-FEB-2002; Project End 31-JAN-2007 Summary: (provided by applicant): We have cloned and functionally identified cDNAs encoding the proteins SAT1 and SAT2 that are the first members of the system A family of Na+-dependent neutral amino acid transporters. Transport of system A substrates, such as glutamine, and alanine, in many cell types are highly regulated since these amino acids play important roles in neurotransmission, energy generation and in nitrogen metabolism. The identification of SAT1 and its neuron-specific expression is an unexpected discovery and suggests an important and unique role of SAT1 in synaptic transmission. The electrogenic uptake of these amino acids in peripheral organs is mediated by SAT2, and in neurons, SAT2 may provide alanine, as a nitrogen donor to alpha-ketoglutarate, to generate a metabolic pool of glutamate. Since glutamine is a critical precursor for neurotransmitter glutamate via the glutamate-glutamine cycle, it is reasonable to propose to test the hypothesis that these transporters play key roles in regulating the synthesis of the major excitatory transmitter in the brain. The purpose of this proposal is to study the regulation of these genes in glutamatergic neurons at the level of protein synthesis, as well as at the level of cycling between cellular compartments, in response to physiological and pathophysiological conditions, and to determine whether SAT1 and SAT2 are potential targets to modulate presynaptic glutamate synthesis and eventual exocytotic release. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POLYGLUTAMINE AGGREGATES Principal Investigator & Institution: Wetzel, Ronald B.; Professor; Medicine; University of Tennessee Knoxville Knoxville, Tn 37996 Timing: Fiscal Year 2002; Project Start 15-JUN-2001; Project End 31-MAY-2005 Summary: (Adapted from applicant's abstract): In the expanded CAG repeat diseases, such as Huntington's Disease, abnormally long polyglutamine sequences have been implicated as the principle causative factor of the disease. The mechanism by which these molecules promote neurodegeneration is not clear, but a large body of evidence suggests that the mechanism has something to do with the enhanced ability of lengthened polyglutamine sequences to self-associate into oligomers or aggregates. While there is an imperfect correlation of disease physiology with the appearance of large aggregates in cellular nuclei, there is also a lot of indirect evidence, such as the widely reported involvement of cellular chaperones, that a misfolding / aggregation process is involved in these diseases. One limitation in our ability to progress more deeply into the disease mechanism is our ignorance of the details of the process and products of polyglutamine aggregation. For example, improved correlation of disease development with polyglutamine aggregation might be obtained if it were possible to distinguish different sizes and types of aggregates. There is significant information on the behavior of polyglutamine sequences from cellular expression experiments, but, owing to the very poor solubility properties of these molecules, there is much less mechanistic and structural information on defined polyglutamine sequences at the in vitro chemical level. This application is based on recent advances in this laboratory in the ability to solubilize these molecules and control their aggregation in vitro. A series of chemically synthesized polyglutamine sequences of different lengths will be developed
42
Glutamine
and used to pursue the following aims. The length dependence of the kinetics and thermodynamics of the aggregation process will be characterized. The length dependence of aggregate structure will also be characterized. Mutational analysis o f the polyglutamine sequence will be conducted in order to better define the unique role of glutamine in aggregation and to better understand aggregate structure at the atomic level. Finally, the abilities of a series of molecular chaperones to retard and reverse the aggregation process will be characterized in vitro. The work should lead to a better understanding of the role of polyglutamine self-association in the disease mechanism and the nature of the toxic entity in turn; this should stimulate new work on the therapeutic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POLYGLUTAMINE NEURODEGENERATION
CONFORMATION
AND
Principal Investigator & Institution: Finkbeiner, Steven M.; Assistant Professor; J. David Gladstone Institutes 365 Vermont St San Francisco, Ca 94103 Timing: Fiscal Year 2003; Project Start 15-FEB-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Huntington's disease (HD) belongs to a family of at least eight inherited, untreatable neurodegenerative diseases. Each is caused by an abnormal polyglutamine (polyQ) expansion in a different protein. In each, disease occurs when the polyQ stretch exceeds a certain length and symptom onset is inversely related to its length. Abnormal deposits of protein called inclusion bodies (IBs) characterize many of these diseases. Whether IBs are pathogenic, an epiphenomenon, or a beneficial defense response is controversial. Abnormal polyQ expansions probably cause degeneration by conferring a toxic gain of function to proteins. PolyQ expansions may adopt a conformation that is different depending on whether huntingtin (htt) is in IBs or not. We hypothesize that abnormal polyQ expansion alters the conformation of soluble mutant htt, enabling it to interact with cellular targets and produce neurodegeneration, independent of IB formation. Certain heat shock proteins (HSPs) can protect cells against polyQ and regulate IB formation. It is unknown whether they act mainly on IBs, oligomers, or malfolded monomers. It is unknown whether htt needs to oligomerize to adopt a toxic conformation and whether the length or the composition of the polyQ stretch is critical to conformation or aggregation. We have used primary neurons to develop a model of HD that recapitulates polyQ-dependent and neuronspecific death and IB formation. We have also developed monoclonal antibodies that bind a conformation of htt that correlates closely with HD symptoms and which distinguishes htt in IBs from more soluble forms. Finally, we have built a robotic microscope so we can simultaneously measure IB formation within living neurons and then track their individual fates. We propose to use these tools to accomplish the following Specific Aims: Aim 1. To determine whether the availability of a diseaseassociated conformation is a better predictor of neurodegeneration than IB formation. Aim 2. To determine whether heat shock proteins regulate htt conformation and to relate the effects of heat shock proteins on neuronal survival to the effects on conformation and on inclusion body formation. Aim 3. To determine whether htt must oligomerize or contain a contiguous stretch of pure glutamine residues to form a disease-associated conformation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
43
Project Title: PPARS AND LXR IN KERATINOCYTE DIFFERENTIATION Principal Investigator & Institution: Feingold, Kenneth R.; Professor; Northern California Institute Res & Educ 4150 Clement Street (151-Nc) San Francisco, Ca 941211545 Timing: Fiscal Year 2003; Project Start 20-SEP-2003; Project End 31-JUL-2008 Summary: The major function of the epidermis is to provide a barrier between the external environment and the organism. To fulfill this function keratinocytes undergo a complex pathway of differentiation, culminating in keratinocyte cornification and in the formation of extracellular lipid-enriched lamellar membranes in the stratum corneum. Despite its great importance, the regulation of keratinocyte differentiation and the factors that allow for the coordinate formation of the corneocytes and extracellular lipid lamellar membranes are largely unknown. Recently it has been recognized that endogenous intracellular lipids activate PPARs and LXR. The ability of these nuclear hormones to sense cellular lipid levels, and then to regulate gene expression has led to the recognition that these receptors are "liposensors". We postulated that activation of these nuclear hormone receptor "liposensors", by the lipids generated during the formation of lamellar bodies and/or by metabolic products of these lipids, could provide a mechanism that coordinately regulates the formation of the corneocytes ("bricks") and extracellular lipid membranes ("mortar") during epidermal differentiation (Lipids->Activate Liposensors->Stimulate Expression of Proteins Required for the Cornified Envelope). As a first step in proving this hypothesis we have shown that activators of PPARs and LXR stimulate epidermal differentiation. In this proposal, we plan to focus on the molecular mechanisms by which activators of PPARs and LXR stimulate differentiation. Hypothesis: PPAR alpha, delta, gamma, and LXR activators stimulate keratinocyte differentiation by increasing the levels of AP-1 proteins, thereby stimulating the expression of a variety of key genes required for keratinocyte differentiation that contain AP-1 regulatory elements in their promoters. Aim 1. To determine if the stimulation of differentiation induced by PPAR delta and PPAR gamma activators is receptor mediated (Studies have already been completed for PPAR alpha and LXR activators during the current funding cycle). Aim 2. To determine if PPAR and LXR activation of AP-1 response elements is a general mechanism accounting for the increased expression of genes important in differentiation. Aim 3. To determine if activators of PPAR alpha, delta, gamma, and LXR increase AP-1 protein levels thereby increasing AP-1 activity and the functional importance of these increases. Aim 4. To determine the mechanism by which activation of PPARs and LXR increase AP-1 protein and mRNA levels we will localize the sites in the promoters of the AP-1 proteins that mediate the increase in expression induced by PPAR alpha, delta, gamma, and LXR activators. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROTEINS CARRYING ONE OR MORE UNNATURAL AMINO ACIDS Principal Investigator & Institution: Rajbhandary, Uttam L.; Professor of Biochemistry; Biology; Massachusetts Institute of Technology Room E19-750 Cambridge, Ma 02139 Timing: Fiscal Year 2004; Project Start 01-FEB-2004; Project End 31-JAN-2008 Summary: (provided by applicant): The major objective of this proposal is to develop methods for the site specific insertion of one or more amino acids analogues into proteins in eubacteria and in eukaryotes. The amino acid analogues to be used could include those that are photoactivatable, those that are fluorescent, those that carry
44
Glutamine
reactive side chains such as keto and azido groups, heavy atoms such as iodine, spectroscopic probes and those that mimic phospho-amino acids. Besides providing a method for the production of proteins with novel chemical and biological properties, proteins carrying such amino acid analogues will have wide applications in biology including studies on the folding, structure, stability and function of proteins, proteinprotein interactions, protein localization and protein dynamics in vivo, crystallographic structure analyses and signal transduction. Two approaches are proposed. The first consists of the use of an amber suppressor transfer RNA (tRNA) aminoacylated in vivo with an amino acid analogue with the help of a mutant aminoacyl-tRNA synthetase, to insert the amino acid analogue at a specific site in a protein. A second, more general, approach is based on the finding in the investigator's laboratory that suppressor tRNAs, including those that are aminoacylated, can be imported into mammalian cells. This finding opens up the possibility of importing suppressor tRNAs aminoacylated in vitro with a variety of amino acid analogues for the site specific insertion of one or more amino acid analogues into proteins. The specific aims are: (1)To isolate mutants of (i) yeast tyrosyl-tRNA synthetase, which aminoacylate amber suppressor tRNA with iodotyrosine, p-trifluoromethyl-diazirinylphenylalanine or p-azido phenylalanine and (ii) E. coli glutaminyl-tRNA synthetase, which aminoacylate amber suppressor tRNA with 2-amino 5-keto hexanoic acid, an analogue of glutamine in which the side chain CH2CH2CONH2 is replaced by - CH2CH2COCH3. (2) To identify, produce and purify amber and ochre suppressor tRNAs, which are not aminoacylated by mammalian aminoacyl-tRNA synthetases and which are highly active in suppression in mammalian cells. (3) To optimize the conditions for import of suppressor tRNAs aminoacylated with amino acid analogues into mammalian cells and to use them for site specific insertion into proteins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF BRAIN NEUROTRANSMITTER SYNTHESIS Principal Investigator & Institution: Hutson, Susan M.; Professor; Biochemistry; Wake Forest University Health Sciences Winston-Salem, Nc 27157 Timing: Fiscal Year 2002; Project Start 05-JUN-2000; Project End 31-MAY-2004 Summary: Glutamate is the most widely used excitatory neurotransmitter in the nervous system. Certain diseases and neurodegenerative disorders are thought to involve disturbances of the glutamatergic systems of the brain or retina. The goal of this proposal is to understand the mechanisms that regulate glutamate levels in the nervous system. Considerable evidence indicates that glial cells rapidly internalize glutamate released by neurons during neurotransmission converting it to glutamine before releasing it back to neurons in the glutamate/glutamine cycle. However, it is now clear that possibly as much as 50 percent of the glutamate taken up by the glia is actually converted to pyruvate and lactate. Therefore, the nervous system must regenerate the lost carbon by carboxylation of pyruvate catalyzed by the anaplerotic enzyme pyruvate carboxylase (PC) which is found is astroglia. Second, it now appears that rather than ammonia the essential branched chain amino acids (BCAA) are needed to provide sufficient alpha-amino nitrogen for optimal rates of de novo glutamate synthesis. Indeed, it is our hypothesis that the BCAA and branched chain aminotransferase isoenzymes (cytosolic BCATc, mitochondrial BCATm) participate in a nitrogen shuttle whereby the glial BCATm and neuron specific BCATc act in series to transfer nitrogen from neurons to astrocytes. The aims of this proposal are designed to understand the mechanisms that regulate glutamate levels in the nervous system and test the BCAA shuttle hypothesis. 1) We will develop methods to simultaneously measure the rate of
Studies
45
de novo glutamate synthesis and the rate of glutamate glutamine cyclin in the ex vivo retina and in brain in vivo and correlate the influence of neuronal activity with flux. Both H14CO3 and 13C NMR spectroscopy will be used in vivo for the kinetic analysis. 2) The function of the BCAT isoenzymes in regulating glutamate synthesis and brain neurotransmitter pool sizes will be quantified in vivo in brain and ex vivo in the retina. The hypothesis that the neuroactive drug gabapentin acts via specific inhibition of cytosolic BCATc will be tested. 3) The degree of control exerted by the anaplerotic enzyme pyruvate carboxylase (PC) relative to that of the BCAT isoenzymes will be assessed. Antisense technology will be used to vary enzyme levels in vivo. Data will be analyzed using control strength theory to determine the relative control strength of the BCAT and PC on the pathways of de novo glutamate synthesis. Finally, understanding the mechanisms that regulate glutamate synthesis will increase our knowledge of certain disease processes and may allow for future generation of novel therapeutic compounds. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF GLUTATHIONE SYNTHESIS IN OXIDATIVE STRESS Principal Investigator & Institution: Forman, Henry J.; Professor; Environmental Health Sciences; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 15-APR-1996; Project End 31-MAR-2005 Summary: (Adapted from the Investigators abstract). This proposal focuses on the signal transduction mechanisms regulating the increase in de novo glutathione (GSH) synthesis that occurs during adaptation to oxidants and other electrophiles. GammaGlutamylcysteine synthetase (GCS), the rate limiting enzyme in de novo GSH synthesis, is composed of two subunits. Both GCS genes are transcriptionally up-regulated in response to stress from oxidants and electrophilic xenobiotics. Nonetheless, a mismatch between expression of the two GCS subunit proteins may result in altered kinetics and/or decreased stability of the enzyme. gamma-Glutamyl transpeptidase (GGT) is an exoenzyme that provides substrates for GSH synthesis by breaking down extracellular GSH. GGT enzymatic activity and mRNA transcription also increases in response to oxidants. While much has been learned over the past few years regarding mechanisms of GSH increases in adaptation, the signaling mechanisms that govern regulation of GCS and GGT on the transcriptional, post-transcriptional and post-translational levels remain largely unresolved. The investigators propose to test the following hypotheses in three aims: 1- that signaling for the transcriptional activation of GCS genes by electrophiles and H2O2-generating compounds occurs through overlapping pathways; 2- that the GCS regulatory subunit (GCS-LS) stabilizes the catalytic subunit against proteolysis as well as regulates the kinetics; 3- that GGT transcription by reactive oxygen species is mediated through activation specific signaling pathways and cis acting element(s) activated by H2O2. These hypotheses will be tested using the agents (2,3dimethoxy-1,4-naphthoquinone (DMNQ), 4-hydroxynonenal (4HNE), and betanaphthoflavone (BNF)) at concentrations and incubation times that cause increased transcription of both GCS subunits. Methods to be used include, dominant negative and constitutively active signaling components, kinase assays, in vivo footprinting, reporter construct, tetracycline regulated antisense transfection, and measurement of reactive oxygen species, glutathione oxidation and alpha-unsaturated aldehydes. These aims will be carried out by using established cell models modified as needed to determine whether the conclusions are unique or generally applicable. The long-range goal of their
46
Glutamine
research is an understanding of the regulation of GSH synthesis and the potential for its pharmacological manipulation to enhance synthesis of this essential cellular constituent. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF THE DEVELOPMENT OF TRYPANOSOMA BRUCEI Principal Investigator & Institution: Wang, C C.; Professor; Pharmaceutical Chemistry; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2004; Project Start 01-DEC-1984; Project End 31-JAN-2009 Summary: (provided by applicant): African trypanosomes are parasitic protozoa and causative pathogens of sleeping sickness in humans and nagana in cattle. They are deeply branched primitive eukaryotes with many simple and unique biological features to make interesting models for basic studies and provide opportunities for chemotherapeutic control of the diseases they cause. The 26S proteasome in Trypanosoma brucei exists in a single species and performs many vital functions including cell cycle regulation. Its substrate specificity differs from that of the human proteasome, which allows specific inhibitor design. Insect form T. brucei has also a very simple cyclin-mediated cell cycle control involving only one essential G1 cyclin and one mitotic cyclin resulting in a leaky checkpoint regulation. There are four specific aims in our proposal; (1) to analyze the activity profiles of individual catalytic subunits in the T. brucei proteasome and compare them with those of the human proteasome. A P1glutamine tetrapeptide has been identified as a preferred substrate by the T. brucei proteasome. Further selective substrate and inhibitor design will be pursued with the increasing understanding of proteasome activity profiles; (2) to crystallize the 19S regulatory complex of T. brucei proteasome for structural analysis. The complex has an extraordinary stability and could become the first to have its structure resolved; (3) to analyze the G2/M checkpoint regulation in the bloodstream and insect forms of T. brucei. A regulatory complex most likely consisting of the mitotic cyclin, cyclindependent protein kinase, anaphase promoting complex (E3), an E2 and the proteasome will be identified and analyzed by the tandem affinity purification system and yeast two-hybrid screen and the functions of individual subunits characterized by RNA interference analysis; (4) to analyze and compare the two different mechanisms of G1/S checkpoint control in the bloodstream and insect forms of T. brucei and identify the two distinctive regulatory complexes by similar experimental approaches as stated above. The two forms of T. brucei share a similar G2/M control but distinctive G1/S regulations. A potential shift from one machinery of G1/S control to another during the differentiation from bloodstream into the insect form will be closely monitored and the triggering factor for this shift will be pursued. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RETINOIC BINDING/TRANSGLUTAMINASE
ACID-ACTIVATED
GTP-
Principal Investigator & Institution: Cerione, Richard A.; Professor; Molecular Medicine; Cornell University Ithaca Office of Sponsored Programs Ithaca, Ny 14853 Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAY-2004 Summary: Tissue transglutaminases (TGases) are GTP-binding/GTPases with an enzymatic (transamidation) activity that catalyzes the covalent linkage between glutamine residues and primary amino groups, resulting in the formation on new protein-protein and protein- polyamine complexes. The TGases have been implicated in
Studies
47
a number of important biological responses including neuronal development and degeneration, as well as retinoic acid-induced cellular differentiation, and apoptosis. Both the GTP-binding and transamidation activities of the TGases are activated by retinoic acid. Recently, we identified two candidate target/binding partners for the TGase, namely, the eukaryotic initiation factor (eIF)5A, and the retinoblastoma gene product (Rb), both of which are essential for cell viability. We also have found that the TGase-catalyzed transamidation of Rb protects it against proteolytic degradation by caspases. The studies outlined in this application are aimed at understanding different aspects of the structure and function of this interesting dual function GTP- binding protein/transamidase and its role in retinoic acid- induced cellular differentiation. There are three specific aims. 1.) Delineate the mechanistic basis for the intramolecular coupling between the GTP-binding and transamidation activities of the TGase. We plan to determine how the TGase is able to bind and hydrolyze GTP and to establish how the GTP-binding/GTP hydrolytic cycle regulates the transamidation activity. The ultimate aim will be to generate TGase mutants that are defective in GTP-binding or that contain GTP-binding/GTP hydrolytic activity that is uncoupled from transamidation activity, since these mutants should be useful for cellular studies of TGase function. 2.) Determine how retinoic acid mediates the cellular regulation of the TGase. In these studies, we plan to determine whether a negative regulatory protein is responsible for maintaining the TGase in an inactive state in the absence or retinoic acid treatment, as well as begin to establish the molecular signals responsible for the retinoic acidstimulated activation of the TGase. 3.) Establish a role for the interactions of the TGase with two new target/binding partners that are essential for cell growth. The main emphasis of these studies will be to determine whether the retinoic acid-dependent interactions of the TGase with Rb and eIF-5A are essential for ensuring cell viability when cells undergo cell-cycle arrest during differentiation. The results of these studies should yield new information regarding the regulation of an important dual function GTP-binding protein/transamidase and its role in mediating the balance between cellular differentiation and apoptosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RIBOZYMES FOR THE EVOLUTION OF THE GENETIC CODE Principal Investigator & Institution: Suga, Hiroaki; Associate Professor; Chemistry; State University of New York at Buffalo Suite 211 Ub Commons Amherst, Ny 14228 Timing: Fiscal Year 2002; Project Start 01-FEB-2000; Project End 31-JAN-2004 Summary: The contemporary aminoacyl-tRNA synthetases (aaRSs) are highly specific toward cognitive amino acids and tRNAs, because the fidelity of translation from genetic code to proteins relies mainly upon the accurate aminoacylation of tRNAs. Consequently, the mechanism of their recognition events is extremely complex, which has made it difficult to engineer the aaRSs with desired specificities. The central goal of this proposal is to devise a novel and practical catalytic system composed of catalytic RNA molecules (ribozymes) for the synthesis of natural and non-natural aminoacyltRNAs. We have recently succeeded in generating a novel ribozyme capable of synthesizing aminoacyl-tRNA. This ribozyme, referred to as ARS ribozyme (aminoacyltRNA synthetase ribozyme), is able to specifically recognize a glutamine cyanomethyl ester and charge the glutaminyl group on a tRNA molecule. In this proposal, we will plan to systematically evolve the ARS ribozyme into highly selective and efficient ARS ribozymes for the synthesis of various aminoacyl-tRNAs. Our ribozyme-based catalytic system will potentially offer a simple and facile method for the synthesis of aminoacyltRNAs in vitro. The results from these experiments will be used to drive future direction
48
Glutamine
of our long-term goal, a cell-free in vitro translation system composed of ARS ribozymes, which facilitates the site-specific incorporation of non-natural amino acids into proteins. Our experiments may also provide new evidence to support an RNAbased translation system postulated in the context of the RNA world hypothesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF HUNTINGTIN IN VESICLE TRANSPORT Principal Investigator & Institution: Difiglia, Marian; Associate Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2002; Project Start 15-AUG-1998; Project End 31-JUL-2006 Summary: (provided by applicant): A polygutamine expansion in the N-terminus of huntingtin (N-hn) causes Huntington's disease (HD). There is no effective treatment for HD. Although mutant N-Fin fragments are known to accumulate in HD neurons and cause cell dysfunction in vitro, a mechanism (or mechanisms) that explains the selective loss of striatal and cortical projection neurons remains elusive. Wild type and mutant htt associate with membranes in the endocytic and secretory pathway. Our overall hypothesis is that mutant N-htt 's association with neuronal membranes contributes to early cellular dysfunction in the cytoplasm in HD. One of these membrane compartments includes the autophagosome/lysosomal system, which accumulates fulllength or large N-htt fragments of mutant htt. Although htt ostensibly lacks transmembrane domains, it associates tightly with membranes. We speculate that candidate domains in the N-terminus involved in protein-protein interactions promote membrane binding. Little is known about the degradative pathways that form N-htt fragments in vivo. Identifying the sites of protease cleavage in the N-terminus of htt is important for understanding how the protein is regulated. Calpain, a calcium dependent protease, which regulates the function of many proteins involved in membrane/cytoskeleton organization, cleaves htt near its N-terminus and produces long-lived N-htt fragments that are enriched in membrane fractions in brain. We speculate that mutant N-htt products of calpain cleavage undergo a different processing from the wt fragments in neurons that leads to cellular dysfunction in HD. HD mice also show abnormal function of striatal NMDA receptors. One way that mutant Fin might cause the dysfunction of NMDA receptors is by disrupting the assembly of NMDA receptor subtypes at the cell surface. The specific aims are: 1: To understand the role of mutant htt induced autophagy in cell dysfunction, 2: To determine whether htt proteolysis by calpain contributes to HD pathogenesis and 3: To determine the effects of mutant htt on protein transport within the secretory pathway. The results of these studies will provide new insights about the mechanisms of cellular dysfunction in HD and suggest novel therapeutic targets that can reduce the potentially harmful effects of mutant N-htt fragments. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE OF PROTEIN PHOSPHATASES IN INSULIN SECRETION Principal Investigator & Institution: Kowluru, Anjaneyulu; Associate Professor; Pharmaceutical Sciences; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: (From applicant's abstract) While a majority of extant studies have focused since on the protein kinases, very little is known of the regulation and roles of protein phosphatases (PPases) in physiologic insulin secretion from the pancreatic beta cell. The catalytic activity of certain enzymes of intermediary metabolism is influenced by their
Studies
49
phosphorylation status. For example, acetyl CoA carboxylase (ACC), a lipogenic enzyme, is modulated by phosphorylation (inactive)- dephosphorylation (active). Here in the investigators describe a novel cytosolic, okadaic acid-sensitive (PP2A-like) PPase that dephosphorylates and activates ACC in the beta cell. Activity of this PPase is augmented by methylation at its C-terminal leucine. Further, the methylated form is converted to its inactive, demethylated form by a cytosolic serine esterease-like enzyme, also localize in the beta cell. Physiologic concentrations of glutamate and magnesium stimulate the carboxyl methylation as well as the catalytic activity of this PPase and concomitantly increase ACC activity. Effects of glutamate and magnesium are specific for ACC-phosphatase, but not ACC-kinase. Insulinotropic concentrations of glucose or glutamine stimulate the carboxyl methylation of this PPase in intact beta cells. More importantly, activity of this ACC-PPase is abolished in islet derived from the GK rat, a model for NIDDM, compared to islets from the control Wistar rats. Using isolated rat islets and pure beta (HIT-T15 and INS-1) cells, the investigators propose to study the regulation of this PPase, and thereby ACC, at 3 cellular levels (i.e. subcellular fractions, intact islets, and purified proteins in reconstituted systems). The investigators will also purify this PPase using microcystin -sepharose affinity columns to determine changes in the (A, B and C) subunit composition of PP2A under various experimental conditions, to establish a link between the carboxyl methylation of the C-subunit and the assembly of PP2A haloenzyme. The investigators will characterize the methylating and demethylating enzymes of PP2 Ac and study the interaction of ACC with its putative PPase. Using similar approaches, the investigators will examine the abnormalities in ACC-phosphatase in the diabetic GK islet and investigate if such a defect is reversed by treatment of diabetic rats with insulin or phlorizin. The proposed studies should establish a link between ACC activation and physiologic insulin secretion from isolated beta cells. These studies will also identify the locus that is causal to the observed defect in ACC-phosphatase and ACC activation signaling cascade in the diabetic beta cell, leading to abnormal insulin secretion demonstrable in this model for NIDDM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SALIVARY PROTEINS IN DENTAL INTEGUMENTS Principal Investigator & Institution: Oppenheim, Frank G.; Professor and Chair; Periodontology & Oral Biology; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-MAY-2005 Summary: The acquired enamel pellicle is a protein film readily formed on tooth mineral surfaces in the oral environment. It has been established that its formation is driven by the adsorption of proteins and peptides derived from oral fluid. Most of these proteins originate from either parotid or submandibular/ sublingual secretions which undergo modifications in the oral cavity before or after adsorption to the hydroxyapatite crystallites of tooth enamel. The composition and the structure of this acquired enamel pellicle are still largely unknown but play functionally a vital role with important physiological/clinical implications. A major thrust of this application is to use state-ofthe-art proteomics to identify and characterize the major components of the in-vivo formed pellicle. Since the pellicle has an inner aspect facing the tooth surface and an outer aspect connected to the bacterial biofilm known as Dental plaque the functions of pellicle are multifaceted and complex. Another major goal is to investigate the protective functions of the pellicle vis-a-vis the maintenance of the mineral phase of enamel and the interplay between molecular entities of the pellicle and those bacteria which constitute the early colonizers of the biofilm forming on the tooth surface. The nature of
50
Glutamine
the pellicle with respect to the early attachment of bacteria including those which are known periodontal pathogens will be studied in vitro and in vivo. The Specific Aims of the project are to: 1) Characterize components from pellicles formed in vivo by a variety of isolation techniques including 2D-electrophoresis followed by proteomic analyses comprising MALDI-TOF MS. LC-ESI MS and LC-MS/MS; 2) Explore the protective functions of the enamel pellicle by determining the affinity of its components to hydroxyapatite, the inhibitory potential of pellicle proteins/peptides of calcium phosphate precipitation from supersaturated solutions, and the capacity to retard demineralization; 3) Determine in vitro binding parameters of individual early pellicle colonizers, assess the role of transglutaminase in pellicle-bacterial interactions and employ biomimetic approaches to modify functional aspects of pellicle components; 4) Investigate with the checkerboard DNA-DNA hybridization assay the in vivo binding of early pellicle colonizers in healthy individuals and gingivitis patients, assess the relative role of exocrine and serum derived proteins/peptides on pellicle colonization in vivo and explore effects of different local environments in the oral cavity on these processes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SCORE PROGRAM AT NEW MEXICO STATE UNIVERSITY, LAS CRUCES Principal Investigator & Institution: Kuehn, Glenn D.; Professor of Biochemistry; Chemistry and Biochemistry; New Mexico State University Las Cruces Las Cruces, Nm 880038001 Timing: Fiscal Year 2002; Project Start 09-SEP-1991; Project End 31-MAY-2004 Summary: This is an application for a new SCORE Program at New Mexico State University (NMSU) at Las Cruces. A goal of NMSU is to expand research is at the institution for participation by ethnic minority students who desire to pursue careers in the biomedical science disciplines. The proposed SCORE Program has its goals: (i) To significantly improve the capabilities of NMSU to conduct biomedically relevant research by increasing the numbers of faculty who conduct biomedical research, increasing the inventory of specialized single-user research instrumentation, and improving the capacity to maintain research instrumentation; (ii) To significantly improve the quantity and quality of biomedical research conducted at NMSU by broadening grantsmanship efforts of faculty participants and increasing the numbers and quality of research publications; (iii) To integrate the activities of the SCORE Program with an anticipated RISE Program to maximize resources for training minority scientists in the biomedical sciences by engaging students in SCORE Program research projects; (iv) To increase the capacity of NMSU to self-evaluate, assess, and monitor its multi- component research programs by engaging trained personnel in the SCORE Program's evaluation plan and subjecting the Program to annual review by an external evaluation committee. This application contains research proposals for nineteen research subprojects and three pilot subprojects. Disciplines represented among these proposals include Agronomy, Animal Science, Anthropology, Biochemistry, Biology, Chemistry, Chemical Engineering, Molecular Biology, Microbiology and Psychology. The research topics of proposed projects include methods for radiolabeling medical diagnostic reagents with technetium and rhenium, avian cardiovascular adaptations, the bacterial proteosome, glycosylation processes in CHO cells, apoptosis, acid tolerance of E. coli O157:h7, metabolic engineering of secondary metabolism, evolution of RNA viruses, cytosolic and chloroplastic glutamine synthase, biological dechlorination reactions, mechanisms of environmental stress resistance, toxicokinetics of swainonine, neuromodulation of growth hormone, maternal/infant synchrony in cortisol and
Studies
51
behavior development, embryonic control of blood pressure, modification of clays for resolving racemic mixtures, gene expressions during inner ear development, and chemical synthesis of cation chelators, steroids and etoposide derivatives, and boronated biomolecules. This SCORE Program will continue a 24-year old MBRS Program which has advanced 280 minority students (83% of participants) on to post baccalaureate programs and produced 52 minority Ph.D. recipients since 1974. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SECRETIN AND GASTRIC MOTILITY Principal Investigator & Institution: Owyang, Chung; Chief, Division of Gastroenterology; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 01-JUN-1990; Project End 31-MAR-2005 Summary: Duodenal acidification inhibits gastric antral contractions, promotes gastric fundic relaxation, and thereby protects the duodenum from excess acid exposure. Secretin plays an important role in this process, mediating duodenal acid-induced gastric relaxation by acting on vagal afferent neurons that activate vagal motor neurons, releasing VIP which then evokes gastric relaxation by way of prostaglandin pathways. The current proposal focuses on vagovagal circuits that are activated by secretin and duodenal acid. It is postulated that secretin activates vagal afferent fibers that release CGRP that then stimulates interneurons in the nucleus tractus solitarius. GABAergic neurons inhibit dorsal motor nucleus of the vagal cholinergic neurons which synapse with intragastric cholinergic neurons, while stimulation of glutaminergic neurons activate dorsal motor nucleus vagal neurons which synapse with intragastric VIP neurons. This provides a mechanism whereby single vagal afferents may concurrently excite and inhibit vagal efferent transmission producing dysfacilitation of cholinergic and activation of nonadrenergic and noncholinergic input to the stomach to optimize gastric relaxation. In the current proposal, the neurotransmitter coding utilized by vagal fibers possessing secretin receptors will be assessed by intracellular recording and labeling techniques. The intracellular mechanisms involved in secretin-stimulated release of CGRP from the nodose ganglia will be explored. Both morphologic and electrophysiologic characterization of duodenal acid and secretin-stimulated nucleus tractus solitarius neurons will be performed and their neurochemical phenotypes examined. In vivo, the secretin-induced release of glutamine and GABA will be quantified using radionucleotide tagging techniques. Finally, the dorsal motor neuron vagoneural circuits mediating the action of secretin and the roles of GABA and NMDA will be explored. This should provide a comprehensive characterization of the neural components of the vagovagal circuit activated by secretin to effect gastric relaxation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SIGNALING CASCADES, ALLOSTERY AND THE PYRIMIDINE PATHWAY Principal Investigator & Institution: Guy, Hedeel I.; Biochem and Molecular Biology; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2002; Project Start 01-FEB-2000; Project End 31-JAN-2004 Summary: In mammalian cells, the rate of de novo pyrimidine biosynthesis is regulated by the multi-functional protein CAD. The protein, which catalyzes the first half of the pathway, consists of six copies of a 243 kDa polypeptide folded into separate structural domains that carry glutamine dependent carbamoyl phosphate synthetase (CPSase),
52
Glutamine
aspartate transcarbomoylase (ATCase) and dihydrooortase (DHOase) activities. The activity of the pathway is precisely controlled and increases when cells are induced to proliferate. Studies of the purified protein have shown that CPSase, which catalyzes the initial, rate limiting step in the pathway is the major locus of regulation and is allosterically controlled by UTP, an inhibitor and PRPP, an activator. In addition, the activity of the complex is regulated by protein kinase A mediated phosphorylation, although its role in regulating the growth state and cell cycle changes in the activity of the pyrimidine biosynthetic pathway is not at all clear. The recent discovery that EGF stimulation results in MAP kinase mediated phosphorylation and activation of CAD makes its possible to resolve this ambiguity. The objective of this research is to decipher the interrelationships and assess the importance of all these control mechanisms on the regulation of pyrimidine biosynthesis in vivo. The rate of de no pyrimidine biosynthesis, the size of the allosteric effector pools and the phosphorylation state of the protein will be examined in mammalian cells grown in culture and in transfectants that express CAD mutants in which one or more of the regulatory mechanisms have been disabled. The approach will be to extrapolate the extensive information developed on the regulation of purified CAD to develop a comprehensive model that can account for the in vivo regulation of de novo pyrimidine biosynthesis in different growth states, phases of the cycle and in cells stimulated by growth factors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SIGNIFICANCE OF GGT EXPRESSION IN TUMORS Principal Investigator & Institution: Hanigan, Marie H.; Associate Professor; Cell Biology; University of Oklahoma Hlth Sciences Ctr Health Sciences Center Oklahoma City, Ok 73126 Timing: Fiscal Year 2002; Project Start 01-AUG-1992; Project End 31-MAR-2004 Summary: (adapted verbatim from the investigator's abstract) Cisplatin is the most effective chemotherapy drug for the treatment of ovarian cancer. Its usefulness in the clinic is restricted by dose-limiting nephrotoxicity and the development of drugresistance within the tumor. During the previous funding period our studies demonstrated that the nephrotoxicity of cisplatin is due to the metabolism of cisplatinglutathione conjugate through a GGT- mediated pathway in the kidney. We further demonstrated that this GGT-mediated toxicity is specific to the kidney. When GGT was transfected into tumor cells it reduced the toxicity of cisplatin rather than increasing it as was seen in the kidney. These findings indicate that there are two distinct mechanisms of cisplatin toxicity. The delineation of these two mechanisms would provide the opportunity to inhibit the side effects of cisplatin without compromising its antitumor activity. The current proposal focuses on defining the mechanisms by which cisplatin exerts its toxic effects and identifying the mechanism by which tumor cells develop resistance to cisplatin. The first specific aim is to further characterize the unstable cisplatin-glutathione conjugate that is a substrate for GGT and follow its metabolism within the kidney. A series of cisplatin-glutathione conjugates will be tested as substrates for GGT-mediated activation to nephrotoxins by LLC-PK1 cells and human renal proximal tubule cells. Cisplatin-glutathione conjugates will be isolated by HPLC and their structure determined by Mass Spectrometry. The pathway by which they are metabolized will be determined with the use of selective inhibitors of enzymes within the pathways. Inhibitors that block the activation of cisplatin in vitro will be tested for their ability to block the nephrotoxicity of cisplatin in vivo. The second specific aim is to identify the mechanism by which tumors become resistant to cisplatin in vivo. Human epithelial ovarian tumors will be propagated in nude mice. Half the mice will be treated
Studies
53
with cisplatin. Cisplatin resistant tumors will be isolated after several courses of treatment. mRNA will be isolated from these tumors and differentially expressed genes will be isolated by representational differential analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SKELETAL MUSCLE NUTRIENT SENSING Principal Investigator & Institution: Obici, Silvana; Medicine; Yeshiva University 500 W 185Th St New York, Ny 10033 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Obesity occurs when caloric intake exceeds expenditure. The increasing prevalence of obesity in industrialized societies has generated new interest in the mechanisms underlying the control of energy balance. In humans, reduced rate of energy expenditure, which is largely accounted for by oxidative phosphorylation in skeletal muscle, is a risk factor for future weight gain. Nutrients, via the activation of nutrient-sensing pathways, activate adipostatic responses (e.g. leptin) that attempt to limit lipid storage by enhancing energy expenditure and inhibiting food intake. A major nutrient-sensing pathway, the hexosamine biosynthetic pathway (HBP) has been recently shown to increase local leptin expression in skeletal muscle. Yet, acute pharmacological activation of HBP induces a dramatic drop in skeletal muscle energy production, by downregulating the expression of genes for oxidative phosphorylation. Based on these observations, we wish to develop animal models designed to define how the physiological regulation of HBP modulates energy homeostasis. In particular, we will use transgenic animal models to discern the metabolic consequences of activation of HBP in muscle from those derived from the associated local induction of leptin. We will generate transgenic mice lines carrying constitutive and moderate elevations of the enzyme glutamine:fructose 6P amidotransferase (GFAT, which catalyzes the first committed step of HBP and regulates the flux through this pathway), or of leptin in skeletal muscle. The careful phenotyping of these animal models should allow one to define the direct and respective roles of muscle HBP and leptin in the regulation of energy expenditure and substrate oxidation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SLEEP MECHANISMS IN CHILDREN: ROLE OF METABOLISM Principal Investigator & Institution: Haddad, Gabriel G.; Pediatrics; Yeshiva University 500 W 185Th St New York, Ny 10033 Timing: Fiscal Year 2002; Project Start 23-SEP-2002; Project End 31-JAN-2007 Summary: (provided by applicant): Sleep and the neurobiological mechanisms controlling sleep/wakefulness have been an enigma in spite of important recent advances in the field. Although it is well known now that sleep affects a variety of systems, including the cardio-respiratory, endocrine and autonomic systems, we still do not understand why we sleep and the mechanisms that control sleep. For example, we do not have a good understanding of the mechanisms that induce or maintain sleep or those mechanisms that are activated with sleep deprivation. One of the potentially important areas that have started to develop is the role of brain metabolism in sleep. Although metabolic studies during sleep have been done in the past few decades, new developments in brain imaging and spectroscopy have made it possible only recently to examine the importance of metabolism in sleep research. Furthermore, and of major interest, is the growing evidence that glia play a critical role in maintaining neuronal
54
Glutamine
function through metabolic support through glutamate re-cycling and possibly by providing neurons with substrates for glucose oxidation. Glycogen is found only in glia and hence glycogen metabolism, the glutamine-glutamate cycling and glucose oxidation involve links between glia and neurons. Hence, in order to understand sleep and its mechanisms, it becomes important to study the functional integrity and coupling of neurons and glia and their relationship as a function of state. For conceptual reasons and in order not to complicate the experimental matrix, we will focus this application on stage III-IV sleep and will address our questions comparing this sleep stage to a well defined state of wakefulness. Furthermore, since previous studies have taught us about sleep and its mechanisms by studying sleep deprivation, we will, in a subset of our children, address the same questions after sleep deprivation. Our specific hypotheses are as follows: 1. Stage IV sleep has a lower metabolic requirement and a lower glutamate turnover rate (tricarboxylic acid cycle rate) in both neurons and glia, as compared to wakefulness. 2. As compared to wakefulness, sleep stage IV is characterized by a lower rate of brain neuronal glutamate release and glial glutamate uptake in children; this reduced glutamate/glutamine cycling during this sleep stage in brain of children is prevented by sleep deprivation. 3. Brain glycogen content increases during the course of sleep in children and sleep deprivation markedly lowers glycogen content. Our long term aims are a) to better understand sleep and b) to be able to better understand diseases that afflict children or adult and which impact on their sleep or diseases that are sleep-related that impact on other functions including neurocognitive, cardiovascular or behavioral functions. As seen from reviewing the state-of-the-art above, there are major gaps in our knowledge and this application focuses on a number of these gaps. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SPECIFICITY IN CLASS I AMINOACYL-TRNA SYNTHETASIS Principal Investigator & Institution: Perona, John J.; Associate Professor; Chemistry and Biochemistry; University of California Santa Barbara 3227 Cheadle Hall Santa Barbara, Ca 93106 Timing: Fiscal Year 2002; Project Start 01-JUN-2001; Project End 31-MAY-2005 Summary: (provided by applicant): A multidasciplinary study aimed at uncovering the structural and energetic basis for amino acid and transfer RNA specificity in several class I aminoacyl-tRNA synthetases is proposed. The experimental plan will focus on the structure-based design of directed modifications in both the synthetase and tRNA, and on the insightful analysis of modified complexes by a variety of enzymological and biophysical methods. The role of the globular tertiary core region of glutamine-specific tRNA in aminoacylation will be explored by exploiting the availability of an extensive tRNA sequence database, as well as by the introduction of highly specific chemical modifications to the sugar-phosphate backbone. Glutaminylation kinetics, together with high-resolution structures bound to synthetase and to Ef-Tu, will be determined to assess the effects of the alterations. In a separate line of experiments, rational structurebased approaches are planned to re-engineer the amino acid specificity from glutamine to glutamate. New methodologies will be applied to improve the chemical and enzymatic synthesis of multimilligram quantities of homogeneous RNAs, and to better characterize the aminoacylation reaction by implementing a new assay useful for both steady-state and transient kinetic measurements. With improved kinetic methods in hand, a functional analysis of glutaminyl-tRNA synthetase will be pursued with the aim of addressing the kinetic basis for the amino acid specificity, the function of divalent metal ions, and the requirement for tRNA to carry out activation of the amino acid.
Studies
55
These approaches will also be used to examine kinetic properties of the homologous cysteinyl-tRNA synthetase. Detailed information on the origins of class I bacterial tRNA synthetase specificities will aid drug-design approaches which exploit the structural differences between bacterial and human synthetases to develop antimicrobial agents. Re-engineering of the amino acid specificities of tRNA synthetases is also the most challenging step in the in viva production of proteins containing non-natural amino acids. Because of the broad applicability of this technology, the development of new synthetases based on the class I active site domain has potential for impact on biomedical research toward therapies for many human diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROTEINS
STRUCTURE
FUNCTION
OF
THE
MAMMALIAN
STRESS
Principal Investigator & Institution: Welch, William J.; Professor; Surgery; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002; Project Start 01-APR-1992; Project End 31-MAR-2005 Summary: (Applicant's abstract): Analysis of the structure and function of heat shock proteins has led to new insights regarding the pathway of protein maturation. Heat shock proteins, in their role as "molecular chaperones," participate in the synthesis, folding and intracellular transport of many, if not all, polypeptides. Increases in the levels of the heat shock proteins, as occurs in cells experiencing different types of metabolic stress, aid in the renaturation of cellular proteins adversely affected by the stress event and facilitate the synthesis and folding of new proteins needed to replace those which have been irreparably damaged. Herein Dr. Welch will continue to examine structure/function of the heat shock proteins. In first aim the identity and role of molecular chaperones interacting with nascent polypeptides still bound to the ribosome will be pursued. Here the idea that two heat shock proteins, hsp70 and hsp90, together constitute a nascent chain binding complex will be examined. Interaction of this putative nascent chain binding complex with nascent chains is suggested to help stabilize maturing polypeptides, preventing inappropriate intra- or inter-molecular interactions that might lead to misfolding and aggregation. Studies described in aim 2 will serve to complement those in aim 1 by focusing on the maturation of one particular polypeptide, the androgen receptor (AR). The rationale for studying AR biogenesis is 3-fold. First, the biological activities of the mature form of AR are known to require the help of different molecular chaperones. Second, assays to study the proper folding of AR are readily available. Finally and most importantly, mutations in AR are the basis of a neurodegenerative disease. Here expansions of a CAG repeat within the gene encoding AR result in an AR protein containing an unusually long run of glutamine residues. As a result, mutant AR readily forms nuclear and cytoplasmic aggregates which over time lead to cell demise. Thus, in aim 2 Dr. Welch will compare and contrast the maturation pathway of wild type and mutant AR and determine the role served by different molecular chaperones. In parallel, studies described in aim 3 will focus on the cellular impact of mutant AR expression. He proposes that the accumulation of mutant ARaggregates leads to the sequestration of molecular chaperones and the eventual development of chronic cellular stress. Exactly what metabolic pathways are adversely affected in the cell experiencing chronic stress will be addressed. Finally, in aim 4 we will continue with the identification and characterization of small molecules that are effective in reducing or preventing abnormal protein folding. The principal investigator anticipates that these studies, in sum, will continue to provide new insights regarding
56
Glutamine
the structure/function of the heat shock proteins and their potential role in human diseases involving abnormal protein folding. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURES AND MECHANISMS OF GLUTAMINE DEPENDENT ENZYMES Principal Investigator & Institution: Davisson, Vincent J.; Professor; Medicinal Chem/Molecular Pharm; Purdue University West Lafayette West Lafayette, in 479072040 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Scientific Focus The long-term goals of this project are to establish a molecular basis for the interdomain communication in glutamine amidotransferases that relates their dynamic properties to the control of their catalytic efficiencies. This investigation aims to delineate the major mechanistic and structural aspects of two enzymes, imidazole glycerol phosphate synthase (IGPS), and guanosine monophosphate synthetase (GMPS), which catalyze the transfer of ammonia from glutamine to a purine nucleotide acceptor substrate. The general hypothesis under consideration for the glutamine amidotransferase sub-family is that the functional link between the two active sites involves the transduction of binding and chemical energy from the acceptor active site to the glutaminase site. Furthermore, the glutamine substrate specificity and catalytic efficiency is controlled by dynamic protein-protein interactions that modulate a molecular tunnel for ammonia transfer. The proposed studies will focus upon structural and mechanistic information to define the domain interactions that control the timing of the nucleotide substrate activation and glutarnine hydrolysis steps. Significance of objectives Because of the unique chemical features present in the metabolic pathway under investigation, and the detailed comparative structural information that will emerge, this project has the potential to impact the discovery and development of new therapeutic agents. In addition, these enzymes represent important examples of convergent evolution that hold many mechanistic details of how proteins transmit specific chemical information over large distances. Overall, the combination of biochemical and biophysical approaches proposed will: a) contribute to a comprehensive knowledge regarding nitrogen metabolism and b) provide critical information for the design of new selective agents of potential pharmacological importance that target essential enzymes in ammonia metabolism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THE ENCEPHALOPATHY
PERMEABILITY
TRANSITION
IN
HEPATIC
Principal Investigator & Institution: Norenberg, Michael D.; Professor; Pathology; University of Miami-Medical Box 248293 Coral Gables, Fl 33124 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): Hepatic encephalopathy (HE) is an important cause of morbidity and mortality in patients with severe liver failure. Acute HE associated with fulminant hepatic failure has an extremely poor prognosis and specific therapy is not available, short of an emergency liver transplantation. Although its pathogenesis remains poorly understood, ammonia is strongly implicated as a neurotoxin, and astrocytes appear to be the primary target of ammonia neurotoxicity. Additionally, altered bioenergetics and oxidative stress are thought to play a major role in this disorder. These facts led to a consideration of the involvement of mitochondrial
Studies
57
permeability transition (MPT) as a factor in the pathogenesis of HE and ammonia neurotoxicity. The MPT is a Ca2+-dependent, cyclosporin A (CsA)-sensitive process due to the opening of a pore in the inner mitochondrial membrane leading to a collapse of ionic gradients and ultimately to mitochondrial dysfunction. We have recently shown that ammonia induced the MPT in cultured astrocytes. We intend to examine the role of the MPT in HE and hyperammonemia using ammonia-treated neural cell cultures and in vivo models of HE/hyperammonemia (HA). Our working hypothesis is that ammonia induces the MPT in astrocytes, culminating in mitochondrial failure and astroglial dysfunction. A corollary of this concept is that inhibition or interference in the development of the MPT in astrocytes may ameliorate CNS dysfunction in HE. The Specific Aims of this proposal are: 1) To identify the factors responsible for the ammonia-induced MPT in cultured neural cells. Our focus will be on agents implicated in the pathogenesis of HE/H that have also been shown to induce the MPT in other cells. Specifically, we will examine the role of Ca 2+, reactive oxygen species, nitric oxide, pH and glutamine. We will determine whether these factors are elevated in ammonia-treated cultures, and whether diminishing their production or blocking their actions reduces or abolishes the MPT. Additionally, we will examine possible sequential interrelationships among these factors. 2) To determine whether ammonia-induced abnormalities in astrocytes (morphological alterations, defects in neurotransmitter uptake, and cell swelling) are mediated by the MPT, we will investigate whether inhibitors of the MPT (CsA, bongkrekik acid) are capable of diminishing or blocking the deleterious effects of ammonia. 3) To investigate the involvement of mitochondrial dysfunction as a potential factor in MPT-mediated cell injury. We will determine the state of mitochondrial function after ammonia treatment, and then investigate whether improving energy metabolism will inhibit ammonia-induced cellular injury. 4) To clarify whether the MPT occurs in in vivo models of HE (thioacetarnide treatment) and hyperammonemia. We will also determine whether factors that inhibit the MPT in vitro (e.g., CsA, trifluoperazine) are also capable of doing so in vivo. Additionally, we will assess the ability of MPT blockers to improve the clinical, histopathologic, neurochemical abnormalities, and the extent of brain swelling observed in HE/HA. We believe that these studies will yield critical data bearing on the pathogenesis of HE, and may potentially aid in the development of novel therapeutic strategies for the treatment of this condition. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TISSUE TRANSGLUTAMINASE: A ROLE IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Lesort, Mathieu J.; Assistant Professor; Psychiatry & Behav Neurobiol; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: (Provided by applicant): Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a pathological expansion of a polyglutamine domain within the protein huntingtin. The precise mechanisms involved in the etiology are still unknown, however there is evidence that impaired mitochondrial function is likely an important factor in HD. A possible clue to the pathogenesis of HD came with the discovery of neuronal intranuclear and cytoplasmic inclusions composed of mutant huntingtin. It has been suggested that Tissue Transglutaminase (tTG) may be a contributing factor to the formation of these aggregates. Tissue TG is a calcium-dependent transamidating enzyme that catalyzed the
58
Glutamine
formation of isopeptide bonds between specific proteins to produce insoluble polymeric structures. Recently we have demonstrated that TG activity and tTG levels are significantly increased in specific brain regions affected by the disease as compared to control cases. Further, studies from the laboratory demonstrated that tTG associates with a truncated huntingtin protein and activation of tTG resulted in the modification of specific proteins associated only with the mutant truncated huntingtin protein. These results suggest that tTG may have a role in the etiology of HD. Our working hypothesis is that impaired mitochondrial function results in an increase in tTG activity and this subsequently results in an increased association of tTG with truncated huntingtin and modification of specific mutant huntingtin associated protein. In this proposal the majority of the experiments will be carried out in human neuroblastoma cells that express in a stable or inducible manner, physiological or pathological huntingtin protein constructs. In this proposal we will: (1) test the hypothesis that mitochondria impairment results in an increase in TG activity, and that the presence of mutant huntingtin potentiates this response, (2) test the hypothesis that tTG interacts selectively with the N-terminal truncated huntingtin protein, and that mitochondria impairment results in an increase in this interaction, (3) test the hypothesis that tTG contributes to the formation and/or stabilization of the aggregates, and that mitochondrial impairment may potentiate this effect, and (4) identify the mutant huntingtin-associated proteins that are tTG substrates and test the hypothesis that modification of these proteins may contribute to the selective neuronal death in HD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRAFFICKING DEFECTS IN HUNTINGTONS DISEASE Principal Investigator & Institution: Mcmurray, Cynthia T.; Professor; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: (from applicant's abstract) It is the aim of this grant to understand defects in vesicular trafficking and cytoskeleton that may underlie Huntington's disease. Expansion of a trinucleotide repeat CAG, encoding glutamine, results in at least eight progressive neurodegenerative disorders, including Huntington's disease (HD). The mechanism by which polyglutamine expansion selectively kills neurons is largely unknown. Aggregation is generally accepted as part of pathogenesis, but it is not known whether toxicity initiates in the nucleus or the cytoplasm. Using time lapse imaging, we have tracked the localization of huntingtin in individual neurons from expression of the mutant protein to cell death. Toxicity initiates in the cytoplasm of primary neurons. Further, we have identified targets of huntingtin-mediated aggregation directly from aggregates in human brain. We show that the expanded Huntington's protein sequesters tubulin and vesicular trafficking motors into insoluble complexes. Direct video imaging of vesicles indicates that the mutant protein indeed inhibits vesicular transport particularly in the anterograde direction. The motor that is most affected appears to be kinesin and the cargo that appears most affected is mitochondria. Our data support a model for HD pathogenesis in which aggregation inhibits proteolysis of the HD protein, disrupts cytoskeletal architecture and impairs motors required for vesicular/organelle trafficking. In this proposal, we aim to test the hypothesis that sequestration of tubulindependent motors underlies HD regional pathology. Using gel filtration, immunoblotting and immunoprecipitation reactions, we will evaluate whether sequestration of tubulin-dependent complexes underlies HD regional pathology in human brain. By establishing primary cultures of affected and resistant neurons, we will directly test whether vesicular trafficking is altered in the presence of normal and
Studies
59
expanded HD protein. Since mitochondria are reduced in number in the presence of the mutant huntingtin, we will monitor the fate and subcellular localization of mitochondria by confocal imaging. Alteration in transport will be correlated with the subcellular localization of the HD protein and trafficking motors using fluorescence-labeled proteins and confocal microscopy. Finally, we will refine our understanding of pathogenesis by identifying other proteins present in aggregates by mass spectrometry. The recent observations that tubulin-dependent complexes and vesicular transport may play a role in pathogenesis of ALS and Alzheimer's disease suggest that there may be common aspects to these neurological diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSCRIPTIONAL REGULATION OF OXIDATIVE DEATH Principal Investigator & Institution: Ratan, Rajiv R.; Director; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2008 Summary: Huntington's Disease (HD) is an autosomal dominant disorder resulting from selective loss of neurons in the striatum and cerebral cortex. Loss of neurons in HD results from pathological expansion of CAG repeats encoding glutamine. Though the precise mechanisms by which glutamine repeats lead to neuronal loss in HD are unclear, oxidative stress, apoptosis, and transcriptional dysregulation have all been implicated in disease pathogenesis. To understand better oxidative and transcriptional mechanisms that may lead to neuronal loss in HD, we have utilized an in vitro model of oxidative stress in primary cortical neurons. In preliminary studies we have shown that oxidative cell death can be fully abrogated by sequence-selective DNA binding drugs, including mithramycin A (MMA) and chromomcyin A3. These agents are members of the aureolic acid antitumor antibiotics that share a common chromophore, aglycon ring, but differ in the nature of the sugar moieties connected to either side of the aglycone ring. Both antibiotics inhibit transcription during macromoleclar biosynthesis by binding to the "GC" rich transcriptional response elements. To test whether aureolic antibiotics can protect neurons in an in vivo model ofneurodegeneration that may inolve oxidative stress, we examined the effect of MMA in the R6/2 transgenic model of HD. We found that MMA prolongs survival in these mice by nearly 30%, a magnitude superior to any other single neuroprotective agent. These preliminary data are consistent with the overall hypothesis to be tested in this proposal: MMA inhibits neuronal death due to oxidative stress and/or mutant Huntington protein in vitro and in vivo by inhibiting the binding of pro-apoptotic zinc finger transcription factors such as TIEG, and enhancing the DNA binding of pro-survival transcription factors such as CREB. We will examine this hypothesis by determining whether protective concentrations of MMA inhibit TIEG binding to its GC rich DNA binding sites and whether TIEG is critical for oxidative death in cortical neurons. In the second aim, we will determine how MMA affects CREB DNA binding and whether increases in CREB DNA binding contribute to MMA's salutary effects. In the last specific aim, we will compare the mechanism of neuroprotection of MMA to those ofhistone deacetylase inhibitors, another class of transcriptional regulators. These studies will provide critical, mechanistic data on neuroprotective modulators of transcription. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
60
•
Glutamine
Project Title: VESICULAR NEUROTRANSMITTERS
TRANSPORT
OF
AMINO
ACID
Principal Investigator & Institution: Reimer, Richard J.; Neurology & Neurological Scis; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 15-APR-1998; Project End 31-JUL-2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “glutamine” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for glutamine in the PubMed Central database: •
[beta]-Glutamate as a Substrate for Glutamine Synthetase. by Robinson P, Neelon K, Schreier HJ, Roberts MF.; 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93190
•
13N isotope studies of glutamine assimilation pathways in Neurospora crassa. by Calderon J, Cooper AJ, Gelbard AS, Mora J.; 1989 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=209816
•
A census of glutamine /asparagine-rich regions: Implications for their conserved function and the prediction of novel prions. by Michelitsch MD, Weissman JS.; 2000 Oct 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17268
•
A glutamine residue in the membrane-associating domain of the bovine papillomavirus type 1 E5 oncoprotein mediates its binding to a transmembrane component of the vacuolar H(+)-ATPase. by Goldstein DJ, Kulke R, Dimaio D, Schlegel R.; 1992 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238300
•
A Glutamine Transport Gene, glnQ, Is Required for Fibronectin Adherence and Virulence of Group B Streptococci. by Tamura GS, Nittayajarn A, Schoentag DL.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=128016
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
61
•
A glutamine-amidotransferase-like protein modulates FixT anti-kinase activity in Sinorhizobium meliloti. by Berges H, Checroun C, Guiral S, Garnerone AM, Boistard P, Batut J.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=32199
•
A Glutamine-Rich Hydrophobic Patch in Transcription Factor Sp1 Contacts the dTAF11110 Component of the Drosophila TFIID Complex and Mediates Transcriptional Activation. by Gill G, Pascal E, Tseng ZH, Tjian R.; 1994 Jan 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42912
•
A method to assess compositional bias in biological sequences and its application to prion-like glutamine/asparagine-rich domains in eukaryotic proteomes. by Harrison PM, Gerstein M.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=193619
•
A mutant lacking the glutamine synthetase gene (glnA) is impaired in the regulation of the nitrate assimilation system in the cyanobacterium Synechocystis sp. strain PCC 6803. by Reyes JC, Florencio FJ.; 1994 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=197208
•
A new type of glutamine synthetase in cyanobacteria: the protein encoded by the glnN gene supports nitrogen assimilation in Synechocystis sp. strain PCC 6803. by Reyes JC, Florencio FJ.; 1994 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205187
•
A novel glutamine --RNA interaction identified by screening libraries in mammalian cells. by Tan R, Frankel AD.; 1998 Apr 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22474
•
A yeast glutamine tRNA signals nitrogen status for regulation of dimorphic growth and sporulation. by Murray LE, Rowley N, Dawes IW, Johnston GC, Singer RA.; 1998 Jul 21; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21125
•
Activation of transcription by PU.1 requires both acidic and glutamine domains. by Klemsz MJ, Maki RA.; 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=231014
•
ADP-ribosylation of glutamine synthetase in the cyanobacterium Synechocystis sp. strain PCC 6803. by Silman NJ, Carr NG, Mann NH.; 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=177058
•
Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid [beta]peptide of amyloid plaques. by Perutz MF, Pope BJ, Owen D, Wanker EE, Scherzinger E.; 2002 Apr 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122815
•
Alteration of the Bacillus subtilis glutamine synthetase results in overproduction of the enzyme. by Dean DR, Hoch JA, Aronson AI.; 1977 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=235556
62
Glutamine
•
Altered regulation of the glnA gene in glutamine synthetase mutants of Bacillus subtilis. by Schreier HJ, Sonenshein AL.; 1986 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=212837
•
Altered regulation of the glnRA operon in a Bacillus subtilis mutant that produces methionine sulfoximine-tolerant glutamine synthetase. by Schreier HJ, Rostkowski CA, Kellner EM.; 1993 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=196239
•
Amino-terminal deletions define a glutamine amide transfer domain in glutamine phosphoribosylpyrophosphate amidotransferase and other PurF-type amidotransferases. by Mei BG, Zalkin H.; 1990 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=209170
•
Ammonium assimilation in Rhizobium phaseoli by the glutamine synthetaseglutamate synthase pathway. by Bravo A, Mora J.; 1988 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=210751
•
An Alternatively Spliced Form of the Transcription Factor Sp1 Containing Only a Single Glutamine-Rich Transactivation Domain. by Persengiev SP, Saffer JD, Kilpatrick DL.; 1995 Sep 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40933
•
An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel [beta]-fibrils. by Bevivino AE, Loll PJ.; 2001 Oct 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59749
•
Asparagine and glutamine rotamers: B-factor cutoff and correction of amide flips yield distinct clustering. by Lovell SC, Word JM, Richardson JS, Richardson DC.; 1999 Jan 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15148
•
Association of glutamine 27 polymorphism of [beta]2 adrenoceptor with reported childhood asthma: population based study. by Hopes E, McDougall C, Christie G, Dewar J, Wheatley A, Hall IP, Helms PJ.; 1998 Feb 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28470
•
Bacillus subtilis citB gene is regulated synergistically by glucose and glutamine. by Rosenkrantz MS, Dingman DW, Sonenshein AL.; 1985 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=214224
•
Bacillus subtilis glutamine synthetase mutants pleiotropically altered in glucose catabolite repression. by Fisher SH, Sonenshein AL.; 1984 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=215290
•
Biosynthetic pathways of the osmolytes N epsilon-acetyl-beta-lysine, beta-glutamine, and betaine in Methanohalophilus strain FDF1 suggested by nuclear magnetic resonance analyses. by Roberts MF, Lai MC, Gunsalus RP.; 1992 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=207655
Studies
63
•
Carbon and Amino Acids Reciprocally Modulate the Expression of Glutamine Synthetase in Arabidopsis. by Oliveira IC, Coruzzi GM.; 1999 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59385
•
Characteristics and Efficiency of Glutamine Production by Coupling of a Bacterial Glutamine Synthetase Reaction with the Alcoholic Fermentation System of Baker's Yeast. by Wakisaka S, Ohshima Y, Ogawa M, Tochikura T, Tachiki T.; 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106798
•
Characterization of glutamine-requiring mutants of Pseudomonas aeruginosa. by Janssen DB, Joosten HM, Herst PM, van der Drift C.; 1982 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=220394
•
Characterization of the gene encoding glutamine synthetase I (glnA) from Bradyrhizobium japonicum. by Carlson TA, Guerinot ML, Chelm BK.; 1985 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218906
•
Cloning and characterization of a glutamine transport operon of Bacillus stearothermophilus NUB36: effect of temperature on regulation of transcription. by Wu L, Welker NE.; 1991 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=208167
•
Cloning and expression of the Thiobacillus ferrooxidans glutamine synthetase gene in Escherichia coli. by Barros ME, Rawlings DE, Woods DR.; 1985 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=219347
•
Cloning and sequencing of the gene encoding glutamine synthetase I from the archaeum Pyrococcus woesei: anomalous phylogenies inferred from analysis of archaeal and bacterial glutamine synthetase I sequences. by Tiboni O, Cammarano P, Sanangelantoni AM.; 1993 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=204614
•
Cloning of the glutamine synthetase I gene from Rhizobium meliloti. by Somerville JE, Kahn ML.; 1983 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=215066
•
Cloning, Expression, and Purification of Glutamine Synthetase from Clostridium acetobutylicum. by Usdin KP, Zappe H, Jones DT, Woods DR.; 1986 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203548
•
Cloning, nucleotide sequence, and potential regulatory elements of the glutamine synthetase gene from murine 3T3-L1 adipocytes. by Bhandari B, Beckwith KD, Miller RE.; 1988 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=281850
64
Glutamine
•
Cloning, primary structure, and regulation of the HIS7 gene encoding a bifunctional glutamine amidotransferase: cyclase from Saccharomyces cerevisiae. by Kuenzler M, Balmelli T, Egli CM, Paravicini G, Braus GH.; 1993 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=206611
•
Close linkage of genes encoding glutamine synthetases I and II in Frankia alni CpI1. by Hosted TJ, Rochefort DA, Benson DR.; 1993 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=204773
•
Combined, Functional Genomic-Biochemical Approach to Intermediary Metabolism: Interaction of Acivicin, a Glutamine Amidotransferase Inhibitor, with Escherichia coli K-12. by Smulski DR, Huang LL, McCluskey MP, Reeve MJ, Vollmer AC, Van Dyk TK, LaRossa RA.; 2001 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99633
•
Comparative Biochemical and Immunological Studies of Bacterial Glutamine Synthetases. by Tronick SR, Ciardi JE, Stadtman ER.; 1973 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=246329
•
Concerted hexose transport curb by tunicamycin is rendered irreversible by glucose or allose in medium containing L-glutamine. by Ullrey DB, Kalckar HM.; 1989 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=287266
•
Conformational effects of substituting amino acids for glutamine-61 on the central transforming region of the P21 proteins. by Pincus MR, Brandt-Rauf PW, Carty RP, Lubowsky J, Avitable M, Gibson KD, Scheraga HA.; 1987 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=299545
•
Conservation of Glutamine-Rich Transactivation Function between Yeast and Humans. by Escher D, Bodmer-Glavas M, Barberis A, Schaffner W.; 2000 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85493
•
Constitutive Overexpression of Cytosolic Glutamine Synthetase (GS1) Gene in Transgenic Alfalfa Demonstrates That GS1 May Be Regulated at the Level of RNA Stability and Protein Turnover. by Ortega JL, Temple SJ, Sengupta-Gopalan C.; 2001 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=102286
•
Contribution of a Thickened Cell Wall and Its Glutamine Nonamidated Component to the Vancomycin Resistance Expressed by Staphylococcus aureus Mu50. by Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90058
•
Control of ftsZ Expression, Cell Division, and Glutamine Metabolism in LuriaBertani Medium by the Alarmone ppGpp in Escherichia coli. by Powell BS, Court DL.; 1998 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106991
•
Crystal structure of a dimeric chymotrypsin inhibitor 2 mutant containing an inserted glutamine repeat. by Chen YW, Stott K, Perutz MF.; 1999 Feb 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15450
Studies
65
•
Cytosolic Glutamine Synthetase in Soybean Is Encoded by a Multigene Family, and the Members Are Regulated in an Organ-Specific and Developmental Manner. by Morey KJ, Ortega JL, Sengupta-Gopalan C.; 2002 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=148970
•
Derepression of nitrogenase activity in glutamine auxotrophs of Rhodopseudomonas capsulata. by Wall JD, Gest H.; 1979 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218340
•
Determination of the rate of the glutamate /glutamine cycle in the human brain by in vivo 13C NMR. by Shen J, Petersen KF, Behar KL, Brown P, Nixon TW, Mason GF, Petroff OA, Shulman GI, Shulman RG, Rothman DL.; 1999 Jul 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22218
•
Diel Rhythms in Ribulose-1,5-Bisphosphate Carboxylase/Oxygenase and Glutamine Synthetase Gene Expression in a Natural Population of Marine Picoplanktonic Cyanobacteria (Synechococcus spp.). by Wyman M.; 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91547
•
Differential expression of a Clostridium acetobutylicum antisense RNA: implications for regulation of glutamine synthetase. by Fierro-Monti IP, Reid SJ, Woods DR.; 1992 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=207476
•
Differential transcription of the two glutamine synthetase genes of Bradyrhizobium japonicum. by Carlson TA, Martin GB, Chelm BK.; 1987 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=214189
•
Distinct Subdomains of Human TAFII130 Are Required for Interactions with Glutamine-Rich Transcriptional Activators. by Saluja D, Vassallo MF, Tanese N.; 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109159
•
Distribution of Glutamine and Asparagine Residues and Their Near Neighbors in Peptides and Proteins. by Robinson AB, Robinson LR.; 1991 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52614
•
Effect of glutamine on enzymes of nitrogen metabolism in Bacillus subtilis. by Deshpande KL, Katze JR, Kane JF.; 1981 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=217177
•
Effect of glutamine on growth and heterocyst differentiation in the cyanobacterium Anabaena variabilis. by Thiel T, Leone M.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213549
•
Effects of Ammonium, -Glutamate, and -Glutamine on Nitrogen Catabolism in Aspergillus nidulans. by Hynes MJ.; 1974 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=245890
66
Glutamine
•
Effects of glutamines and glutamates at sites of covalent modification of a methylaccepting transducer. by Park C, Dutton DP, Hazelbauer GL.; 1990 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=210843
•
Effects of l-Glutamine Deprivation on Growth of HVJ (Sendai Virus) in BHK Cells. by Ito Y, Kimura Y, Nagata I, Kunii A.; 1974 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=355338
•
Effects of Salmonella typhimurium Infection and Ofloxacin Treatment on Glucose and Glutamine Metabolism in Caco-2/TC-7 Cells. by Posho L, Delbos-Bocage L, Gueylard D, Farinotti R, Carbon C.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105971
•
Electrogenic glutamine uptake by Peptostreptococcus anaerobius and generation of a transmembrane potential. by Beck BJ, Russell JB.; 1994 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205193
•
Electron Transport Controls Glutamine Synthetase Activity in the Facultative Heterotrophic Cyanobacterium Synechocystis sp. PCC 6803. by Reyes JC, Crespo JL, Garcia-Dominguez M, Florencio FJ.; 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=161391
•
Enzymatic synthesis of aminocyclitol moieties of aminoglycoside antibiotics from inositol by Streptomyces spp.: detection of glutamine-aminocyclitol aminotransferase and diaminocyclitol aminotransferase activities in a spectinomycin producer. by Walker JB.; 1995 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=176663
•
Expression of the Bacillus subtilis glutamine synthetase gene in Escherichia coli. by Gardner AL, Aronson AI.; 1984 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=215536
•
Fe2 +-Tetracycline-Mediated Cleavage of the Tn10 Tetracycline Efflux Protein TetA Reveals a Substrate Binding Site near Glutamine 225 in Transmembrane Helix 7. by McMurry LM, Aldema-Ramos ML, Levy SB.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=135328
•
Feedback inhibition of ammonium (methylammonium) ion transport in Escherichia coli by glutamine and glutamine analogs. by Jayakumar A, Hong JS, Barnes EM Jr.; 1987 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=211813
•
Formation of glutamine from [13n]ammonia, [13n]dinitrogen, and [14C]glutamate by heterocysts isolated from Anabaena cylindrica. by Thomas J, Meeks JC, Wolk CP, Shaffer PW, Austin SM.; 1977 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=235134
Studies
67
•
Genetic and biochemical characterization of glutamine synthetase from Neurospora crassa glutamine auxotrophs and their revertants. by Davila G, Brom S, Mora Y, Palacios R, Mora J.; 1983 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=217941
•
Genetic and Physiological Analysis of Germination Efficiency in Maize in Relation to Nitrogen Metabolism Reveals the Importance of Cytosolic Glutamine Synthetase. by Limami AM, Rouillon C, Glevarec G, Gallais A, Hirel B.; 2002 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=166697
•
Genetic control of glutamine synthetase in Klebiella aerogenes. by Streicher SL, Bender RA, Magasanik B.; 1975 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=285646
•
Genetic selection for active E.coli amber tRNA(Asn) exclusively led to glutamine inserting suppressors. by Martin F, Eriani G, Reinbolt J, Dirheimer G, Gangloff J.; 1995 Mar 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=306759
•
Genetics and physiology of Neurospora crassa glutamine auxotrophs. by Davila G, Sanchez F, Palacios R, Mora J.; 1978 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=222312
•
Genetics of the glutamine transport system in Escherichia coli. by Masters PS, Hong JS.; 1981 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=216116
•
Glutamine /proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. by Faber PW, Voisine C, King DC, Bates EA, Hart AC.; 2002 Dec 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=139281
•
Glutamine and glutamate transport by Anabaena variabilis. by Chapman JS, Meeks JC.; 1983 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=215059
•
Glutamine and proline accumulation by Staphylococcus aureus with reduction in water activity. by Anderson CB, Witter LD.; 1982 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=244260
•
Glutamine and related analogs regulate guanosine monophosphate reductase in Salmonella typhimurium. by Garber BB, Jochimsen BU, Gots JS.; 1980 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=294189
•
Glutamine as a feedback inhibitor of the Rhodopseudomonas sphaeroides nitrogenase system. by Jones BL, Monty KJ.; 1979 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218049
68
Glutamine
•
Glutamine auxotrophs of Bacillus subtilis that overproduce glutamine synthetase antigen have altered conserved amino acids in or near the active site. by Zhang J, Strauch M, Aronson AI.; 1989 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=210090
•
Glutamine Repeats as Polar Zippers: Their Possible Role in Inherited Neurodegenerative Diseases. by Perutz MF, Johnson T, Suzuki M, Finch JT.; 1994 Jun 7; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43993
•
Glutamine synthesis is a regulatory signal controlling glucose catabolism in Saccharomyces cerevisiae. by Flores-Samaniego B, Olivera H, Gonzalez A.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=206930
•
Glutamine synthetase and nitrogen cycling in colonies of the marine diazotrophic cyanobacteria Trichodesmium spp. by Carpenter EJ, Bergman B, Dawson R, Siddiqui PJ, Soderback E, Capone DG.; 1992 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=183058
•
Glutamine Synthetase GlnA1 Is Essential for Growth of Mycobacterium tuberculosis in Human THP-1 Macrophages and Guinea Pigs. by Tullius MV, Harth G, Horwitz MA.; 2003 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=162033
•
Glutamine synthetase of Klebsiella aerogenes: genetic and physiological properties of mutants in the adenylylation system. by Janssen KA, Magasanik B.; 1977 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=235039
•
Glutamine synthetase of pseudomonads: some biochemical and physicochemical properties. by Meyer JM, Stadtman ER.; 1981 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=217015
•
Glutamine synthetase protects against neuronal degeneration in injured retinal tissue. by Gorovits R, Avidan N, Avisar N, Shaked I, Vardimon L.; 1997 Jun 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21278
•
Glutamine-stimulated amino acid and peptide incorporation in Bacteroides melaninogenicus. by Lev M.; 1980 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=294358
•
Glu-tRNAGln amidotransferase: A novel heterotrimeric enzyme required for correct decoding of glutamine codons during translation. by Curnow AW, Hong KW, Yuan R, Kim SI, Martins O, Winkler W, Henkin TM, Soll D.; 1997 Oct 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23611
•
Gut mucosal and plasma concentrations of glutamine: a comparison between two enriched enteral feeding solutions in critically ill patients. by Preiser JC, Peres-Bota D, Eisendrath P, Vincent JL, Van Gossum A.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=270008
Studies
69
•
Helicobacter pylori Glutamine Synthetase Lacks Features Associated with Transcriptional and Posttranslational Regulation. by Garner RM, Fulkerson J Jr, Mobley HL.; 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108133
•
Heterogeneity in the polyglutamine tract of the glucocorticoid receptor from different rat strains. by Gearing KL, Gustafsson JA, Okret S.; 1993 Apr 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=309449
•
High Extracellular Levels of Mycobacterium tuberculosis Glutamine Synthetase and Superoxide Dismutase in Actively Growing Cultures Are Due to High Expression and Extracellular Stability Rather than to a Protein-Specific Export Mechanism. by Tullius MV, Harth G, Horwitz MA.; 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=98770
•
Identification of the structural gene for glutamine synthetase in Klebsiella aerogenes. by Deleo AB, Magasanik B.; 1975 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=285645
•
Immunochemical characterization of glutamine synthetase from Neurospora crassa glutamine auxotrophs. by Sanchez F, Davila G, Mora J, Palacios R.; 1979 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=216901
•
In Situ Glutamine Synthetase Activity in a Marine Unicellular Alga (Development of a Sensitive Colorimetric Assay and the Effects of Nitrogen Status on Enzyme Activity). by Rees T, Larson TR, Heldens J, Huning F.; 1995 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=157675
•
In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate --glutamine cycling. by Sibson NR, Dhankhar A, Mason GF, Behar KL, Rothman DL, Shulman RG.; 1997 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20152
•
In Vivo Regulation of Glutamine Synthetase Activity in the Marine Chlorophyll bContaining Cyanobacterium Prochlorococcus sp. Strain PCC 9511 (Oxyphotobacteria). by El Alaoui S, Diez J, Humanes L, Toribio F, Partensky F, Garcia-Fernandez JM.; 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92856
•
Incorporation of Glutamine Repeats Makes Protein Oligomerize: Implications for Neurodegenerative Diseases. by Stott K, Blackburn JM, Butler PJ, Perutz M.; 1995 Jul 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41547
•
Inhibition of Glutamate Transport in Synechococcus cedrorum by Glutamine. by Wan AY, Floyd KW, Hatch MT.; 1975 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=235998
•
Inhibition of Mycobacterium tuberculosis Glutamine Synthetase as a Novel Antibiotic Strategy against Tuberculosis: Demonstration of Efficacy In Vivo. by Harth G, Horwitz MA.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=143262
70
Glutamine
•
Isolation and characterization of a Neurospora crassa mutant altered in the alpha polypeptide of glutamine synthetase. by Calderon J, Martinez LM, Mora J.; 1990 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213155
•
Isolation of Klebsiella aerogenes mutants cis-dominant for glutamine synthetase expression. by Rothstein DM, Magasanik B.; 1980 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=293674
•
Isolation, characterization, and complementation of Rhizobium meliloti 104A14 mutants that lack glutamine synthetase II activity. by Somerville JE, Shatters RG, Kahn ML.; 1989 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=210320
•
Kinetic properties of a phosphate-bond-driven glutamate-glutamine transport system in Streptococcus lactis and Streptococcus cremoris. by Poolman B, Smid EJ, Konings WN.; 1987 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=212181
•
l-Glutamine as a Substrate for l-Asparaginase from Serratia marcescens. by Novak EK, Phillips AW.; 1974 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=285550
•
L-Glutamine formation by Flavobacterium rigense. by Yamada S, Nabe K, Ujimaru T, Izuo N, Chibata I.; 1979 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=243354
•
Lipase and Its Modulator from Pseudomonas sp. Strain KFCC 10818: Proline-toGlutamine Substitution at Position 112 Induces Formation of Enzymatically Active Lipase in the Absence of the Modulator. by Kim EK, Jang WH, Ko JH, Kang JS, Noh MJ, Yoo OJ.; 2001 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99672
•
Long-term regulation of neuronal high-affinity glutamate and glutamine uptake in Aplysia. by Levenson J, Endo S, Kategaya LS, Fernandez RI, Brabham DG, Chin J, Byrne JH, Eskin A.; 2000 Nov 7; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18854
•
Mechanism of -Glutamine Production by an -Glutamine-Producing Mutant of Flavobacterium rigense. by Nabe K, Yamada S, Chibata I.; 1981 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=244069
•
Metabolic regulation of the gene encoding glutamine-dependent asparagine synthetase in Arabidopsis thaliana. by Lam HM, Peng SS, Coruzzi GM.; 1994 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=159672
•
Methionine sulfoxide is transported by high-affinity methionine and glutamine transport systems in Salmonella typhimurium. by Ayling PD.; 1981 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=216234
Studies
71
•
Molecular analysis of the Azotobacter vinelandii glnA gene encoding glutamine synthetase. by Toukdarian A, Saunders G, Selman-Sosa G, Santero E, Woodley P, Kennedy C.; 1990 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213009
•
Molecular and regulatory properties of glutamine synthetase from the phototrophic bacterium Rhodopseudomonas capsulata E1F1. by Caballero FJ, Cejudo FJ, Florencio FJ, Cardenas J, Castillo F.; 1985 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218924
•
Molecular Basis of a Null Mutation in Soybean Lipoxygenase 2: Substitution of Glutamine for an Iron-Ligand Histidine. by Wang WH, Takano T, Shibata D, Kitamura K, Takeda G.; 1994 Jun 21; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=44090
•
Mutational Analysis of Bacillus subtilis Glutamine Phosphoribosylpyrophosphate Amidotransferase Propeptide Processing. by Li S, Smith JL, Zalkin H.; 1999 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93527
•
Mutations affecting glutamine synthetase activity in Salmonella typhimurium. by Kustu SG, McKereghan K.; 1975 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=246153
•
Mutations that alter the covalent modification of glutamine synthetase in Salmonella typhimurium. by Bancroft S, Rhee SG, Neumann C, Kustu S.; 1978 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=222354
•
Na +/Glutamine (Asparagine) Cotransport by Staphylococcus lugdunensis and Corynebacterium amycolatum. by Sarker RI, Maloney PC.; 2001 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=94982
•
Natural UAG suppressor glutamine tRNA is elevated in mouse cells infected with Moloney murine leukemia virus. by Kuchino Y, Beier H, Akita N, Nishimura S.; 1987 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=304719
•
Neurospora crassa mutant impaired in glutamine regulation. by Gonzalez A, Tenorio M, Vaca G, Mora J.; 1983 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=217643
•
New class of Bacillus subtilis glutamine-requiring mutants. by Reysset G.; 1981 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=216252
•
Nitrogen control of Salmonella typhimurium: co-regulation of synthesis of glutamine synthetase and amino acid transport systems. by Kustu SG, McFarland NC, Hui SP, Esmon B, Ames GF.; 1979 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218260
72
Glutamine
•
Nitrogen source regulates glutamine synthetase mRNA levels in Neurospora crassa. by Sanchez F, Campomanes M, Quinto C, Hansberg W, Mora J, Palacios R.; 1978 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218521
•
Normal Myeloid Development Requires Both the Glutamine-Rich Transactivation Domain and the PEST Region of Transcription Factor PU.1 but Not the Potent Acidic Transactivation Domain. by Fisher RC, Olson MC, Pongubala JM, Perkel JM, Atchison ML, Scott EW, Simon MC.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109018
•
Nuclear respiratory factors 1 and 2 utilize similar glutamine-containing clusters of hydrophobic residues to activate transcription. by Gugneja S, Virbasius CM, Scarpulla RC.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=231571
•
Omega-amidase pathway in the degradation of glutamine in Neurospora crassa. by Calderon J, Morett E, Mora J.; 1985 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=214962
•
Organization and nucleotide sequence of the glutamine synthetase (glnA) gene from Lactobacillus delbrueckii subsp. bulgaricus. by Ishino Y, Morgenthaler P, Hottinger H, Soll D.; 1992 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=183065
•
Overexpression of Cytosolic Glutamine Synthetase. Relation to Nitrogen, Light, and Photorespiration. by Oliveira IC, Brears T, Knight TJ, Clark A, Coruzzi GM.; 2002 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=166511
•
Oxidative Turnover of Soybean Root Glutamine Synthetase. In Vitro and in Vivo Studies. by Ortega JL, Roche D, Sengupta-Gopalan C.; 1999 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=32034
•
Oxygen-dependent inactivation of glutamine phosphoribosylpyrophosphate amidotransferase in stationary-phase cultures of Bacillus subtilis. by Turnbough CL Jr, Switzer RL.; 1975 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=285619
•
Oxygen-dependent inactivation of glutamine phosphoribosylpyrophosphate amidotransferase in vitro inactivation. by Turnbough CL Jr, Switzer RL.; 1975 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=285620
•
Pathway of proton transfer in bacterial reaction centers: replacement of glutamic acid 212 in the L subunit by glutamine inhibits quinone (secondary acceptor) turnover. by Paddock ML, Rongey SH, Feher G, Okamura MY.; 1989 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=297892
•
Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: Relevance to diseases of the nervous system. by Kahlem P, Terre C, Green H, Djian P.; 1996 Dec 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26176
Studies
73
•
Peroxynitrite-Mediated Nitration of Tyrosine Residues in Escherichia coli Glutamine Synthetase Mimics Adenylylation: Relevance to Signal Transduction. by Berlett BS, Friguet B, Yim MB, Chock PB, Stadtman ER.; 1996 Mar 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39857
•
Photorespiratory NH4 + Production in Leaves of Wild-Type and Glutamine Synthetase 2 Antisense Oilseed Rape. by Husted S, Mattsson M, Mollers C, Wallbraun M, Schjoerring JK.; 2002 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=166624
•
Phytochrome-Mediated Photoperiod Perception, Shoot Growth, Glutamine, Calcium, and Protein Phosphorylation Influence the Activity of the Poplar Bark Storage Protein Gene Promoter (bspA). by Zhu B, Coleman GD.; 2001 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=102308
•
Poliovirus capsid proteins derived from P1 precursors with glutamine-valine cleavage sites have defects in assembly and RNA encapsidation. by Ansardi DC, Morrow CD.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238192
•
Promoter-specific transactivation of hepatitis B virus transcription by a glutamineand proline-rich domain of hepatocyte nuclear factor 1. by Raney AK, Easton AJ, Milich DR, McLachlan A.; 1991 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=250238
•
Properties of the Bacillus licheniformis A5 glutamine synthetase purified from cells grown in the presence of ammonia or nitrate. by Donohue TJ, Bernlohr RW.; 1981 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=216080
•
Purification of PII and PII-UMP and In Vitro Studies of Regulation of Glutamine Synthetase in Rhodospirillum rubrum. by Johansson M, Nordlund S.; 1999 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=103790
•
Rapid biosynthesis of N-linolenoyl-l-glutamine, an elicitor of plant volatiles, by membrane-associated enzyme(s) in Manduca sexta. by Lait CG, Alborn HT, Teal PE, Tumlinson JH III.; 2003 Jun 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=165824
•
Reactions catalyzed by purified L-glutamine: keto-scyllo-inositol aminotransferase, an enzyme required for biosynthesis of aminocyclitol antibiotics. by Lucher LA, Chen YM, Walker JB.; 1989 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=172459
•
Regulation of a glutamine amidotransferase subunit from Bacillus subtilis by a cloned trpE gene from Bacillus pumilus. by Kane JF, Hill RJ.; 1980 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=293734
74
Glutamine
•
Regulation of Anabaena sp. strain PCC 7120 glutamine synthetase activity in a Synechocystis sp. strain PCC 6803 derivative strain bearing the Anabaena glnA gene and a mutated host glnA gene. by Merida A, Flores E, Florencio FJ.; 1992 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205765
•
Regulation of Bacillus subtilis glutamine phosphoribosylpyrophosphate amidotransferase inactivation in vivo. by Bernlohr DA, Switzer RL.; 1983 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=221717
•
Regulation of enzyme formation in Klebsiella aerogenes by episomal glutamine synthetase of Escherichia coli. by Streicher SL, Deleo AB, Magasanik B.; 1976 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=233050
•
Regulation of glutamine synthesis by glycine and serine in Neurospora crassa. by Hernandez G, Mora Y, Mora J.; 1986 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=214380
•
Regulation of glutamine synthetase activity in the unicellular cyanobacterium Synechocystis sp. strain PCC 6803 by the nitrogen source: effect of ammonium. by Merida A, Candau P, Florencio FJ.; 1991 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=208058
•
Regulation of glutamine synthetase by regulatory protein PII in Klebsiella aerogenes mutants lacking adenylyltransferase. by Reuveny Z, Foor F, Magasanik B.; 1981 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=217020
•
Regulation of glutamine synthetase formation in Escherichia coli: characterization of mutants lacking the uridylyltransferase. by Bloom FR, Levin MS, Foor F, Tyler B.; 1978 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=222288
•
Regulation of glutamine synthetase II activity in Rhizobium meliloti 104A14. by Shatters RG, Somerville JE, Kahn ML.; 1989 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=210321
•
Regulation of Glutamine Synthetase II. Patterns of Feedback Inhibition in Microorganisms. by Hubbard JS, Stadtman ER.; 1967 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=276552
•
Regulation of glutamine synthetase in Streptomyces coelicolor. by Fisher SH, Wray LV Jr.; 1989 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=209911
Studies
75
•
Regulation of Glutamine Synthetase V. Partial Purification and Properties of Glutamine Synthetase from Bacillus licheniformis. by Hubbard JS, Stadtman ER.; 1967 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=276769
•
Regulation of Glutamine Synthetase VI. Interactions of Inhibitors for Bacillus licheniformis Glutamine Synthetase. by Hubbard JS, Stadtman ER.; 1967 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=276770
•
Regulation of Glutamine Synthetase X. Effect of Growth Conditions on the Susceptibility of Escherichia coli Glutamine Synthetase to Feedback Inhibition. by Kingdon HS, Stadtman ER.; 1967 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=276760
•
Regulation of Glutamine Transport in Escherichia coli. by Willis RC, Iwata KK, Furlong CE.; 1975 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=246156
•
Regulation of Nitrogen Fixation in Klebsiella pneumoniae: Evidence for a Role of Glutamine Synthetase as a Regulator of Nitrogenase Synthesis. by Streicher SL, Shanmugam KT, Ausubel F, Morandi C, Goldberg RB.; 1974 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=245843
•
Regulation of nitrogen metabolism in glutamine auxotrophs of Klebsiella pneumoniae. by Leonardo JM, Goldberg RB.; 1980 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=293910
•
Regulation of Synthesis of Glutamine Synthase in Bacillus subtilis. by Rebello JL, Strauss N.; 1969 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=284872
•
Regulation of the activity of the Bacillus licheniformis A5 glutamine synthetase. by Donohue TJ, Bernlohr RW.; 1981 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=216179
•
Regulation of the biosynthesis of aminoacyl-transfer ribonucleic acid synthetases and of transfer ribonucleic acid in Escherichia coli. VI. Mutants with increased levels of glutaminyl-transfer ribonucleic acid synthetase and of glutamine transfer ribonucleic acid. by Cheung A, Morgan S, Low KB, Soll D.; 1979 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=216843
•
Regulation of the glutamate-glutamine transport system by intracellular pH in Streptococcus lactis. by Poolman B, Hellingwerf KJ, Konings WN.; 1987 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=212150
76
Glutamine
•
Regulatory mutations in the Klebsiella aerogenes structural gene for glutamine synthetase. by Bender RA, Magasanik B.; 1977 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=221831
•
Relation between the adenylylation state of glutamine synthetase and the expression of other genes involved in nitrogen metabolism. by Goldberg RB, Hanau R.; 1979 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218311
•
Repression of nitrate reductase in Neurospora studied by using L-methionine-DLsulfoximine and glutamine auxotroph gln-1b. by Premakumar R, Sorger GJ, Gooden D.; 1980 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=294258
•
Requirement for membrane potential in active transport of glutamine by Escherichia coli. by Plate CA.; 1979 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218439
•
Rhizobium meliloti 1021 has three differentially regulated loci involved in glutamine biosynthesis, none of which is essential for symbiotic nitrogen fixation. by de Bruijn FJ, Rossbach S, Schneider M, Ratet P, Messmer S, Szeto WW, Ausubel FM, Schell J.; 1989 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=209797
•
Role of glnA-linked genes in regulation of glutamine synthetase and histidase formation in Klebsiella aerogenes. by Rothman N, Rothstein D, Foor F, Magasanik B.; 1982 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=220102
•
Role of Glutamine 17 of the Bovine Papillomavirus E5 Protein in Platelet-Derived Growth Factor [beta] Receptor Activation and Cell Transformation. by Klein O, Polack GW, Surti T, Kegler-Ebo D, Smith SO, DiMaio D.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110309
•
Role of Glutamine Synthetase in Nitrogen Metabolite Repression in Aspergillus nidulans. by Margelis S, D'Souza C, Small AJ, Hynes MJ, Adams TH, Davis MA.; 2001 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99658
•
Role of glutamine synthetase in the uptake and metabolism of methylammonium by Azotobacter vinelandii. by Barnes EM Jr, Zimniak P, Jayakumar A.; 1983 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=217892
•
Role of Glutamine-117 in the Ribonucleolytic Activity of Human Angiogenin. by Russo N, Shapiro R, Acharya KR, Riordan JF, Vallee BL.; 1994 Apr 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43486
Studies
77
•
Salmonella typhimurium LT-2 mutants with altered glutamine synthetase levels and amino acid uptake activities. by Funanage VL, Ayling PD, Dendinger SM, Brenchley JE.; 1978 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=218583
•
Search for revertants of the glutamine mischarging mutans of Escherichia coli su+3 tyrosine suppressor tRNA that are able to insert tyrosine at the site of amber mutation. by Celis JE, Squire M, Kaltoft K, Riisom E.; 1977 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=342609
•
Sequence of the GLN1 gene of Saccharomyces cerevisiae: role of the upstream region in regulation of glutamine synthetase expression. by Minehart PL, Magasanik B.; 1992 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205784
•
Simultaneous prevention of glutamine synthesis and high-affinity transport attenuates Salmonella typhimurium virulence. by Klose KE, Mekalanos JJ.; 1997 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=176100
•
Stimulation of glutamine transport by osmotic stress in Escherichia coli K-12. by Gehring K, Hofnung M, Nikaido H.; 1990 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213319
•
Streptomyces hygroscopicus has two glutamine synthetase genes. by Kumada Y, Takano E, Nagaoka K, Thompson CJ.; 1990 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213198
•
Structural role for a conserved region in the CTP synthetase glutamine amide transfer domain. by Weng ML, Zalkin H.; 1987 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=212343
•
Subunit Interactions and Glutamine Utilization by Escherichia coli Imidazole Glycerol Phosphate Synthase. by Klem TJ, Chen Y, Davisson VJ.; 2001 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=94967
•
Suppression of a deletion mutation in the glutamine amidotransferase region of the Salmonella typhimurium trpD gene by mutations in pheA and tyrA. by Tanemura S, Bauerle R.; 1979 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=216906
•
Switching tRNAGln Identity from Glutamine to Tryptophan. by Rogers MJ, Adachi T, Inokuchi H, Soll D.; 1992 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48888
78
Glutamine
•
Temperature-Dependent Function of the Glutamine Phosphoribosylpyrophosphate Amidotransferase Ammonia Channel and Coupling with Glycinamide Ribonucleotide Synthetase in a Hyperthermophile. by Bera AK, Chen S, Smith JL, Zalkin H.; 2000 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=94544
•
The actinorhizal root-nodule symbiont Frankia sp. strain CpI1 has two glutamine synthetases. by Edmands J, Noridge NA, Benson DR.; 1987 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=299021
•
The central hydrophobic domain of the bovine papillomavirus E5 transforming protein can be functionally replaced by many hydrophobic amino acid sequences containing a glutamine. by Kulke R, Horwitz BH, Zibello T, DiMaio D.; 1992 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238311
•
The femC locus of Staphylococcus aureus required for methicillin resistance includes the glutamine synthetase operon. by Gustafson J, Strassle A, Hachler H, Kayser FH, Berger-Bachi B.; 1994 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205213
•
The glutamine-rich activation domains of human Sp1 do not stimulate transcription in Saccharomyces cerevisiae. by Ponticelli AS, Pardee TS, Struhl K.; 1995 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=231990
•
The hemK gene in Escherichia coli encodes the N5-glutamine methyltransferase that modifies peptide release factors. by Heurgue-Hamard V, Champ S, Engstrom A, Ehrenberg M, Buckingham RH.; 2002 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=125846
•
The Metastatic Suppressor Nm23-H1 Interacts with EBNA3C at Sequences Located between the Glutamine- and Proline-Rich Domains and Can Cooperate in Activation of Transcription. by Subramanian C, Robertson ES.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136985
•
The Saccharomyces cerevisiae YCC5 (YCL025c) Gene Encodes an Amino Acid Permease, Agp1, Which Transports Asparagine and Glutamine. by Schreve JL, Sin JK, Garrett JM.; 1998 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=107201
•
The structures of anthranilate synthase of Serratia marcescens crystallized in the presence of (i) its substrates, chorismate and glutamine, and a product, glutamate, and (ii) its end-product inhibitor, l-tryptophan. by Spraggon G, Kim C, Nguyen-Huu X, Yee MC, Yanofsky C, Mills SE.; 2001 May 22; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33415
•
The Synechococcus Strain PCC 7942 glnN Product (Glutamine Synthetase III) Helps Recovery from Prolonged Nitrogen Chlorosis. by Sauer J, Dirmeier U, Forchhammer K.; 2000 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111011
Studies
79
•
The TOR-controlled transcription activators GLN3, RTG1, and RTG3 are regulated in response to intracellular levels of glutamine. by Crespo JL, Powers T, Fowler B, Hall MN.; 2002 May 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=124480
•
Transport of glutamine by Streptococcus bovis and conversion of glutamine to pyroglutamic acid and ammonia. by Chen GJ, Russell JB.; 1989 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=210004
•
Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-l-glutamate /glutamine cell wall structure, and bacterial replication. by Harth G, Zamecnik PC, Tang JY, Tabatadze D, Horwitz MA.; 2000 Jan 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26678
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with glutamine, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “glutamine” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for glutamine (hyperlinks lead to article summaries): •
A brain-specific isoform of small glutamine-rich tetratricopeptide repeat-containing protein binds to Hsc70 and the cysteine string protein. Author(s): Tobaben S, Varoqueaux F, Brose N, Stahl B, Meyer G. Source: The Journal of Biological Chemistry. 2003 October 3; 278(40): 38376-83. Epub 2003 July 23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878599&dopt=Abstract
•
A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions. Author(s): Michelitsch MD, Weissman JS. Source: Proceedings of the National Academy of Sciences of the United States of America. 2000 October 24; 97(22): 11910-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11050225&dopt=Abstract
6 PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
80
Glutamine
•
A glutamine transport gene, glnQ, is required for fibronectin adherence and virulence of group B streptococci. Author(s): Tamura GS, Nittayajarn A, Schoentag DL. Source: Infection and Immunity. 2002 June; 70(6): 2877-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010975&dopt=Abstract
•
A method to assess compositional bias in biological sequences and its application to prion-like glutamine/asparagine-rich domains in eukaryotic proteomes. Author(s): Harrison PM, Gerstein M. Source: Genome Biology. 2003; 4(6): R40. Epub 2003 May 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12801414&dopt=Abstract
•
A novel glutamine-rich putative transcriptional adaptor protein (TIG-1), preferentially expressed in placental and bone-marrow tissues. Author(s): Abraham S, Solomon WB. Source: Gene. 2000 September 19; 255(2): 389-400. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11024300&dopt=Abstract
•
A novel variant of glutamine: fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in striated muscle. Author(s): DeHaven JE, Robinson KA, Nelson BA, Buse MG. Source: Diabetes. 2001 November; 50(11): 2419-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11679416&dopt=Abstract
•
A radiometric assay for glutamine:fructose-6-phosphate amidotransferase. Author(s): Broschat KO, Gorka C, Kasten TP, Gulve EA, Kilpatrick B. Source: Analytical Biochemistry. 2002 June 1; 305(1): 10-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12018941&dopt=Abstract
•
A randomized, controlled trial of parenteral glutamine in ill, very low birth-weight neonates. Author(s): Thompson SW, McClure BG, Tubman TR. Source: Journal of Pediatric Gastroenterology and Nutrition. 2003 November; 37(5): 5503. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14581795&dopt=Abstract
•
Acute effects of intravenous glutamine supplementation on protein metabolism in very low birth weight infants: a stable isotope study. Author(s): des Robert C, Le Bacquer O, Piloquet H, Roze JC, Darmaun D. Source: Pediatric Research. 2002 January; 51(1): 87-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11756645&dopt=Abstract
Studies
81
•
Acute enteral glutamine infusion enhances heme oxygenase-1 expression in human duodenal mucosa. Author(s): Coeffier M, Le Pessot F, Leplingard A, Marion R, Lerebours E, Ducrotte P, Dechelotte P. Source: The Journal of Nutrition. 2002 September; 132(9): 2570-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12221210&dopt=Abstract
•
Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Author(s): Michael N, Erfurth A, Ohrmann P, Gossling M, Arolt V, Heindel W, Pfleiderer B. Source: Psychopharmacology. 2003 July; 168(3): 344-6. Epub 2003 April 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684737&dopt=Abstract
•
Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid betapeptide of amyloid plaques. Author(s): Perutz MF, Pope BJ, Owen D, Wanker EE, Scherzinger E. Source: Proceedings of the National Academy of Sciences of the United States of America. 2002 April 16; 99(8): 5596-600. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11960015&dopt=Abstract
•
Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Author(s): Jana NR, Zemskov EA, Wang Gh, Nukina N. Source: Human Molecular Genetics. 2001 May 1; 10(10): 1049-59. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11331615&dopt=Abstract
•
Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. Author(s): Romero-Gomez M, Grande L, Camacho I, Benitez S, Irles JA, Castro M. Source: Journal of Hepatology. 2002 December; 37(6): 781-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12445419&dopt=Abstract
•
Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Author(s): Chen S, Berthelier V, Hamilton JB, O'Nuallain B, Wetzel R. Source: Biochemistry. 2002 June 11; 41(23): 7391-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044172&dopt=Abstract
82
Glutamine
•
An alternative method to supplement glutamine in parenteral nutrition? Author(s): Sandifer DP. Source: Critical Care Medicine. 2000 November; 28(11): 3761-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11098992&dopt=Abstract
•
An arginine/glutamine difference at the juxtaposition of transmembrane domain 6 and the third extracellular loop contributes to the markedly different nucleotide selectivities of human and canine P2Y11 receptors. Author(s): Qi AD, Zambon AC, Insel PA, Nicholas RA. Source: Molecular Pharmacology. 2001 December; 60(6): 1375-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11723245&dopt=Abstract
•
An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils. Author(s): Bevivino AE, Loll PJ. Source: Proceedings of the National Academy of Sciences of the United States of America. 2001 October 9; 98(21): 11955-60. Epub 2001 September 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11572942&dopt=Abstract
•
Androgen receptor gene polyglutamine length is associated with testicular histology in infertile patients. Author(s): Casella R, Maduro MR, Misfud A, Lipshultz LI, Yong EL, Lamb DJ. Source: The Journal of Urology. 2003 January; 169(1): 224-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478141&dopt=Abstract
•
Androgen receptors containing expanded polyglutamine tracts exhibit progressive toxicity when stably expressed in the neuroblastoma cell line, SH-SY 5Y. Author(s): Avila DM, Allman DR, Gallo JM, McPhaul MJ. Source: Experimental Biology and Medicine (Maywood, N.J.). 2003 September; 228(8): 982-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12968071&dopt=Abstract
•
Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema. Author(s): Picker JD, Puga AC, Levy HL, Marsden D, Shih VE, Degirolami U, Ligon KL, Cederbaum SD, Kern RM, Cox GF. Source: The Journal of Pediatrics. 2003 March; 142(3): 349-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12640389&dopt=Abstract
•
Assessment of the safety of glutamine and other amino acids. Author(s): Garlick PJ. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2556S-61S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533313&dopt=Abstract
Studies
83
•
Association study between CAG trinucleotide repeats in the PCQAP gene (PC2 glutamine/Q-rich-associated protein) and schizophrenia. Author(s): De Luca A, Conti E, Grifone N, Amati F, Spalletta G, Caltagirone C, Bonaviri G, Pasini A, Gennarelli M, Stefano B, Berti L, Mittler G, Meisterernst M, Dallapiccola B, Novelli G. Source: American Journal of Medical Genetics. 2003 January 1; 116B(1): 32-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12497610&dopt=Abstract
•
Atypical MELAS syndrome associated with a new mitochondrial tRNA glutamine point mutation. Author(s): Bataillard M, Chatzoglou E, Rumbach L, Sternberg D, Tournade A, Laforet P, Jardel C, Maisonobe T, Lombes A. Source: Neurology. 2001 February 13; 56(3): 405-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11171912&dopt=Abstract
•
Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Author(s): La Heij EC, van de Waarenburg MP, Blaauwgeers HG, Kessels AG, Liem AT, Theunissen C, Steinbusch H, Hendrikse F. Source: American Journal of Ophthalmology. 2002 September; 134(3): 367-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12208248&dopt=Abstract
•
Beyond the Qs in the polyglutamine diseases. Author(s): Orr HT. Source: Genes & Development. 2001 April 15; 15(8): 925-32. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11316786&dopt=Abstract
•
Can glutamine and growth hormone promote protein anabolism in children with cystic fibrosis? Author(s): Hayes V, Schaeffer D, Mauras N, Punati J, Darmaun D. Source: Hormone Research. 2002; 58 Suppl 1: 21-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12373009&dopt=Abstract
•
Can glutamine modify the apparent immunodepression observed after prolonged, exhaustive exercise? Author(s): Castell LM. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 May; 18(5): 371-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11985938&dopt=Abstract
84
Glutamine
•
Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Author(s): Perutz MF, Windle AH. Source: Nature. 2001 July 12; 412(6843): 143-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11449262&dopt=Abstract
•
Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease. Author(s): Robinson SR. Source: Journal of Neuroscience Research. 2001 December 1; 66(5): 972-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11746426&dopt=Abstract
•
Changes in the nutritional state and immune-serological parameters of esophagectomized patients fed jejunaly with glutamine-poor and glutamine-rich nutriments. Author(s): Hallay J, Kovacs G, Kiss Sz S, Farkas M, Lakos G, Sipka S, Bodolay E, Sapy P. Source: Hepatogastroenterology. 2002 November-December; 49(48): 1555-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12397734&dopt=Abstract
•
Characteristics of L-glutamine transport during Caco-2 cell differentiation. Author(s): Costa C, Huneau J, Tome D. Source: Biochimica Et Biophysica Acta. 2000 December 20; 1509(1-2): 95-102. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11118521&dopt=Abstract
•
Characterization of L-glutamine transport by a human neuroblastoma cell line. Author(s): Wasa M, Wang HS, Okada A. Source: American Journal of Physiology. Cell Physiology. 2002 June; 282(6): C1246-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11997238&dopt=Abstract
•
Clinical evidence for enteral nutritional support with glutamine: a systematic review. Author(s): Garcia-de-Lorenzo A, Zarazaga A, Garcia-Luna PP, Gonzalez-Huix F, LopezMartinez J, Mijan A, Quecedo L, Casimiro C, Usan L, del Llano J. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2003 September; 19(9): 805-11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12921894&dopt=Abstract
•
Cloning and characterization of mouse glutamine:fructose-6-phosphate amidotransferase 2 gene promoter. Author(s): Yamazaki K, Mizui Y, Oki T, Okada M, Tanaka I. Source: Gene. 2000 December 31; 261(2): 329-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11167021&dopt=Abstract
Studies
85
•
Combination of recombinant human growth hormone and glutamine-enriched total parenteral nutrition to surgical patients: effects on circulating amino acids. Author(s): Kolstad O, Jenssen TG, Ingebretsen OC, Vinnars E, Revhaug A. Source: Clinical Nutrition (Edinburgh, Lothian). 2001 December; 20(6): 503-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11883998&dopt=Abstract
•
Combined growth hormone/insulin-like growth factor I in addition to glutaminesupplemented TPN results in net protein anabolism in critical illness. Author(s): Carroll PV, Jackson NC, Russell-Jones DL, Treacher DF, Sonksen PH, Umpleby AM. Source: American Journal of Physiology. Endocrinology and Metabolism. 2004 January; 286(1): E151-7. Epub 2003 May 20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12759221&dopt=Abstract
•
Comparison of a immunonutrition formula enriched arginine, glutamine and omega3 fatty acid, with a currently high-enriched enteral nutrition for trauma patients. Author(s): Chuntrasakul C, Siltham S, Sarasombath S, Sittapairochana C, Leowattana W, Chockvivatanavanit S, Bunnak A. Source: J Med Assoc Thai. 2003 June; 86(6): 552-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12924804&dopt=Abstract
•
Compartmentation of glutamine, glutamate, and GABA metabolism in neurons and astrocytes: functional implications. Author(s): Waagepetersen HS, Sonnewald U, Schousboe A. Source: The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 2003 October; 9(5): 398-403. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14580123&dopt=Abstract
•
Conditionally indispensable amino acids (glutamine, cyst(e)ine, tyrosine, arginine, ornithine, taurine) in enteral feeding and the dipeptide concept. Author(s): Furst P. Source: Nestle Nutr Workshop Ser Clin Perform Programme. 2000; 3: 199-217; Discussion 217-9. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11490607&dopt=Abstract
•
Continuous and intermittent exposure to the hypoxia of altitude: implications for glutamine metabolism and exercise performance. Author(s): Bailey DM, Castell LM, Newsholme EA, Davies B. Source: British Journal of Sports Medicine. 2000 June; 34(3): 210-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10854022&dopt=Abstract
86
Glutamine
•
Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Author(s): Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Source: Antimicrobial Agents and Chemotherapy. 2000 September; 44(9): 2276-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10952568&dopt=Abstract
•
Cost-containment with glutamine dipeptide-supplemented TPN. Author(s): Sitges-Serra A. Source: Clinical Nutrition (Edinburgh, Lothian). 2001 June; 20(3): 285-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11407879&dopt=Abstract
•
Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)HMRS at 0.5 T. Author(s): Antuono PG, Jones JL, Wang Y, Li SJ. Source: Neurology. 2001 March 27; 56(6): 737-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11274307&dopt=Abstract
•
Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Author(s): Garrel D, Patenaude J, Nedelec B, Samson L, Dorais J, Champoux J, D'Elia M, Bernier J. Source: Critical Care Medicine. 2003 October; 31(10): 2444-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14530749&dopt=Abstract
•
Decreased plasma and cerebrospinal fluid glutamine concentrations in a patient with bialaphos poisoning. Author(s): Ohtake T, Yasuda H, Takahashi H, Goto T, Suzuki K, Yonemura K, Hishida A. Source: Human & Experimental Toxicology. 2001 August; 20(8): 429-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11727795&dopt=Abstract
•
Deficiency in peripheral glutamine production in pediatric patients with burns. Author(s): Gore DC, Jahoor F. Source: The Journal of Burn Care & Rehabilitation. 2000 March-April; 21(2): 171; Discussion 172-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10752751&dopt=Abstract
•
Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2. Author(s): Miyashita T, Enosawa S, Suzuki S, Tamura A, Tanaka H, Amemiya H, Matsumura T, Omasa T, Suga K, Aoki T, Koyanagi Y. Source: Transplantation Proceedings. 2000 November; 32(7): 2355-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11120198&dopt=Abstract
Studies
87
•
Does glutamine enable severely ill intensive care patients to cope better with infection and increase their chance of survival? Author(s): Hardy G. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 September; 18(9): 712-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297200&dopt=Abstract
•
Dysregulatory dysequilibrium of gene transcription and of nuclear transport in polyglutamine neuro-degeneration. Author(s): Agius LM. Source: Medical Hypotheses. 2003 June; 60(6): 869-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12699716&dopt=Abstract
•
Early endosomal localization of hrs requires a sequence within the proline- and glutamine-rich region but not the FYVE finger. Author(s): Hayakawa A, Kitamura N. Source: The Journal of Biological Chemistry. 2000 September 22; 275(38): 29636-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10889197&dopt=Abstract
•
Effect of a glutamine-enriched enteral diet on intestinal permeability and infectious morbidity at 28 days in critically ill patients with systemic inflammatory response syndrome: a randomized, single-blind, prospective, multicenter study. Author(s): Conejero R, Bonet A, Grau T, Esteban A, Mesejo A, Montejo JC, Lopez J, Acosta JA. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 September; 18(9): 716-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297203&dopt=Abstract
•
Effect of a short CAG (glutamine) repeat on human androgen receptor function. Author(s): Ding D, Xu L, Menon M, Reddy GP, Barrack ER. Source: The Prostate. 2004 January 1; 58(1): 23-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14673949&dopt=Abstract
•
Effect of blood ammonia elevation following oral glutamine load on the psychometric performance of cirrhotic patients. Author(s): Masini A, Efrati C, Merli M, Nicolao F, Amodio P, Del Piccolo F, Riggio O. Source: Metabolic Brain Disease. 2003 March; 18(1): 27-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12603080&dopt=Abstract
88
Glutamine
•
Effect of enteral glutamine on leucine, phenylalanine and glutamine metabolism in hypercortisolemic subjects. Author(s): Claeyssens S, Bouteloup-Demange C, Gachon P, Hecketsweiler B, Lerebours E, Lavoinne A, Dechelotte P. Source: American Journal of Physiology. Endocrinology and Metabolism. 2000 May; 278(5): E817-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10780937&dopt=Abstract
•
Effect of enteral supplementation with glutamine on mesenteric blood flow in premature neonates. Author(s): Mercier A, Eurin D, Poulet-Young V, Marret S, Dechelotte P. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 April; 22(2): 133-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12706129&dopt=Abstract
•
Effect of glutamine and protein supplementation on exercise-induced decreases in salivary IgA. Author(s): Krzywkowski K, Petersen EW, Ostrowski K, Link-Amster H, Boza J, Halkjaer-Kristensen J, Pedersen BK. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2001 August; 91(2): 832-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11457800&dopt=Abstract
•
Effect of glutamine in short-bowel syndrome. Author(s): Scolapio JS, McGreevy K, Tennyson GS, Burnett OL. Source: Clinical Nutrition (Edinburgh, Lothian). 2001 August; 20(4): 319-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11478829&dopt=Abstract
•
Effect of glutamine supplementation combined with resistance training in young adults. Author(s): Candow DG, Chilibeck PD, Burke DG, Davison KS, Smith-Palmer T. Source: European Journal of Applied Physiology. 2001 December; 86(2): 142-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11822473&dopt=Abstract
•
Effect of glutamine supplementation on exercise-induced changes in lymphocyte function. Author(s): Krzywkowski K, Petersen EW, Ostrowski K, Kristensen JH, Boza J, Pedersen BK. Source: American Journal of Physiology. Cell Physiology. 2001 October; 281(4): C125965. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11546663&dopt=Abstract
Studies
89
•
Effect of glutamine-enriched total parenteral nutrition in patients with acute pancreatitis. Author(s): Ockenga J, Borchert K, Rifai K, Manns MP, Bischoff SC. Source: Clinical Nutrition (Edinburgh, Lothian). 2002 October; 21(5): 409-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12381339&dopt=Abstract
•
Effect of growth hormone and glutamine on the short bowel: five years later. Author(s): Scolapio JS. Source: Gut. 2000 August; 47(2): 164. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10896902&dopt=Abstract
•
Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Author(s): Szkudlarek J, Jeppesen PB, Mortensen PB. Source: Gut. 2000 August; 47(2): 199-205. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10896910&dopt=Abstract
•
Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study. Author(s): Jeppesen PB, Szkudlarek J, Hoy CE, Mortensen PB. Source: Scandinavian Journal of Gastroenterology. 2001 January; 36(1): 48-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11218239&dopt=Abstract
•
Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Author(s): Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO. Source: Gut. 2000 October; 47(4): 571-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10986219&dopt=Abstract
•
Effect of oral glutamine supplementation during bone marrow transplantation. Author(s): Coghlin Dickson TM, Wong RM, offrin RS, Shizuru JA, Johnston LJ, Hu WW, Blume KG, Stockerl-Goldstein KE. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2000 March-April; 24(2): 61-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10772184&dopt=Abstract
90
Glutamine
•
Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants. Author(s): Poindexter BB, Ehrenkranz RA, Stoll BJ, Koch MA, Wright LL, Oh W, Papile LA, Bauer CR, Carlo WA, Donovan EF, Fanaroff AA, Korones SB, Laptook AR, Shankaran S, Stevenson DK, Tyson JE, Lemons JA; National Institute of Child Health and Human Development Neonatal Research Network. Source: The American Journal of Clinical Nutrition. 2003 March; 77(3): 737-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12600870&dopt=Abstract
•
Effect of replacing the aspartic acid/glutamic acid residues of bullfrog sialic acid binding lectin with asparagine/glutamine and arginine on the inhibition of cell proliferation in murine leukemia P388 cells. Author(s): Ogawa Y, Iwama M, Ohgi K, Tsuji T, Irie M, Itagaki T, Kobayashi H, Inokuchi N. Source: Biological & Pharmaceutical Bulletin. 2002 June; 25(6): 722-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12081136&dopt=Abstract
•
Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Author(s): Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Source: The American Journal of Gastroenterology. 2000 December; 95(12): 3574-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11151894&dopt=Abstract
•
Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Author(s): Pfleiderer B, Michael N, Erfurth A, Ohrmann P, Hohmann U, Wolgast M, Fiebich M, Arolt V, Heindel W. Source: Psychiatry Research. 2003 April 1; 122(3): 185-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12694892&dopt=Abstract
•
Effects of an oral mixture containing glycine, glutamine and niacin on memory, GH and IGF-I secretion in middle-aged and elderly subjects. Author(s): Arwert LI, Deijen JB, Drent ML. Source: Nutritional Neuroscience. 2003 October; 6(5): 269-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14609312&dopt=Abstract
•
Effects of arginine, L-alanyl-L-glutamine or taurine on neutrophil (PMN) free amino acid profiles and immune functions in vitro. Author(s): Muhling J, Fuchs M, Fleck C, Sablotzki A, Krull M, Dehne MG, Gonter J, Weiss S, Engel J, Hempelmann G. Source: Amino Acids. 2002; 22(1): 39-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12025873&dopt=Abstract
Studies
91
•
Effects of enteral glutamine on gut mucosal protein synthesis in healthy humans receiving glucocorticoids. Author(s): Bouteloup-Demange C, Claeyssens S, Maillot C, Lavoinne A, Lerebours E, Dechelotte P. Source: American Journal of Physiology. Gastrointestinal and Liver Physiology. 2000 May; 278(5): G677-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10801259&dopt=Abstract
•
Effects of glutamine deprivation on protein synthesis in a model of human enterocytes in culture. Author(s): Le Bacquer O, Nazih H, Blottiere H, Meynial-Denis D, Laboisse C, Darmaun D. Source: American Journal of Physiology. Gastrointestinal and Liver Physiology. 2001 December; 281(6): G1340-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11705738&dopt=Abstract
•
Effects of glutamine isomers on human (Caco-2) intestinal epithelial proliferation, strain-responsiveness, and differentiation. Author(s): Murnin M, Kumar A, Li GD, Brown M, Sumpio BE, Basson MD. Source: Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract. 2000 July-August; 4(4): 435-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11058864&dopt=Abstract
•
Effects of glutamine on tumor growth and apoptosis of hepatoma cells. Author(s): Liu SL, Shi DY, Shen ZH, Wu YD. Source: Acta Pharmacologica Sinica. 2000 July; 21(7): 668-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11360680&dopt=Abstract
•
Effects of oral supplement of L-glutamine on diverted colon wall. Author(s): Paulo FL. Source: Journal of Cellular and Molecular Medicine. 2002 July-September; 6(3): 377-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12417053&dopt=Abstract
•
Enteral glutamine stimulates protein synthesis and decreases ubiquitin mRNA level in human gut mucosa. Author(s): Coeffier M, Claeyssens S, Hecketsweiler B, Lavoinne A, Ducrotte P, Dechelotte P. Source: American Journal of Physiology. Gastrointestinal and Liver Physiology. 2003 August; 285(2): G266-73. Epub 2003 April 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12702496&dopt=Abstract
92
Glutamine
•
Enteral glutamine supplementation and morbidity in low birth weight infants. Author(s): Vaughn P, Thomas P, Clark R, Neu J. Source: The Journal of Pediatrics. 2003 June; 142(6): 662-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12838195&dopt=Abstract
•
Epidermal growth factor activation of intestinal glutamine transport is mediated by mitogen-activated protein kinases. Author(s): Wolfgang CL, Lin C, Meng Q, Karinch AM, Vary TC, Pan M. Source: Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract. 2003 January; 7(1): 149-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12559196&dopt=Abstract
•
Exercise-induced immunodepression- plasma glutamine is not the link. Author(s): Hiscock N, Pedersen BK. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2002 September; 93(3): 813-22. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12183472&dopt=Abstract
•
Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. Author(s): Song C, Perides G, Liu YF. Source: The Journal of Biological Chemistry. 2002 February 22; 277(8): 6703-7. Epub 2001 December 03. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11733534&dopt=Abstract
•
Free and protein-bound glutamine have identical splanchnic extraction in healthy human volunteers. Author(s): Boza JJ, Dangin M, Moennoz D, Montigon F, Vuichoud J, Jarret A, Pouteau E, Gremaud G, Oguey-Araymon S, Courtois D, Woupeyi A, Finot PA, Ballevre O. Source: American Journal of Physiology. Gastrointestinal and Liver Physiology. 2001 July; 281(1): G267-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11408280&dopt=Abstract
•
Free glutamine and glutamic acid increase in human milk through a three-month lactation period. Author(s): Agostoni C, Carratu B, Boniglia C, Lammardo AM, Riva E, Sanzini E. Source: Journal of Pediatric Gastroenterology and Nutrition. 2000 November; 31(5): 50812. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11144435&dopt=Abstract
Studies
93
•
Full-sized RanBPM cDNA encodes a protein possessing a long stretch of proline and glutamine within the N-terminal region, comprising a large protein complex. Author(s): Nishitani H, Hirose E, Uchimura Y, Nakamura M, Umeda M, Nishii K, Mori N, Nishimoto T. Source: Gene. 2001 July 11; 272(1-2): 25-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11470507&dopt=Abstract
•
Functional integration of the transport of ammonium, glutamate and glutamine in astrocytes. Author(s): Brookes N. Source: Neurochemistry International. 2000 August-September; 37(2-3): 121-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10812197&dopt=Abstract
•
Functional mapping of the GAGA factor assigns its transcriptional activity to the Cterminal glutamine-rich domain. Author(s): Vaquero A, Espinas ML, Azorin F, Bernues J. Source: The Journal of Biological Chemistry. 2000 June 30; 275(26): 19461-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10764754&dopt=Abstract
•
Further evidence for the beneficial effects of glutamine in the nutrition of ICU patients. Author(s): Wernerman J. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 September; 18(9): 722. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297204&dopt=Abstract
•
Glucocorticoid induced expression of glutamine synthetase in hepatoma cells. Author(s): Gaunitz F, Heise K, Schumann R, Gebhardt R. Source: Biochemical and Biophysical Research Communications. 2002 August 30; 296(4): 1026-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12200152&dopt=Abstract
•
Glucose, but not glutamine, protects against spontaneous and anti-Fas antibodyinduced apoptosis in human neutrophils. Author(s): Healy DA, Watson RW, Newsholme P. Source: Clinical Science (London, England : 1979). 2002 August; 103(2): 179-89. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149110&dopt=Abstract
94
Glutamine
•
Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Author(s): Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, Schaefer B, Densmore M, Drost DJ. Source: The American Journal of Psychiatry. 2003 December; 160(12): 2231-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14638596&dopt=Abstract
•
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Author(s): Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC. Source: The American Journal of Psychiatry. 2002 November; 159(11): 1944-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12411236&dopt=Abstract
•
Glutamate-glutamine cycling in the epileptic human hippocampus. Author(s): Petroff OA, Errante LD, Rothman DL, Kim JH, Spencer DD. Source: Epilepsia. 2002 July; 43(7): 703-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12102672&dopt=Abstract
•
Glutamine and acute illness. Author(s): Wernerman J. Source: Current Opinion in Critical Care. 2003 August; 9(4): 279-85. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12883282&dopt=Abstract
•
Glutamine and arginine affect Caco-2 cell proliferation by promotion of nucleotide synthesis. Author(s): Yamauchi K, Komatsu T, Kulkarni AD, Ohmori Y, Minami H, Ushiyama Y, Nakayama M, Yamamoto S. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 April; 18(4): 329-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11934546&dopt=Abstract
•
Glutamine and barrier function in cultured Caco-2 epithelial cell monolayers. Author(s): DeMarco VG, Li N, Thomas J, West CM, Neu J. Source: The Journal of Nutrition. 2003 July; 133(7): 2176-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12840174&dopt=Abstract
Studies
95
•
Glutamine and glutamate as vital metabolites. Author(s): Newsholme P, Lima MM, Procopio J, Pithon-Curi TC, Doi SQ, Bazotte RB, Curi R. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 2003 February; 36(2): 153-63. Epub 2003 January 29. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12563517&dopt=Abstract
•
Glutamine and glutamate--their central role in cell metabolism and function. Author(s): Newsholme P, Procopio J, Lima MM, Pithon-Curi TC, Curi R. Source: Cell Biochemistry and Function. 2003 March; 21(1): 1-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12579515&dopt=Abstract
•
Glutamine and gut barrier function. Author(s): MacFie J, McNaught C. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 May; 18(5): 433-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11985953&dopt=Abstract
•
Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. Author(s): Mates JM, Perez-Gomez C, Nunez de Castro I, Asenjo M, Marquez J. Source: The International Journal of Biochemistry & Cell Biology. 2002 May; 34(5): 43958. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11906817&dopt=Abstract
•
Glutamine and KGF each regulate extracellular thiol/disulfide redox and enhance proliferation in Caco-2 cells. Author(s): Jonas CR, Gu LH, Nkabyo YS, Mannery YO, Avissar NE, Sax HC, Jones DP, Ziegler TR. Source: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2003 December; 285(6): R1421-9. Epub 2003 August 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12947032&dopt=Abstract
•
Glutamine and wound healing. Author(s): Collins N. Source: Advances in Skin & Wound Care. 2002 September-October; 15(5): 233-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12368714&dopt=Abstract
•
Glutamine attenuates post-traumatic glutathione depletion in human muscle. Author(s): Flaring UB, Rooyackers OE, Wernerman J, Hammarqvist F. Source: Clinical Science (London, England : 1979). 2003 March; 104(3): 275-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12605586&dopt=Abstract
96
Glutamine
•
Glutamine attenuates tumor necrosis factor-alpha release and enhances heat shock protein 72 in human peripheral blood mononuclear cells. Author(s): Wischmeyer PE, Riehm J, Singleton KD, Ren H, Musch MW, Kahana M, Chang EB. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2003 January; 19(1): 1-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12507630&dopt=Abstract
•
Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in-vitro. Author(s): Coeffier M, Marion R, Leplingard A, Lerebours E, Ducrotte P, Dechelotte P. Source: Cytokine. 2002 April 21; 18(2): 92-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12096924&dopt=Abstract
•
Glutamine delays spontaneous apoptosis in neutrophils. Author(s): Pithon-Curi TC, Schumacher RI, Freitas JJ, Lagranha C, Newsholme P, Palanch AC, Doi SQ, Curi R. Source: American Journal of Physiology. Cell Physiology. 2003 June; 284(6): C1355-61. Epub 2003 January 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12529242&dopt=Abstract
•
Glutamine deprivation facilitates tumour necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate. Author(s): Clark EC, Patel SD, Chadwick PR, Warhurst G, Curry A, Carlson GL. Source: Gut. 2003 February; 52(2): 224-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12524404&dopt=Abstract
•
Glutamine distribution in patients with ulcerative colitis and in patients with familial adenomatous polyposis coli before and after restorative proctocolectomy. Author(s): Heuschen UA, Allemeyer EH, Hinz U, Langer K, Heuschen G, DeckerBaumann C, Herfarth C, Stern J. Source: International Journal of Colorectal Disease. 2002 July; 17(4): 245-52. Epub 2001 December 18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12073073&dopt=Abstract
•
Glutamine for short-bowel syndrome. Author(s): Buchman AL. Source: Current Gastroenterology Reports. 2002 August; 4(4): 321. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149172&dopt=Abstract
•
Glutamine in pediatrics: where next? Author(s): Ball PA, Hardy G. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 June; 18(6): 451-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044814&dopt=Abstract
Studies
97
•
Glutamine metabolism in the fetus and critically ill low birth weight neonate. Author(s): Neu J, Auestad N, DeMarco VG. Source: Adv Pediatr. 2002; 49: 203-26. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12214772&dopt=Abstract
•
Glutamine preserves protein synthesis and paracellular permeability in Caco-2 cells submitted to “luminal fasting”. Author(s): Le Bacquer O, Laboisse C, Darmaun D. Source: American Journal of Physiology. Gastrointestinal and Liver Physiology. 2003 July; 285(1): G128-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799310&dopt=Abstract
•
Glutamine prevents cytokine-induced apoptosis in human colonic epithelial cells. Author(s): Evans ME, Jones DP, Ziegler TR. Source: The Journal of Nutrition. 2003 October; 133(10): 3065-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14519785&dopt=Abstract
•
Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels. Author(s): Chang WK, Yang KD, Chuang H, Jan JT, Shaio MF. Source: Clinical Immunology (Orlando, Fla.). 2002 August; 104(2): 151-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12165276&dopt=Abstract
•
Glutamine repeats: structural hypotheses and neurodegeneration. Author(s): Masino L, Pastore A. Source: Biochemical Society Transactions. 2002 August; 30(4): 548-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196134&dopt=Abstract
•
Glutamine starvation of monocytes inhibits the ubiquitin-proteasome proteolytic pathway. Author(s): Zellner M, Gerner C, Munk Eliasen M, Wurm S, Pollheimer J, Spittler A, Brostjan C, Roth E, Oehler R. Source: Biochimica Et Biophysica Acta. 2003 July 14; 1638(2): 138-48. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12853119&dopt=Abstract
•
Glutamine stimulates argininosuccinate synthetase gene expression through cytosolic O-glycosylation of Sp1 in Caco-2 cells. Author(s): Brasse-Lagnel C, Fairand A, Lavoinne A, Husson A. Source: The Journal of Biological Chemistry. 2003 December 26; 278(52): 52504-10. Epub 2003 October 21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14570901&dopt=Abstract
98
Glutamine
•
Glutamine supplementation and deprivation: effect on artificially reared rat small intestinal morphology. Author(s): Potsic B, Holliday N, Lewis P, Samuelson D, DeMarco V, Neu J. Source: Pediatric Research. 2002 September; 52(3): 430-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12193680&dopt=Abstract
•
Glutamine supplementation fails to affect muscle protein kinetics in critically ill patients. Author(s): Gore DC, Wolfe RR. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2002 November-December; 26(6): 342-9; Discussion 349-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405645&dopt=Abstract
•
Glutamine supplementation further enhances exercise-induced plasma IL-6. Author(s): Hiscock N, Petersen EW, Krzywkowski K, Boza J, Halkjaer-Kristensen J, Pedersen BK. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2003 July; 95(1): 145-8. Epub 2003 February 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12611772&dopt=Abstract
•
Glutamine supplementation in bone marrow transplantation. Author(s): Ziegler TR. Source: The British Journal of Nutrition. 2002 January; 87 Suppl 1: S9-15. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11895159&dopt=Abstract
•
Glutamine supplementation in critically ill and elective surgical patients: does the evidence warrant its use? Author(s): Miskovitz P. Source: Critical Care Medicine. 2002 September; 30(9): 2152-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352061&dopt=Abstract
•
Glutamine supplementation in serious illness: a systematic review of the evidence. Author(s): Novak F, Heyland DK, Avenell A, Drover JW, Su X. Source: Critical Care Medicine. 2002 September; 30(9): 2022-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352035&dopt=Abstract
•
Glutamine supplementation in vitro and in vivo, in exercise and in immunodepression. Author(s): Castell L. Source: Sports Medicine (Auckland, N.Z.). 2003; 33(5): 323-45. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12696982&dopt=Abstract
Studies
99
•
Glutamine supplements in premature infants: why and how. Author(s): Neu J. Source: Journal of Pediatric Gastroenterology and Nutrition. 2003 November; 37(5): 5335. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14581791&dopt=Abstract
•
Glutamine supports recovery from loss of transepithelial resistance and increase of permeability induced by media change in Caco-2 cells. Author(s): Li N, DeMarco VG, West CM, Neu J. Source: The Journal of Nutritional Biochemistry. 2003 July; 14(7): 401-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12915221&dopt=Abstract
•
Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Author(s): Burbaeva GSh, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina OK, Tereshkina EB. Source: Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2003 June; 27(4): 675-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12787856&dopt=Abstract
•
Glutamine synthetase GlnA1 is essential for growth of Mycobacterium tuberculosis in human THP-1 macrophages and guinea pigs. Author(s): Tullius MV, Harth G, Horwitz MA. Source: Infection and Immunity. 2003 July; 71(7): 3927-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12819079&dopt=Abstract
•
Glutamine synthetase in brain: effect of ammonia. Author(s): Suarez I, Bodega G, Fernandez B. Source: Neurochemistry International. 2002 August-September; 41(2-3): 123-42. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12020613&dopt=Abstract
•
Glutamine synthetase isolated from human brain: octameric structure and homology of partial primary structure with human liver glutamine synthetase. Author(s): Boksha IS, Schonfeld HJ, Langen H, Muller F, Tereshkina EB, Burbaeva GSh. Source: Biochemistry. Biokhimiia. 2002 September; 67(9): 1012-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12387715&dopt=Abstract
•
Glutamine to intensive care unit patients. Author(s): Wernerman J. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2003 July-August; 27(4): 302-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12903897&dopt=Abstract
100
Glutamine
•
Glutamine, a life-saving nutrient, but why? Author(s): Preiser JC, Wernerman J. Source: Critical Care Medicine. 2003 October; 31(10): 2555-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14530768&dopt=Abstract
•
Glutamine-enhanced nutrition in the critically ill patient. Author(s): Andrews F, Griffiths R. Source: Hosp Med. 2002 March; 63(3): 144-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11933816&dopt=Abstract
•
Glutamine-enriched enteral nutrition decreases infectious complications in trauma patients. Author(s): Boelens PG, Houdijk AP, Haarman HJ, Nijveldt RJ, van Leeuwen PA. Source: The American Journal of Clinical Nutrition. 2002 July; 76(1): 253-4; Author Reply 254-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12081843&dopt=Abstract
•
Glutamine-enriched enteral nutrition increases HLA-DR expression on monocytes of trauma patients. Author(s): Boelens PG, Houdijk AP, Fonk JC, Nijveldt RJ, Ferwerda CC, Von BlombergVan Der Flier BM, Thijs LG, Haarman HJ, Puyana JC, Van Leeuwen PA. Source: The Journal of Nutrition. 2002 September; 132(9): 2580-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12221212&dopt=Abstract
•
Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Author(s): Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M, Rutella S, Cicconi S, Fiorini A, D'Onofrio G, Leone G, Sica S. Source: Haematologica. 2003 February; 88(2): 192-200. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12604409&dopt=Abstract
•
Hepatic glutamine metabolism. Author(s): Watford M, Chellaraj V, Ismat A, Brown P, Raman P. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 April; 18(4): 301-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11934540&dopt=Abstract
•
Histone H3 is aberrantly phosphorylated in glutamine-repeat diseases. Author(s): Yazawa I, Hazeki N, Nakase H, Kanazawa I, Tanaka M. Source: Biochemical and Biophysical Research Communications. 2003 February 28; 302(1): 144-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12593861&dopt=Abstract
Studies
101
•
Human 293 cell metabolism in low glutamine-supplied culture: interpretation of metabolic changes through metabolic flux analysis. Author(s): Nadeau I, Sabatie J, Koehl M, Perrier M, Kamen A. Source: Metabolic Engineering. 2000 October; 2(4): 277-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11120640&dopt=Abstract
•
Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Author(s): Yu ZX, Li SH, Nguyen HP, Li XJ. Source: Human Molecular Genetics. 2002 April 15; 11(8): 905-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11971872&dopt=Abstract
•
Identification of a cis-acting element and a novel trans-acting factor of the glutamine synthetase gene in liver cells. Author(s): Gaunitz F, Weber S, Scheja L, Gebhardt R. Source: Biochemical and Biophysical Research Communications. 2001 June 8; 284(2): 377-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11394889&dopt=Abstract
•
Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Author(s): Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S, Nordhoff E, Lurz R, Schugardt N, Rautenberg S, Herhaus C, Barnickel G, Bottcher H, Lehrach H, Wanker EE. Source: Proceedings of the National Academy of Sciences of the United States of America. 2002 December 10; 99 Suppl 4: 16400-6. Epub 2002 August 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12200548&dopt=Abstract
•
Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle. Author(s): Niimi M, Ogawara T, Yamashita T, Yamamoto Y, Ueyama A, Kambe T, Okamoto T, Ban T, Tamanoi H, Ozaki K, Fujiwara T, Fukui H, Takahashi EI, Kyushiki H, Tanigami A. Source: Journal of Human Genetics. 2001; 46(10): 566-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11587069&dopt=Abstract
•
Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans. Author(s): Comte B, Kasumov T, Pierce BA, Puchowicz MA, Scott ME, Dahms W, Kerr D, Nissim I, Brunengraber H. Source: Journal of Mass Spectrometry : Jms. 2002 June; 37(6): 581-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12112740&dopt=Abstract
102
Glutamine
•
II. Glutamine and glutamate. Author(s): Tapiero H, Mathe G, Couvreur P, Tew KD. Source: Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2002 November; 56(9): 446-57. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12481981&dopt=Abstract
•
Immunoassay for serum glutamine synthetase in serum: development, reference values, and preliminary study in dementias. Author(s): Takahashi M, Stanton E, Moreno JI, Jackowski G. Source: Clinical Chemistry. 2002 February; 48(2): 375-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11805026&dopt=Abstract
•
Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteers. Author(s): Valencia E, Marin A, Hardy G. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 May; 18(5): 367-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11985937&dopt=Abstract
•
Impaired energy metabolism during neonatal sepsis: the effects of glutamine. Author(s): Eaton S. Source: The Proceedings of the Nutrition Society. 2003 August; 62(3): 745-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14692610&dopt=Abstract
•
Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Author(s): Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB. Source: Brain; a Journal of Neurology. 2002 August; 125(Pt 8): 1908-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135980&dopt=Abstract
•
Improved fermentation processes for NS0 cell lines expressing human antibodies and glutamine synthetase. Author(s): Dempsey J, Ruddock S, Osborne M, Ridley A, Sturt S, Field R. Source: Biotechnology Progress. 2003 January-February; 19(1): 175-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12573022&dopt=Abstract
•
Improving glucose and glutamine metabolism of human HEK 293 and Trichoplusia ni insect cells engineered to express a cytosolic pyruvate carboxylase enzyme. Author(s): Elias CB, Carpentier E, Durocher Y, Bisson L, Wagner R, Kamen A. Source: Biotechnology Progress. 2003 January-February; 19(1): 90-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12573011&dopt=Abstract
Studies
103
•
Improving nutritional support in critically Ill septic patients: glutamine alone or in combination? Author(s): Chiolero RL, Berger MM. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 September; 18(9): 723-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297205&dopt=Abstract
•
In vivo measurements of glutamine + glutamate (Glx) and N-acetyl aspartate (NAA) levels in human partial epilepsy. Author(s): Savic I, Thomas AM, Ke Y, Curran J, Fried I, Engel J Jr. Source: Acta Neurologica Scandinavica. 2000 September; 102(3): 179-88. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10987378&dopt=Abstract
•
In vivo nuclear magnetic resonance studies of glutamate-gamma-aminobutyric acidglutamine cycling in rodent and human cortex: the central role of glutamine. Author(s): Behar KL, Rothman DL. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2498S-504S; Discussion 2523S-4S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533301&dopt=Abstract
•
Infection, multiple organ failure, and survival in the intensive care unit: influence of glutamine-supplemented parenteral nutrition on acquired infection. Author(s): Griffiths RD, Allen KD, Andrews FJ, Jones C. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 July-August; 18(7-8): 54652. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12093428&dopt=Abstract
•
Influence of glutamine and glycyl-glutamine on in vitro lymphocyte proliferation in children with solid tumors. Author(s): Kohler H, Klowik M, Brand O, Gobel U, Schroten H. Source: Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 2001 June; 9(4): 261-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11430422&dopt=Abstract
•
Influence of glutamine on cytokine production by human gut in vitro. Author(s): Coeffier M, Miralles-Barrachina O, Le Pessot F, Lalaude O, Daveau M, Lavoinne A, Lerebours E, Dechelotte P. Source: Cytokine. 2001 February 7; 13(3): 148-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11161457&dopt=Abstract
104
Glutamine
•
Influence of glutamine-enriched parenteral nutrition on nitrogen balance and immunologic status in patients undergoing elective aortic aneurysm repair. Author(s): Karwowska KA, Dworacki G, Trybus M, Zeromski J, Szulc R. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2001 June; 17(6): 475-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11399407&dopt=Abstract
•
Influence of glutamine-supplemented Caco-2 cells on cytokine production of mononuclear cells. Author(s): Aosasa S, Wells-Byrum D, Alexander JW, Ogle CK. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2003 September-October; 27(5): 333-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12971733&dopt=Abstract
•
Influence of polymeric enteral nutrition supplemented with different doses of glutamine on gut permeability in critically ill patients. Author(s): Velasco N, Hernandez G, Wainstein C, Castillo L, Maiz A, Lopez F, Guzman S, Bugedo G, Acosta AM, Bruhn A. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2001 November-December; 17(11-12): 907-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11744338&dopt=Abstract
•
Inhibition of glutamine synthetase in a549 cells during hyperoxia. Author(s): McGrath-Morrow SA, Stahl J. Source: American Journal of Respiratory Cell and Molecular Biology. 2002 July; 27(1): 99-106. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12091252&dopt=Abstract
•
Inhibition of glutamine transport depletes glutamate and GABA neurotransmitter pools: further evidence for metabolic compartmentation. Author(s): Rae C, Hare N, Bubb WA, McEwan SR, Broer A, McQuillan JA, Balcar VJ, Conigrave AD, Broer S. Source: Journal of Neurochemistry. 2003 April; 85(2): 503-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12675927&dopt=Abstract
•
Inhibition of muscle glutamine formation in hypercatabolic patients. Author(s): Biolo G, Fleming RY, Maggi SP, Nguyen TT, Herndon DN, Wolfe RR. Source: Clinical Science (London, England : 1979). 2000 September; 99(3): 189-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11787470&dopt=Abstract
Studies
105
•
Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of efficacy in vivo. Author(s): Harth G, Horwitz MA. Source: Infection and Immunity. 2003 January; 71(1): 456-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12496196&dopt=Abstract
•
Insulin-like growth factor-I stimulates amino acid transport in a glutamine-deprived human neuroblastoma cell line. Author(s): Wasa M, Wang HS, Tazuke Y, Okada A. Source: Biochimica Et Biophysica Acta. 2001 February 16; 1525(1-2): 118-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11342260&dopt=Abstract
•
Interaction between glutamine availability and metabolism of glycogen, tricarboxylic acid cycle intermediates and glutathione. Author(s): Rennie MJ, Bowtell JL, Bruce M, Khogali SE. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2488S-90S; Discussion 2496S-7S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533298&dopt=Abstract
•
Intravenous glutamine does not stimulate mixed muscle protein synthesis in healthy young men and women. Author(s): Zachwieja JJ, Witt TL, Yarasheski KE. Source: Metabolism: Clinical and Experimental. 2000 December; 49(12): 1555-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11145116&dopt=Abstract
•
Is glutamine beneficial in ischemic heart disease? Author(s): Khogali SE, Pringle SD, Weryk BV, Rennie MJ. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 February; 18(2): 123-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844641&dopt=Abstract
•
Is there a requirement for glutamine catabolism in the small intestine? Author(s): Watford M. Source: The British Journal of Nutrition. 1999 April; 81(4): 261-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10999012&dopt=Abstract
•
John M. Kinney International Awards. Looking back: a human reason for studying the effects of glutamine in patients with AIDS. Author(s): Shabert JK. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2001 March; 17(3): 205. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11312061&dopt=Abstract
106
Glutamine
•
Kinetic characterization of human glutamine-fructose-6-phosphate amidotransferase I: potent feedback inhibition by glucosamine 6-phosphate. Author(s): Broschat KO, Gorka C, Page JD, Martin-Berger CL, Davies MS, Huang Hc HC, Gulve EA, Salsgiver WJ, Kasten TP. Source: The Journal of Biological Chemistry. 2002 April 26; 277(17): 14764-70. Epub 2002 February 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11842094&dopt=Abstract
•
Levels of basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in subretinal fluid from patients with retinal detachment. Author(s): La Heij EC, Van De Waarenburg MP, Blaauwgeers HG, Kessels AG, De Vente J, Liem AT, Steinbusch H, Hendrikse F. Source: American Journal of Ophthalmology. 2001 October; 132(4): 544-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11589877&dopt=Abstract
•
L-glutamine supplementation improves nelfinavir-associated diarrhea in HIVinfected individuals. Author(s): Huffman FG, Walgren ME. Source: Hiv Clinical Trials. 2003 September-October; 4(5): 324-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14583848&dopt=Abstract
•
Limited heat-shock protein 72 induction in Caco-2 cells by L-glutamine. Author(s): Lindemann G, Grohs M, Stange EF, Fellermann K. Source: Digestion. 2001; 64(2): 81-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11684820&dopt=Abstract
•
Longitudinal pattern of glutamine/glutamate balance across the leg in long-stay intensive care unit patients. Author(s): Vesali RF, Klaude M, Rooyackers OE, TJader I, Barle H, Wernerman J. Source: Clinical Nutrition (Edinburgh, Lothian). 2002 December; 21(6): 505-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12468371&dopt=Abstract
•
Long-term culture of glutamine synthetase-transfected HepG2 cells in circulatory flow bioreactor for development of a bioartificial liver. Author(s): Enosawa S, Miyashita T, Suzuki S, Li XK, Tsunoda M, Amemiya H, Yamanaka M, Hiramatsu S, Tanimura N, Omasa T, Suga K, Matsumura T. Source: Cell Transplantation. 2000 September-October; 9(5): 711-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11144971&dopt=Abstract
Studies
107
•
Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Author(s): Eid T, Thomas MJ, Spencer DD, Runden-Pran E, Lai JC, Malthankar GV, Kim JH, Danbolt NC, Ottersen OP, de Lanerolle NC. Source: Lancet. 2004 January 3; 363(9402): 28-37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14723991&dopt=Abstract
•
Low plasma glutamine after multiple trauma: relationship with intracellular glutamine in polymorphonuclear neutrophils during prolonged ICU stay. Author(s): Engel JM, Muhling J, Weiss S, Lohr T, Simonis Y, Menges T, Hempelmann G. Source: Acta Anaesthesiologica Scandinavica. 2003 July; 47(6): 707-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12803588&dopt=Abstract
•
Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease: effect of enteral nutritional support and glutamine supplementation. Author(s): Akobeng AI, Clayton PE, Miller V, Hall CM, Thomas AG. Source: Scandinavian Journal of Gastroenterology. 2002 December; 37(12): 1422-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12523592&dopt=Abstract
•
Lymphocyte proliferation is possible with low concentrations of glycyl-glutamine. Author(s): Kohler H, Hartig-Knecht H, Ruggeberg J, Adam R, Schroten H. Source: European Journal of Nutrition. 2000 June; 39(3): 103-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10918991&dopt=Abstract
•
Metabolic response of muscle to alanine, glutamine, and valine supplementation during severe illness. Author(s): Gore DC, Wolfe RR. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2003 September-October; 27(5): 307-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12971729&dopt=Abstract
•
Mitochondrial glutathione depletion by glutamine in growing tumor cells. Author(s): Carretero J, Obrador E, Pellicer JA, Pascual A, Estrela JM. Source: Free Radical Biology & Medicine. 2000 November 1; 29(9): 913-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11063916&dopt=Abstract
•
Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Author(s): Coeffier M, Marion R, Ducrotte P, Dechelotte P. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 August; 22(4): 407-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12880609&dopt=Abstract
108
Glutamine
•
Molecular and functional analysis of glutamine uptake in human hepatoma and liverderived cells. Author(s): Bode BP, Fuchs BC, Hurley BP, Conroy JL, Suetterlin JE, Tanabe KK, Rhoads DB, Abcouwer SF, Souba WW. Source: American Journal of Physiology. Gastrointestinal and Liver Physiology. 2002 November; 283(5): G1062-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12381519&dopt=Abstract
•
Molecular identification of human glutamine- and ammonia-dependent NAD synthetases. Carbon-nitrogen hydrolase domain confers glutamine dependency. Author(s): Hara N, Yamada K, Terashima M, Osago H, Shimoyama M, Tsuchiya M. Source: The Journal of Biological Chemistry. 2003 March 28; 278(13): 10914-21. Epub 2003 January 23. Erratum In: J Biol Chem. 2003 October 17; 278(42): 41572. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12547821&dopt=Abstract
•
Multiple replacements of glutamine 143 in human manganese superoxide dismutase: effects on structure, stability, and catalysis. Author(s): Leveque VJ, Stroupe ME, Lepock JR, Cabelli DE, Tainer JA, Nick HS, Silverman DN. Source: Biochemistry. 2000 June 20; 39(24): 7131-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10852710&dopt=Abstract
•
Muscle glutamine production in burn patients: the physiological meaning of tracer estimates. Author(s): Wagenmakers AJ. Source: Clinical Science (London, England : 1979). 2001 March; 100(3): 299-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11222116&dopt=Abstract
•
NAC, glutamine, and alpha lipoic acid. Interview by John S. James. Author(s): Lands L. Source: Aids Treat News. 1997 April 4; (No 268): 2-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11364196&dopt=Abstract
•
Neurodegeneration. A glutamine-rich trail leads to transcription factors. Author(s): Freiman RN, Tjian R. Source: Science. 2002 June 21; 296(5576): 2149-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12077389&dopt=Abstract
•
Neuroprotection by glutamine synthetase. Author(s): Vardimon L. Source: Isr Med Assoc J. 2000 July; 2 Suppl: 46-51. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10909417&dopt=Abstract
Studies
109
•
New data and concepts on glutamine and glucose metabolism in the gut. Author(s): Mithieux G. Source: Current Opinion in Clinical Nutrition and Metabolic Care. 2001 July; 4(4): 26771. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11458019&dopt=Abstract
•
New developments in glutamine delivery. Author(s): Furst P. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2562S-8S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533314&dopt=Abstract
•
Nitric oxide regulates the phosphorylation of the threonine-glutamine-tyrosine motif in proteins of human spermatozoa during capacitation. Author(s): Thundathil J, de Lamirande E, Gagnon C. Source: Biology of Reproduction. 2003 April; 68(4): 1291-8. Epub 2002 October 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12606410&dopt=Abstract
•
Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. Author(s): Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Source: Journal of Neurochemistry. 2000 May; 74(5): 2108-19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10800956&dopt=Abstract
•
N-terminal extension of canine glutamine synthetase created by splicing alters its enzymatic property. Author(s): Shin D, Park C. Source: The Journal of Biological Chemistry. 2004 January 9; 279(2): 1184-90. Epub 2003 October 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14583610&dopt=Abstract
•
Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. Author(s): Nucifora FC Jr, Ellerby LM, Wellington CL, Wood JD, Herring WJ, Sawa A, Hayden MR, Dawson VL, Dawson TM, Ross CA. Source: The Journal of Biological Chemistry. 2003 April 11; 278(15): 13047-55. Epub 2002 December 02. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12464607&dopt=Abstract
110
Glutamine
•
Nutrients and HIV: part three - N-acetylcysteine, alpha-lipoic acid, L-glutamine, and L-carnitine. Author(s): Patrick L. Source: Alternative Medicine Review : a Journal of Clinical Therapeutic. 2000 August; 5(4): 290-305. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10956377&dopt=Abstract
•
Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, doubleblind, placebo-controlled study. Author(s): Clark RH, Feleke G, Din M, Yasmin T, Singh G, Khan FA, Rathmacher JA. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2000 May-June; 24(3): 133-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10850936&dopt=Abstract
•
Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Author(s): Cockerham MB, Weinberger BB, Lerchie SB. Source: The Annals of Pharmacotherapy. 2000 March; 34(3): 300-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10917373&dopt=Abstract
•
Oral glutamine in paediatric oncology patients: a dose finding study. Author(s): Ward E, Picton S, Reid U, Thomas D, Gardener C, Smith M, Henderson M, Holden V, Kinsey S, Lewis I, Allgar V. Source: European Journal of Clinical Nutrition. 2003 January; 57(1): 31-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548294&dopt=Abstract
•
Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Author(s): Daniele B, Perrone F, Gallo C, Pignata S, De Martino S, De Vivo R, Barletta E, Tambaro R, Abbiati R, D'Agostino L. Source: Gut. 2001 January; 48(1): 28-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11115819&dopt=Abstract
•
Oral glutamine supplements in autologous hematopoietic transplant: impact on gastrointestinal toxicity and plasma protein levels. Author(s): Canovas G, Leon-Sanz M, Gomez P, Valero MA, Gomis P, La Huerta JJ. Source: Haematologica. 2000 November; 85(11): 1229-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11064482&dopt=Abstract
•
Oral glutamine: does it make sense? Author(s): Roth E. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2001 January; 17(1): 52-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11165889&dopt=Abstract
Studies
111
•
Overexpression of the complementary DNA for human glutamine:fructose-6phosphate amidotransferase in mesangial cells enhances glucose-induced fibronectin synthesis and transcription factor cyclic adenosine monophosphate-responsive element binding phosphorylation. Author(s): Singh LP, Alexander M, Greene K, Crook ED. Source: Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research. 2003 February; 51(1): 32-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12580319&dopt=Abstract
•
Oxidation of glutamine by the splanchnic bed in humans. Author(s): Haisch M, Fukagawa NK, Matthews DE. Source: American Journal of Physiology. Endocrinology and Metabolism. 2000 April; 278(4): E593-602. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10751191&dopt=Abstract
•
Palmitate-induced activation of the hexosamine pathway in human myotubes: increased expression of glutamine:fructose-6-phosphate aminotransferase. Author(s): Weigert C, Klopfer K, Kausch C, Brodbeck K, Stumvoll M, Haring HU, Schleicher ED. Source: Diabetes. 2003 March; 52(3): 650-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12606504&dopt=Abstract
•
Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients. Author(s): Goeters C, Wenn A, Mertes N, Wempe C, Van Aken H, Stehle P, Bone HG. Source: Critical Care Medicine. 2002 September; 30(9): 2032-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352037&dopt=Abstract
•
Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. Author(s): Kozelsky TF, Meyers GE, Sloan JA, Shanahan TG, Dick SJ, Moore RL, Engeler GP, Frank AR, McKone TK, Urias RE, Pilepich MV, Novotny PJ, Martenson JA; North Central Cancer Treatment Group. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 May 1; 21(9): 1669-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12721240&dopt=Abstract
•
Phenotypic effects of expanded ataxin-1 polyglutamines with interruptions in vitro. Author(s): Calabresi V, Guida S, Servadio A, Jodice C. Source: Brain Research Bulletin. 2001 October-November 1; 56(3-4): 337-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719269&dopt=Abstract
112
Glutamine
•
Phorbol esters rapidly attenuate glutamine uptake and growth in human colon carcinoma cells. Author(s): Pawlik TM, Souba WW, Sweeney TJ, Bode BP. Source: The Journal of Surgical Research. 2000 May 15; 90(2): 149-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10792956&dopt=Abstract
•
Phosphorylation of human glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity. Author(s): Chang Q, Su K, Baker JR, Yang X, Paterson AJ, Kudlow JE. Source: The Journal of Biological Chemistry. 2000 July 21; 275(29): 21981-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10806197&dopt=Abstract
•
Plasma glutamine and ammonia concentrations in ornithine carbamoyltransferase deficiency and citrullinaemia. Author(s): Wilson CJ, Lee PJ, Leonard JV. Source: Journal of Inherited Metabolic Disease. 2001 December; 24(7): 691-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11804205&dopt=Abstract
•
Plasma glutamine and glutamate concentrations in Gabonese children with Plasmodium falciparum infection. Author(s): Planche T, Dzeing A, Emmerson AC, Onanga M, Kremsner PG, Engel K, Kombila M, Ngou-Milama E, Krishna S. Source: Qjm : Monthly Journal of the Association of Physicians. 2002 February; 95(2): 8997. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11861956&dopt=Abstract
•
Plasma glutamine depletion and patient outcome in acute ICU admissions. Author(s): Oudemans-van Straaten HM, Bosman RJ, Treskes M, van der Spoel HJ, Zandstra DF. Source: Intensive Care Medicine. 2001 January; 27(1): 84-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11280678&dopt=Abstract
•
Plasma taurine concentrations increase after enteral glutamine supplementation in trauma patients and stressed rats. Author(s): Boelens PG, Houdijk AP, de Thouars HN, Teerlink T, van Engeland MI, Haarman HJ, van Leeuwen PA. Source: The American Journal of Clinical Nutrition. 2003 January; 77(1): 250-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12499349&dopt=Abstract
•
Polyglutamine protein aggregates are dynamic. Author(s): Kim S, Nollen EA, Kitagawa K, Bindokas VP, Morimoto RI. Source: Nature Cell Biology. 2002 October; 4(10): 826-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12360295&dopt=Abstract
Studies
113
•
Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Author(s): Monoi H, Futaki S, Kugimiya S, Minakata H, Yoshihara K. Source: Biophysical Journal. 2000 June; 78(6): 2892-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10827970&dopt=Abstract
•
Postoperative glycyl-glutamine infusion reduces immunosuppression: partial prevention of the surgery induced decrease in HLA-DR expression on monocytes. Author(s): Spittler A, Sautner T, Gornikiewicz A, Manhart N, Oehler R, Bergmann M, Fugger R, Roth E. Source: Clinical Nutrition (Edinburgh, Lothian). 2001 February; 20(1): 37-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11161542&dopt=Abstract
•
Potential role of glutamine administration in inflammatory bowel disease. Author(s): Jonas CR, Ziegler TR. Source: Nestle Nutr Workshop Ser Clin Perform Programme. 1999; 2: 217-30; Discussion 230-5. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11490624&dopt=Abstract
•
Presence of glutamine:fructose-6-phosphate amidotransferase for glucosamine-6phosphate synthesis in endothelial cells: effects of hyperglycaemia and glutamine. Author(s): Wu G, Haynes TE, Yan W, Meininger CJ. Source: Diabetologia. 2001 February; 44(2): 196-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11270676&dopt=Abstract
•
Prevention of chemotherapy and radiation toxicity with glutamine. Author(s): Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Source: Cancer Treatment Reviews. 2003 December; 29(6): 501-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14585260&dopt=Abstract
•
Primary structure, genomic organization, and functional and electrogenic characteristics of human system N 1, a Na+- and H+-coupled glutamine transporter. Author(s): Fei YJ, Sugawara M, Nakanishi T, Huang W, Wang H, Prasad PD, Leibach FH, Ganapathy V. Source: The Journal of Biological Chemistry. 2000 August 4; 275(31): 23707-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10823827&dopt=Abstract
•
Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma. Author(s): Osada T, Nagashima I, Tsuno NH, Kitayama J, Nagawa H. Source: Journal of Hepatology. 2000 August; 33(2): 247-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10952242&dopt=Abstract
114
Glutamine
•
Properties and regulation of glutamine transporter SN1 by protein kinases SGK and PKB. Author(s): Boehmer C, Okur F, Setiawan I, Broer S, Lang F. Source: Biochemical and Biophysical Research Communications. 2003 June 20; 306(1): 156-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12788082&dopt=Abstract
•
Proteasomal interactors control activities as diverse as the cell cycle and glutaminergic neurotransmission. Author(s): Rezvani K, Mee M, Dawson S, McIlhinney J, Fujita J, Mayer RJ. Source: Biochemical Society Transactions. 2003 April; 31(2): 470-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12653665&dopt=Abstract
•
Protective effects of estrogens on polyglutamine-expanded androgen receptor aggregation in mice. Author(s): Darrington RS, Leigh PN, Gallo JM. Source: Neuroscience Letters. 2003 October 16; 350(1): 37-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12962912&dopt=Abstract
•
Protein binding of a DRPLA family through arginine-glutamic acid dipeptide repeats is enhanced by extended polyglutamine. Author(s): Yanagisawa H, Bundo M, Miyashita T, Okamura-Oho Y, Tadokoro K, Tokunaga K, Yamada M. Source: Human Molecular Genetics. 2000 May 22; 9(9): 1433-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10814707&dopt=Abstract
•
Protein kinase C activation of intestinal glutamine transport is mediated by mitogenactivated protein kinases. Author(s): Pan M, Wolfgang CA, Karinch AM, Lin C, Meng Q, Vary TC, Souba WW. Source: The Journal of Surgical Research. 2002 July; 106(1): 137-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12127819&dopt=Abstract
•
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Author(s): Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Source: Free Radical Biology & Medicine. 2002 August 15; 33(4): 562-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12160938&dopt=Abstract
Studies
115
•
Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Author(s): Hattori N, Abe K, Sakoda S, Sawada T. Source: Neuroreport. 2002 January 21; 13(1): 183-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11924885&dopt=Abstract
•
Purification and characterization of glutamine:fructose 6-phosphate amidotransferase from rat liver. Author(s): Huynh QK, Gulve EA, Dian T. Source: Archives of Biochemistry and Biophysics. 2000 July 15; 379(2): 307-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10898949&dopt=Abstract
•
Purification of polyglutamine aggregates and identification of elongation factor1alpha and heat shock protein 84 as aggregate-interacting proteins. Author(s): Mitsui K, Nakayama H, Akagi T, Nekooki M, Ohtawa K, Takio K, Hashikawa T, Nukina N. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2002 November 1; 22(21): 9267-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12417652&dopt=Abstract
•
Quantification of glutamine in dried blood spots and plasma by tandem mass spectrometry for the biochemical diagnosis and monitoring of ornithine transcarbamylase deficiency. Author(s): Trinh MU, Blake J, Harrison JR, Gerace R, Ranieri E, Fletcher JM, Johnson DW. Source: Clinical Chemistry. 2003 April; 49(4): 681-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12651832&dopt=Abstract
•
Recruitment of nonexpanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease. Author(s): Takahashi J, Tanaka J, Arai K, Funata N, Hattori T, Fukuda T, Fujigasaki H, Uchihara T. Source: Journal of Neuropathology and Experimental Neurology. 2001 April; 60(4): 36976. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11305872&dopt=Abstract
•
Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Author(s): Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2001 May; 7(5): 1192-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11350883&dopt=Abstract
116
Glutamine
•
Regulation of glutamine transport by the type I insulin-like growth factor receptor in a human neuroblastoma cell line. Author(s): Wang HS, Wasa M, Okada A. Source: Cancer Letters. 2001 July 10; 168(1): 81-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11368881&dopt=Abstract
•
Regulative capacity of glutamine. Author(s): Oehler R, Roth E. Source: Current Opinion in Clinical Nutrition and Metabolic Care. 2003 May; 6(3): 27782. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690259&dopt=Abstract
•
Regulative potential of glutamine--relation to glutathione metabolism. Author(s): Roth E, Oehler R, Manhart N, Exner R, Wessner B, Strasser E, Spittler A. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 March; 18(3): 217-21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11882392&dopt=Abstract
•
Relation between glutamine, branched-chain amino acids, and protein metabolism. Author(s): Holecek M. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 February; 18(2): 130-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844643&dopt=Abstract
•
Relative effects of glucose and glutamine on reactive oxygen intermediate production by neutrophils. Author(s): Furukawa S, Saito H, Matsuda T, Inoue T, Fukatsu K, Han I, Ikeda S, Hidemura A, Muto T. Source: Shock (Augusta, Ga.). 2000; 13(4): 274-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10774615&dopt=Abstract
•
Response of glutamine metabolism to glutamine-supplemented parenteral nutrition. Author(s): van Acker BA, Hulsewe KW, Wagenmakers AJ, von Meyenfeldt MF, Soeters PB. Source: The American Journal of Clinical Nutrition. 2000 September; 72(3): 790-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10966901&dopt=Abstract
•
Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Author(s): May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Source: American Journal of Surgery. 2002 April; 183(4): 471-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11975938&dopt=Abstract
Studies
117
•
Role of glucose in the regulation of glutamine metabolism in health and in type 1 insulin-dependent diabetes. Author(s): Hankard RG, Haymond MW, Darmaun D. Source: American Journal of Physiology. Endocrinology and Metabolism. 2000 September; 279(3): E608-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10950829&dopt=Abstract
•
Role of glutamine depletion in severe illness. Author(s): Darmaun D. Source: Diabetes Nutr Metab. 2000 February; 13(1): 25-30. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10824720&dopt=Abstract
•
Role of glutamine in cerebral nitrogen metabolism and ammonia neurotoxicity. Author(s): Cooper AJ. Source: Mental Retardation and Developmental Disabilities Research Reviews. 2001; 7(4): 280-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11754523&dopt=Abstract
•
Role of glutamine on the de novo purine nucleotide synthesis in Caco-2 cells. Author(s): Boza JJ, Moennoz D, Bournot CE, Blum S, Zbinden I, Finot PA, Ballevre O. Source: European Journal of Nutrition. 2000 February; 39(1): 38-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10900556&dopt=Abstract
•
Role of L-glutamine in critical illness: new insights. Author(s): Kelly D, Wischmeyer PE. Source: Current Opinion in Clinical Nutrition and Metabolic Care. 2003 March; 6(2): 21722. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12589192&dopt=Abstract
•
SCA1 molecular genetics: a history of a 13 year collaboration against glutamines. Author(s): Orr HT, Zoghbi HY. Source: Human Molecular Genetics. 2001 October 1; 10(20): 2307-11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11673415&dopt=Abstract
•
SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Author(s): Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I. Source: Human Molecular Genetics. 2001 July 1; 10(14): 1441-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11448935&dopt=Abstract
118
Glutamine
•
Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Author(s): Vossler DG, Wilensky AJ, Cawthon DF, Kraemer DL, Ojemann LM, Caylor LM, Morgan JD. Source: Epilepsia. 2002 February; 43(2): 154-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11903461&dopt=Abstract
•
Small glutamine-rich protein/viral protein U-binding protein is a novel cochaperone that affects heat shock protein 70 activity. Author(s): Angeletti PC, Walker D, Panganiban AT. Source: Cell Stress & Chaperones. 2002 July; 7(3): 258-68. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12482202&dopt=Abstract
•
Small glutamine-rich tetratricopeptide repeat-containing protein (SGT) interacts with the ubiquitin-dependent endocytosis (UbE) motif of the growth hormone receptor. Author(s): Schantl JA, Roza M, De Jong AP, Strous GJ. Source: The Biochemical Journal. 2003 August 1; 373(Pt 3): 855-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12735788&dopt=Abstract
•
Solution studies of chymotrypsin inhibitor-2 glutamine insertion mutants show no interglutamine interactions. Author(s): Gordon-Smith DJ, Carbajo RJ, Stott K, Neuhaus D. Source: Biochemical and Biophysical Research Communications. 2001 January 26; 280(3): 855-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11162601&dopt=Abstract
•
Somatic instability of the DNA sequences encoding the polymorphic polyglutamine tract of the AIB1 gene. Author(s): Dai P, Wong LJ. Source: Journal of Medical Genetics. 2003 December; 40(12): 885-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14684685&dopt=Abstract
•
Special feature for the Olympics: effects of exercise on the immune system: modification of immune responses to exercise by carbohydrate, glutamine and antioxidant supplements. Author(s): Gleeson M, Bishop NC. Source: Immunology and Cell Biology. 2000 October; 78(5): 554-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11050539&dopt=Abstract
Studies
119
•
Specific glutamine and asparagine residues of gamma-S crystallin are resistant to in vivo deamidation. Author(s): Takemoto L, Boyle D. Source: The Journal of Biological Chemistry. 2000 August 25; 275(34): 26109-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10843993&dopt=Abstract
•
Specificity determining residues in ammonia- and glutamine-dependent carbamoyl phosphate synthetases. Author(s): Saeed-Kothe A, Powers-Lee SG. Source: The Journal of Biological Chemistry. 2002 March 1; 277(9): 7231-8. Epub 2001 December 27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11756425&dopt=Abstract
•
Spinocerebellar ataxia type 6: channelopathy or glutamine repeat disorder? Author(s): Frontali M. Source: Brain Research Bulletin. 2001 October-November 1; 56(3-4): 227-31. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719255&dopt=Abstract
•
Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Author(s): Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, Kozak T. Source: Bone Marrow Transplantation. 2002 December; 30(12): 953-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12476290&dopt=Abstract
•
Starvation-induced lysosomal degradation of aldolase B requires glutamine 111 in a signal sequence for chaperone-mediated transport. Author(s): Susan PP, Dunn WA Jr. Source: Journal of Cellular Physiology. 2001 April; 187(1): 48-58. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11241348&dopt=Abstract
•
Steroid receptor coactivator-3 glutamine repeat polymorphism and the androgen insensitivity syndrome. Author(s): Mongan NP, Jaaskelainen J, Bhattacharyya S, Leu RM, Hughes IA. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2003 February; 148(2): 277-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12590649&dopt=Abstract
120
Glutamine
•
Strong aggregation and increased toxicity of polyleucine over polyglutamine stretches in mammalian cells. Author(s): Dorsman JC, Pepers B, Langenberg D, Kerkdijk H, Ijszenga M, den Dunnen JT, Roos RA, van Ommen GJ. Source: Human Molecular Genetics. 2002 June 15; 11(13): 1487-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12045202&dopt=Abstract
•
Structural features associated with the binding of glutamine-containing peptides to Factor XIII. Author(s): Marinescu A, Cleary DB, Littlefield TR, Maurer MC. Source: Archives of Biochemistry and Biophysics. 2002 October 1; 406(1): 9-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12234485&dopt=Abstract
•
Sub-lethal concentrations of activated complement increase rat lymphocyte glutamine utilization and oxidation while lethal concentrations cause death by a mechanism involving ATP depletion. Author(s): Bacurau RF, O'Toole CE, Newsholme P, Costa Rosa LF. Source: Cell Biochemistry and Function. 2002 September; 20(3): 183-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12125093&dopt=Abstract
•
SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death. Author(s): Terashima T, Kawai H, Fujitani M, Maeda K, Yasuda H. Source: Neuroreport. 2002 December 3; 13(17): 2359-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12488827&dopt=Abstract
•
Supplemental glutamine augments phagocytosis and reactive oxygen intermediate production by neutrophils and monocytes from postoperative patients in vitro. Author(s): Furukawa S, Saito H, Inoue T, Matsuda T, Fukatsu K, Han I, Ikeda S, Hidemura A. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2000 May; 16(5): 323-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10793298&dopt=Abstract
•
The anabolic effects of recombinant human growth hormone and glutamine on parenterally fed, short bowel rats. Author(s): Gu Y, Wu ZH. Source: World Journal of Gastroenterology : Wjg. 2002 August; 8(4): 752-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174391&dopt=Abstract
Studies
121
•
The BCAA-BCKA cycle: its relation to alanine and glutamine synthesis and protein balance. Author(s): Holecek M. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2001 January; 17(1): 70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11165898&dopt=Abstract
•
The conserved glutamine-rich region of chick csal1 and csal3 mediates protein interactions with other spalt family members. Implications for Townes-Brocks syndrome. Author(s): Sweetman D, Smith T, Farrell ER, Chantry A, Munsterberg A. Source: The Journal of Biological Chemistry. 2003 February 21; 278(8): 6560-6. Epub 2002 December 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12482848&dopt=Abstract
•
The effect of glutamine on protein balance and amino acid flux across arm and leg tissues in healthy volunteers. Author(s): Svanberg E, Moller-Loswick AC, Matthews DE, Korner U, Lundholm K. Source: Clinical Physiology (Oxford, England). 2001 July; 21(4): 478-89. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11442580&dopt=Abstract
•
The effect of glutamine supplementation in patients following elective surgery and accidental injury. Author(s): Wilmore DW. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2543S-9S; Discussion 2550S-1S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533310&dopt=Abstract
•
The effect of glutamine-supplemented total parenteral nutrition on nitrogen economy depends on severity of diseases in surgical patients. Author(s): Lin MT, Kung SP, Yeh SL, Lin C, Lin TH, Chen KH, Liaw KY, Lee PH, Chang KJ, Chen WJ. Source: Clinical Nutrition (Edinburgh, Lothian). 2002 June; 21(3): 213-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12127929&dopt=Abstract
•
The effect of polyglutamine expansion in the human androgen receptor on its ability to suppress beta-catenin-Tcf/Lef dependent transcription. Author(s): Cullen DA, Killick R, Leigh PN, Gallo JM. Source: Neuroscience Letters. 2004 January 2; 354(1): 54-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14698481&dopt=Abstract
122
Glutamine
•
The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. Author(s): Zhou YP, Jiang ZM, Sun YH, Wang XR, Ma EL, Wilmore D. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2003 July-August; 27(4): 241-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12903886&dopt=Abstract
•
The effectiveness of growth hormone, glutamine and a low-fat diet containing highcarbohydrate on the enhancement of the function of remnant intestine among patients with short bowel syndrome: a review of published trials. Author(s): Li-Ling, Irving M. Source: Clinical Nutrition (Edinburgh, Lothian). 2001 June; 20(3): 199-204. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11407865&dopt=Abstract
•
The effects of 8 weeks of creatine monohydrate and glutamine supplementation on body composition and performance measures. Author(s): Lehmkuhl M, Malone M, Justice B, Trone G, Pistilli E, Vinci D, Haff EE, Kilgore JL, Haff GG. Source: Journal of Strength and Conditioning Research / National Strength & Conditioning Association. 2003 August; 17(3): 425-38. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12930166&dopt=Abstract
•
The effects of high-dose glutamine ingestion on weightlifting performance. Author(s): Antonio J, Sanders MS, Kalman D, Woodgate D, Street C. Source: Journal of Strength and Conditioning Research / National Strength & Conditioning Association. 2002 February; 16(1): 157-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11834123&dopt=Abstract
•
The evidence for glutamine use in the critically-ill. Author(s): Griffiths RD. Source: The Proceedings of the Nutrition Society. 2001 August; 60(3): 403-10. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11681816&dopt=Abstract
•
The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. Author(s): Gonzalez Sanchez JL, Proenza AM, Martinez Larrad MT, Ramis JM, Fernandez Perez C, Palou A, Serrano Rios M. Source: Clinical Endocrinology. 2003 October; 59(4): 476-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14510910&dopt=Abstract
Studies
123
•
The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine. Author(s): Broer A, Wagner CA, Lang F, Broer S. Source: The Biochemical Journal. 2000 August 1; 349 Pt 3: 787-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10903140&dopt=Abstract
•
The influence of diet and exercise on muscle and plasma glutamine concentrations. Author(s): Blanchard MA, Jordan G, Desbrow B, MacKinnon LT, Jenkins DG. Source: Medicine and Science in Sports and Exercise. 2001 January; 33(1): 69-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11194114&dopt=Abstract
•
The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. Author(s): Honegger A, Pluckthun A. Source: Journal of Molecular Biology. 2001 June 8; 309(3): 687-99. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11397089&dopt=Abstract
•
The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1). Author(s): Orr HT. Source: Neurobiology of Disease. 2000 June; 7(3): 129-34. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10860780&dopt=Abstract
•
The local vascular tolerance to an intravenous infusion of a concentrated glutamine solution in ICU patients. Author(s): Berg A, Forsberg E, Wernerman J. Source: Clinical Nutrition (Edinburgh, Lothian). 2002 April; 21(2): 135-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12056785&dopt=Abstract
•
The metastatic suppressor Nm23-H1 interacts with EBNA3C at sequences located between the glutamine- and proline-rich domains and can cooperate in activation of transcription. Author(s): Subramanian C, Robertson ES. Source: Journal of Virology. 2002 September; 76(17): 8702-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12163590&dopt=Abstract
•
The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunitspecific enhanced activation of P/Q-type calcium channels in Xenopus oocytes. Author(s): Restituito S, Thompson RM, Eliet J, Raike RS, Riedl M, Charnet P, Gomez CM. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2000 September 1; 20(17): 6394-403. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10964945&dopt=Abstract
124
Glutamine
•
The polyglutamine motif is highly conserved at the Clock locus in various organisms and is not polymorphic in humans. Author(s): Saleem Q, Anand A, Jain S, Brahmachari SK. Source: Human Genetics. 2001 August; 109(2): 136-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11511917&dopt=Abstract
•
The potential mechanism for glutamine-induced collagen biosynthesis in cultured human skin fibroblasts. Author(s): Karna E, Miltyk W, Wolczynski S, Palka JA. Source: Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology. 2001 August; 130(1): 23-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11470441&dopt=Abstract
•
The relation between glutamine and the immunodepression observed in exercise. Author(s): Castell LM, Newsholme EA. Source: Amino Acids. 2001; 20(1): 49-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11310930&dopt=Abstract
•
The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia. Author(s): Al-Hassnan ZN, Boyadjiev SA, Praphanphoj V, Hamosh A, Braverman NE, Thomas GH, Geraghty MT. Source: Journal of Inherited Metabolic Disease. 2003; 26(1): 89-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12872849&dopt=Abstract
•
The role of L-alanyl-L-glutamine in the immune response in vitro. Author(s): Kircher B, Eibl G, Enrich B, Latzer K, Herold M, Niederwieser D. Source: Wiener Klinische Wochenschrift. 2002 August 30; 114(15-16): 702-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12602115&dopt=Abstract
•
The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Author(s): Divine KK, Gilliland FD, Crowell RE, Stidley CA, Bocklage TJ, Cook DL, Belinsky SA. Source: Mutation Research. 2001 January 5; 461(4): 273-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11104903&dopt=Abstract
•
Total parenteral nutrition enriched with arginine and glutamate generates glutamine and limits protein catabolism in surgical patients hospitalized in intensive care units. Author(s): Berard MP, Zazzo JF, Condat P, Vasson MP, Cynober L. Source: Critical Care Medicine. 2000 November; 28(11): 3637-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11098966&dopt=Abstract
Studies
125
•
Transfer of glutamine between astrocytes and neurons. Author(s): Broer S, Brookes N. Source: Journal of Neurochemistry. 2001 May; 77(3): 705-19. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11331400&dopt=Abstract
•
Transglutamines and endocrine system (minireview). Author(s): Dvorcakova M, Macejova D, Pallet V, Higueret P, Vasson MP, Rock E, Brtko J. Source: Endocrine Regulations. 2002 March; 36(1): 31-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11971749&dopt=Abstract
•
Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine. Author(s): Hazeki N, Tsukamoto T, Yazawa I, Koyama M, Hattori S, Someki I, Iwatsubo T, Nakamura K, Goto J, Kanazawa I. Source: Biochemical and Biophysical Research Communications. 2002 June 7; 294(2): 429-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12051730&dopt=Abstract
•
Unregulated elevation of glutamate dehydrogenase activity induces glutaminestimulated insulin secretion: identification and characterization of a GLUD1 gene mutation and insulin secretion studies with MIN6 cells overexpressing the mutant glutamate dehydrogenase. Author(s): Tanizawa Y, Nakai K, Sasaki T, Anno T, Ohta Y, Inoue H, Matsuo K, Koga M, Furukawa S, Oka Y. Source: Diabetes. 2002 March; 51(3): 712-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11872671&dopt=Abstract
•
Uptake of 14C- and 11C-labeled glutamate, glutamine and aspartate in vitro and in vivo. Author(s): Wu F, Orlefors H, Bergstrom M, Antoni G, Omura H, Eriksson B, Watanabe Y, Langstrom B. Source: Anticancer Res. 2000 January-February; 20(1A): 251-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10769663&dopt=Abstract
•
Where is the glutamine? Intradialytic supplementation may not solve all issues in amino acid balance. Author(s): Solomons NW, Stehle P, Furst P. Source: The American Journal of Clinical Nutrition. 2000 November; 72(5): 1236-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11063458&dopt=Abstract
126
•
Glutamine
Whole body and skeletal muscle glutamine metabolism in healthy subjects. Author(s): Mittendorfer B, Volpi E, Wolfe RR. Source: American Journal of Physiology. Endocrinology and Metabolism. 2001 February; 280(2): E323-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11158937&dopt=Abstract
127
CHAPTER 2. NUTRITION AND GLUTAMINE Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and glutamine.
Finding Nutrition Studies on Glutamine The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “glutamine” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7 Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
128
Glutamine
The following is a typical result when searching for recently indexed consumer information on glutamine: •
Glutamine in total parenteral nutrition. Author(s): Texas A&M University, Round Rock, TX. Source: Shipley, S.G. Nutrition-today (USA). (April 1996). volume 31(2) page 74-77.
Additional consumer oriented references include: •
Is glutamine a conditionally essential amino acid. Source: Nutr-Rev. New York, N.Y. : Springer-Verlag New York Inc. August 1990. volume 48 (8) page 297-309. 0029-6643
•
Muscle provides glutamine to the immune system. Source: Nutr-Rev. New York, N.Y. : Springer-Verlag New York Inc. October 1990. volume 48 (10) page 390-392. 0029-6643
•
The Journal of Biological Chemistry, Volume 249, 1974: Uptake and metabolism of plasma glutamine by the small intestine. Source: Windmueller, H G Spaeth, A E Nutr-Revolume 1990 August; 48(8): 310-2 00296643
The following information is typical of that found when using the “Full IBIDS Database” to search for “glutamine” (or a synonym): •
Both glucose-insulin-potassium and glutamine in warm blood cardioplegia increase the rates of myocardial glucose and free fatty acid oxidation. Author(s): Department of Cardiothoracic and Vascular Surgery, School of Medicine, University of Tromso, Norway.
[email protected] Source: Elvenes, O P Korvald, C Irtun, O Larsen, T Sorlie, D Scand-Cardiovasc-J. 2002 February; 36(1): 19-26 1401-7431
•
Changes in the nutritional state and immune-serological parameters of esophagectomized patients fed jejunaly with glutamine-poor and glutamine-rich nutriments. Author(s): Second Department of Surgery, Medical and Health Science Centre School of Medicine, University of Debrecen, Moricz Zs. Krt. 22., Debrecen H-4004, Hungary.
[email protected] Source: Hallay, J Kovacs, G Kiss Sz, S Farkas, M Lakos, G Sipka, S Bodolay, E Sapy, P Hepatogastroenterology. 2002 Nov-December; 49(48): 1555-9 0172-6390
•
Clinical application of glutamine therapy. Source: Abood, S.K. Proc-North-Am-Vet-Conf. [Gainesville, Fla.] : Eastern States Veterinary Association, 1992-. 1998. volume 12 page 429.
•
Conditionally indispensable amino acids (glutamine, cyst(e)ine, tyrosine, arginine, ornithine, taurine) in enteral feeding and the dipeptide concept. Author(s): Institute for Biological Chemistry and Nutrition, Stuttgart, Germany. Source: Furst, P Nestle-Nutr-Workshop-Ser-Clin-Perform-Programme. 2000; 3: 199-217; discussion 217-9 1422-7584
•
Effect of glutamine supplementation combined with resistance training in young adults. Author(s): College of Kinesiology, University of Saskatchewan, Saskatoon, Canada.
Nutrition
129
Source: Candow, D G Chilibeck, P D Burke, D G Davison, K S Smith Palmer, T Eur-JAppl-Physiol. 2001 December; 86(2): 142-9 1439-6319 •
Effects of oral supplement of L-glutamine on diverted colon wall. Author(s): Colorectal Surgery Division, Department of Surgery, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
[email protected] Source: Paulo, F L J-Cell-Mol-Med. 2002 Jul-September; 6(3): 377-82 1582-1838
•
Evidence that glutamine is involved in neutrophil function. Author(s): Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sao Paulo, SP, Brazil.
[email protected] Source: Pithon Curi, Tania C Trezena, Ariane G Tavares Lima, Wothan Curi, Rui CellBiochem-Funct. 2002 June; 20(2): 81-6 0263-6484
•
Glutamine and wound healing. Author(s): Pembroke Pines, FL, USA.
[email protected] Source: Collins, N Adv-Skin-Wound-Care. 2002 Sep-October; 15(5): 233-4 1527-7941
•
Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in-vitro. Author(s): Appareil Digestif Environnement et Nutrition (ADEN EA 3234), Rouen, France. Source: Coeffier, M Marion, R Leplingard, A Lerebours, E Ducrotte, P Dechelotte, P Cytokine. 2002 April 21; 18(2): 92-7 1043-4666
•
Glutamine for short-bowel syndrome. Source: Buchman, A L Curr-Gastroenterol-Repage 2002 August; 4(4): 321 1522-8037
•
Glutamine metabolism in the fetus and critically ill low birth weight neonate. Author(s): University of Florida, Shands Children's Hospital at the University of Florida, Gainesville, USA. Source: Neu, J Auestad, N DeMarco, V G Adv-Pediatr. 2002; 49: 203-26 0065-3101
•
Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels. Author(s): Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, Kaohsiung, Taiwan. Source: Chang, W K Yang, K D Chuang, H January, J T Shaio, M F Clin-Immunol. 2002 August; 104(2): 151-60 1521-6616
•
Glutamine supplementation for prevention of morbidity in preterm infants (Cochrane Review). Author(s): Neonatal Intensive Care Unit, Royal Maternity Hospital, Grosvenor Road, Belfast, Northern Ireland, UK.
[email protected] Source: Tubman, T R Thompson, S W Cochrane-Database-Syst-Revolume 2001; 4: CD001457 1469-493X
•
Glutamine-enhanced nutrition in the critically ill patient. Author(s): Intensive Care Medicine Research Group, Department of Medicine, University of Liverpool, Liverpool L69 3GA. Source: Andrews, Francis Griffiths, Richard Hosp-Med. 2002 March; 63(3): 144-7 14623935
•
Identification of L-glutamine: 2-deoxy-scyllo-inosose aminotransferase required for the biosynthesis of butirosin in Bacillus circulans. Author(s): Department of Chemistry, Tokyo Institute of Technology, Japan. Source: Tamegai, H Nango, E Kuwahara, M Yamamoto, H Ota, Y Kuriki, H Eguchi, T Kakinuma, K J-Antibiot-(Tokyo). 2002 August; 55(8): 707-14 0021-8820
130
Glutamine
•
Influence of glutamine and glycyl-glutamine on in vitro lymphocyte proliferation in children with solid tumors. Author(s): Department of Pediatrics, Heinrich-Heine-Universitat, Dusseldorf, Germany. Source: Kohler, H Klowik, M Brand, O Gobel, U Schroten, H Support-Care-Cancer. 2001 June; 9(4): 261-6 0941-4355
•
Inhibition of glutamine synthetase in a549 cells during hyperoxia. Author(s): Department of Pediatrics, Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
[email protected] Source: McGrath Morrow, S A Stahl, J Am-J-Respir-Cell-Mol-Biol. 2002 July; 27(1): 99106 1044-1549
•
Lethality of standard total parenteral nutrition following major liver resection in rats is prevented by high arginine and high branched chain amino acids but not by glutamine. Author(s): Department of Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA. Source: Qiu, J G Delany, H M Teh, E L Gliedman, M L Chang, C J Levenson, S M JAssoc-Acad-Minor-Phys. 2001 March; 12(1-2): 109-18 1048-9886
•
L-glutamine. Source: Anonymous Altern-Med-Revolume 2001 August; 6(4): 406-10 1089-5159
•
Plasma glutamine and glutamate concentrations in Gabonese children with Plasmodium falciparum infection. Author(s): Department of Infectious Diseases, St George's Hospital Medical School, Cranmer Terrace, London, UK. Source: Planche, T Dzeing, A Emmerson, A C Onanga, M Kremsner, P G Engel, K Kombila, M Ngou Milama, E Krishna, S QJM. 2002 February; 95(2): 89-97 1460-2725
•
Possible role of glutamate, aspartate, glutamine, GABA or taurine on cadmium toxicity on the hypothalamic pituitary axis activity in adult male rats. Author(s): Laboratorio de Toxicologia, Facultad de Ciencias, Universidad de Vigo, Las Lagunas, Orense, Spain.
[email protected] Source: Lafuente, A Esquifino, A I Biometals. 2002 June; 15(2): 183-7 0966-0844
•
Potential role of glutamine administration in inflammatory bowel disease. Author(s): Department of Medicine, Division of Endocrinology and Metabolism, Nutrition and Health Sciences Program, Emory University School of Medicine, Atlanta, Ga., USA. Source: Jonas, C R Ziegler, T R Nestle-Nutr-Workshop-Ser-Clin-Perform-Programme. 1999; 2: 217-30; discussion 230-5 1422-7584
•
Preference for a solution of branched-chain amino acids plus glutamine and arginine correlates with free running activity in rats: involvement of serotonergic-dependent processes of lateral hypothalamus. Author(s): Ajinomoto Co. Inc., Central Research Laboratories, Kawasaki, Japan.
[email protected] Source: Smriga, M Kameishi, M Tanaka, T Kondoh, T Torii, K Nutr-Neurosci. 2002 June; 5(3): 189-99 1028-415X
•
Preventive effect of glutamine on intestinal barrier dysfunction induced by severe trauma. Author(s): Burn Institute, Chinese PLA 304 Hospital, 51 Fu Cheng Road, Beijing 100037,China.
[email protected]
Nutrition
131
Source: Li, June You Lu, Yi Hu, Sen Sun, Dan Yao, Yong Ming World-J-Gastroenterol. 2002 February; 8(1): 168-71 1007-9327 •
Prolonged dietary treatment with conjugated linoleic acid stimulates porcine muscle peroxisome proliferator activated receptor gamma and glutamine-fructose aminotransferase gene expression in vivo. Author(s): Meat Research Section, Agriculture and Agri-Food Canada, Lacombe Research Centre, 6000 C&E Trail, Alberta, Canada T4L 1W1.
[email protected] Source: Meadus, W J MacInnis, R Dugan, M E R J-Mol-Endocrinol. 2002 April; 28(2): 7986 0952-5041
•
Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Author(s): BF Research Institute, Inc, National Cardiovascular Center, Suita, Osaka, Japan. Source: Hattori, Noriaki Abe, Kazuo Sakoda, Saburo Sawada, Tohru Neuroreport. 2002 January 21; 13(1): 183-6 0959-4965
•
Synthesis, screening and quantitative structure-activity relationship (QSAR) studies of some glutamine analogues for possible anticancer activity. Author(s): Division of Medicinal Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700 032, India.
[email protected] Source: Srikanth, K KuMarch, ChA Ghosh, B Jha, T Bioorg-Med-Chem. 2002 July; 10(7): 2119-31 0968-0896
•
The amino acids precursory to proteins are primary human food: proline, glutamine, and arginine found free in the juices of common vegetables and herbs. Source: Kapuler, A.M. Gurusiddiah, S. J-med-food. Larchmont, NY : Mary Ann Liebert, Inc., c1998-. 1998. volume 1 (2) page 97-115. 1096-620X
•
The anabolic effects of recombinant human growth hormone and glutamine on parenterally fed, short bowel rats. Author(s): Department of General Surgery, Shanghai Ninth People's Hospital, Shanghai Second Medical University, Shanghai 200011, China.
[email protected] Source: Gu, Y Wu, Z H World-J-Gastroenterol. 2002 August; 8(4): 752-7 1007-9327
•
The effects of high-dose glutamine ingestion on weightlifting performance. Author(s): Sports Science Laboratory, University of Delaware, Newark, Delaware 19716, USA. Source: Antonio, Jose Sanders, Michael S Kalman, Douglas Woodgate, Derek Street, Chris J-Strength-Cond-Res. 2002 February; 16(1): 157-60 1064-8011
•
The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Author(s): Department of Industrial and Physical Pharmacy, School of Pharmacy, Purdue University, West Lafayette, Indiana, USA. Source: Shaw, Andrew A Hall, Stephen D Franklin, Michael R Galinsky, Raymond E Drug-Metab-Dispos. 2002 February; 30(2): 177-82 0090-9556
•
Thermostability of manganese- and iron-superoxide dismutases from Escherichia coli is determined by the characteristic position of a glutamine residue. Author(s): Department of Physiology and Biochemistry, University of Malta, Msida, Malta. Source: Hunter, T Bannister, J V Hunter, G J Eur-J-Biochem. 2002 November; 269(21): 5137-48 0014-2956
132
Glutamine
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMD®Health: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
Nutrition
133
The following is a specific Web list relating to glutamine; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Minerals Cisplatin Source: Healthnotes, Inc.; www.healthnotes.com
•
Food and Diet HMB Source: Healthnotes, Inc.; www.healthnotes.com Wound Healing Source: Healthnotes, Inc.; www.healthnotes.com
135
CHAPTER 3. ALTERNATIVE MEDICINE AND GLUTAMINE Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to glutamine. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to glutamine and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “glutamine” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to glutamine: •
5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Author(s): Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D, Shelley MD, Elia M. Source: British Journal of Cancer. 1994 October; 70(4): 732-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7917930&dopt=Abstract
•
A cDNA sequence encoding glutamine synthetase is preferentially expressed in nodules of Vigna aconitifolia. Author(s): Lin Z, Miao GH, Verma DP. Source: Plant Physiology. 1995 January; 107(1): 279-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7870822&dopt=Abstract
136
Glutamine
•
A clinical study of the effectiveness of oral glutamine supplementation during total parenteral nutrition: influence on mesenteric mononuclear cells. Author(s): Aosasa S, Mochizuki H, Yamamoto T, Ono S, Ichikura T. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1999 September-October; 23(5 Suppl): S41-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10483893&dopt=Abstract
•
A double blind, randomised, controlled trial of glutamine supplementation in parenteral nutrition. Author(s): Powell-Tuck J, Jamieson CP, Bettany GE, Obeid O, Fawcett HV, Archer C, Murphy DL. Source: Gut. 1999 July; 45(1): 82-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10369709&dopt=Abstract
•
A strong constitutive positive element is essential for the ammonium-regulated expression of a soybean gene encoding cytosolic glutamine synthetase. Author(s): Terce-Laforgue T, Carrayol E, Cren M, Desbrosses G, Hecht V, Hirel B. Source: Plant Molecular Biology. 1999 February; 39(3): 551-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10092182&dopt=Abstract
•
Acute effects of intravenous glutamine supplementation on protein metabolism in very low birth weight infants: a stable isotope study. Author(s): des Robert C, Le Bacquer O, Piloquet H, Roze JC, Darmaun D. Source: Pediatric Research. 2002 January; 51(1): 87-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11756645&dopt=Abstract
•
Altered kinetic properties of tyrosine-183 to cysteine mutation in glutamine synthetase of anabaena variabilis strain SA1 is responsible for excretion of ammonium ion produced by nitrogenase. Author(s): Healy FG, Latorre C, Albrecht SL, Reddy PM, Shanmugam KT. Source: Current Microbiology. 2003 June; 46(6): 423-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12732949&dopt=Abstract
•
An alternative method to supplement glutamine in parenteral nutrition? Author(s): Sandifer DP. Source: Critical Care Medicine. 2000 November; 28(11): 3761-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11098992&dopt=Abstract
•
Antipeptide antibodies that can distinguish specific subunit polypeptides of glutamine synthetase from bean (Phaseolus vulgaris L.). Author(s): Cai X, Henry RL, Takemoto LJ, Guikema JA, Wong PP.
Alternative Medicine 137
Source: Plant Physiology. 1992; 98: 402-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11537881&dopt=Abstract •
Assessment of the safety of glutamine and other amino acids. Author(s): Garlick PJ. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2556S-61S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533313&dopt=Abstract
•
Bcl-xL expression interferes with the effects of L-glutamine supplementation on hybridoma cultures. Author(s): Charbonneau JR, Furtak T, Lefebvre J, Gauthier ER. Source: Biotechnology and Bioengineering. 2003 February 5; 81(3): 279-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12474250&dopt=Abstract
•
Bidirectional supply of glutamine maintains enterocyte ATP content in the in vitro using chamber model. Author(s): Yang H, Soderholm JD, Larsson J, Permert J, Lindgren J, Wiren M. Source: International Journal of Colorectal Disease. 2000 November; 15(5-6): 291-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11151432&dopt=Abstract
•
Cloning and characterisation of glutamine synthetase from Colletotrichum gloeosporioides and demonstration of elevated expression during pathogenesis on Stylosanthes guianensis. Author(s): Stephenson SA, Green JR, Manners JM, Maclean DJ. Source: Current Genetics. 1997 May; 31(5): 447-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9162117&dopt=Abstract
•
Comparison of a immunonutrition formula enriched arginine, glutamine and omega3 fatty acid, with a currently high-enriched enteral nutrition for trauma patients. Author(s): Chuntrasakul C, Siltham S, Sarasombath S, Sittapairochana C, Leowattana W, Chockvivatanavanit S, Bunnak A. Source: J Med Assoc Thai. 2003 June; 86(6): 552-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12924804&dopt=Abstract
•
Complementary expression of glutamine synthetase and carbamoylphosphate synthetase I in ornithine carbamoyltransferase-deficient mouse liver (spf-ash mouse). Author(s): Shiojiri N, Ohta T, Ogawa K, Gebhardt R. Source: Histochemistry and Cell Biology. 1997 December; 108(6): 489-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9450631&dopt=Abstract
•
Control of de novo purine biosynthesis genes in ureide-producing legumes: induction of glutamine phosphoribosylpyrophosphate amidotransferase gene and
138
Glutamine
characterization of its cDNA from soybean and Vigna. Author(s): Kim JH, Delauney AJ, Verma DP. Source: The Plant Journal : for Cell and Molecular Biology. 1995 January; 7(1): 77-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7894513&dopt=Abstract •
Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Author(s): Garrel D, Patenaude J, Nedelec B, Samson L, Dorais J, Champoux J, D'Elia M, Bernier J. Source: Critical Care Medicine. 2003 October; 31(10): 2444-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14530749&dopt=Abstract
•
Decreased mortality and infectious morbidity in adult burn patients with enteral glutamine supplements. Author(s): Garrel DR, Bernier J. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 August; 22(S1): S78. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14684041&dopt=Abstract
•
Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs. Author(s): Wu G, Meier SA, Knabe DA. Source: The Journal of Nutrition. 1996 October; 126(10): 2578-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8857520&dopt=Abstract
•
Dietary glutamine supplementation reduces plasma nitrate levels in rats. Author(s): Houdijk AP, Visser JJ, Rijnsburger ER, Teerlink T, van Leeuwen PA. Source: Clinical Nutrition (Edinburgh, Lothian). 1998 February; 17(1): 11-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10205309&dopt=Abstract
•
Dietary L-glutamine supplementation reduces the growth of the Morris Hepatoma 7777 in exercise-trained and sedentary rats. Author(s): Shewchuk LD, Baracos VE, Field CJ. Source: The Journal of Nutrition. 1997 January; 127(1): 158-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9040560&dopt=Abstract
•
Does glutamine reduce bacterial translocation? A study in two animal models with impaired gut barrier. Author(s): Foitzik T, Kruschewski M, Kroesen AJ, Hotz HG, Eibl G, Buhr HJ. Source: International Journal of Colorectal Disease. 1999 August; 14(3): 143-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10460904&dopt=Abstract
•
Does glutamine supplementation increase radioresistance in squamous cell carcinoma of the cervix? Author(s): Santoso JT, Lucci JA 3rd, Coleman RL, Hatch S, Wong P, Miller D, Mathis JM.
Alternative Medicine 139
Source: Gynecologic Oncology. 1998 December; 71(3): 359-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9887231&dopt=Abstract •
Early gastrointestinal regulatory peptide response to intestinal resection in the rat is stimulated by enteral glutamine supplementation. Author(s): Wiren M, Adrian TE, Arnelo U, Permert J, Staab P, Larsson J. Source: Digestive Surgery. 1999; 16(3): 197-203. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10436367&dopt=Abstract
•
Effect of carbohydrate supplementation on plasma glutamine during prolonged exercise and recovery. Author(s): van Hall G, Saris WH, Wagenmakers AJ. Source: International Journal of Sports Medicine. 1998 February; 19(2): 82-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9562214&dopt=Abstract
•
Effect of enteral supplementation with glutamine on mesenteric blood flow in premature neonates. Author(s): Mercier A, Eurin D, Poulet-Young V, Marret S, Dechelotte P. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 April; 22(2): 133-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12706129&dopt=Abstract
•
Effect of glutamine and protein supplementation on exercise-induced decreases in salivary IgA. Author(s): Krzywkowski K, Petersen EW, Ostrowski K, Link-Amster H, Boza J, Halkjaer-Kristensen J, Pedersen BK. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2001 August; 91(2): 832-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11457800&dopt=Abstract
•
Effect of glutamine on the intestinal permeability changes induced by indomethacin in humans. Author(s): Hond ED, Peeters M, Hiele M, Bulteel V, Ghoos Y, Rutgeerts P. Source: Alimentary Pharmacology & Therapeutics. 1999 May; 13(5): 679-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10233193&dopt=Abstract
•
Effect of glutamine supplement and hepatectomy on DNA and protein synthesis in the remnant liver. Author(s): Yoshida S, Yunoki T, Aoyagi K, Ohta J, Ishibashi N, Noake T, Kakegawa T. Source: The Journal of Surgical Research. 1995 October; 59(4): 475-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7564320&dopt=Abstract
•
Effect of glutamine supplementation combined with resistance training in young adults. Author(s): Candow DG, Chilibeck PD, Burke DG, Davison KS, Smith-Palmer T.
140
Glutamine
Source: European Journal of Applied Physiology. 2001 December; 86(2): 142-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11822473&dopt=Abstract •
Effect of glutamine supplementation of the diet on tissue protein synthesis rate of glucocorticoid-treated rats. Author(s): Boza JJ, Turini M, Moennoz D, Montigon F, Vuichoud J, Gueissaz N, Gremaud G, Pouteau E, Piguet-Welsch C, Finot PA, Ballevre O. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2001 January; 17(1): 35-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11165886&dopt=Abstract
•
Effect of glutamine supplementation on changes in the immune system induced by repeated exercise. Author(s): Rohde T, MacLean DA, Pedersen BK. Source: Medicine and Science in Sports and Exercise. 1998 June; 30(6): 856-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9624643&dopt=Abstract
•
Effect of glutamine supplementation on exercise-induced changes in lymphocyte function. Author(s): Krzywkowski K, Petersen EW, Ostrowski K, Kristensen JH, Boza J, Pedersen BK. Source: American Journal of Physiology. Cell Physiology. 2001 October; 281(4): C125965. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11546663&dopt=Abstract
•
Effect of glutamine supplementation on protein metabolism and glutathione in tumor-bearing rats. Author(s): Yoshida S, Kaibara A, Yamasaki K, Ishibashi N, Noake T, Kakegawa T. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1995 November-December; 19(6): 492-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8748364&dopt=Abstract
•
Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Author(s): Szkudlarek J, Jeppesen PB, Mortensen PB. Source: Gut. 2000 August; 47(2): 199-205. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10896910&dopt=Abstract
•
Effect of L-glutamine supplementation on impaired glucose regulation during intravenous lipid administration. Author(s): Ballard TC, Farag A, Branum GD, Akwari OE, Opara EC.
Alternative Medicine 141
Source: Nutrition (Burbank, Los Angeles County, Calif.). 1996 May; 12(5): 349-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8875520&dopt=Abstract •
Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. Author(s): Den Hond E, Hiele M, Peeters M, Ghoos Y, Rutgeerts P. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1999 January-February; 23(1): 7-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9888411&dopt=Abstract
•
Effect of low- and high-carbohydrate diets on the plasma glutamine and circulating leukocyte responses to exercise. Author(s): Gleeson M, Blannin AK, Walsh NP, Bishop NC, Clark AM. Source: Int J Sport Nutr. 1998 March; 8(1): 49-59. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9534081&dopt=Abstract
•
Effect of oral glutamine supplementation during bone marrow transplantation. Author(s): Coghlin Dickson TM, Wong RM, offrin RS, Shizuru JA, Johnston LJ, Hu WW, Blume KG, Stockerl-Goldstein KE. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2000 March-April; 24(2): 61-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10772184&dopt=Abstract
•
Effect of oral glutamine supplementation on human neutrophil lipopolysaccharidestimulated degranulation following prolonged exercise. Author(s): Walsh NP, Blannin AK, Bishop NC, Robson PJ, Gleeson M. Source: International Journal of Sport Nutrition and Exercise Metabolism. 2000 March; 10(1): 39-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10722780&dopt=Abstract
•
Effect of parenteral glutamine supplementation on lymphocyte subpopulations in critically ill patients receiving glutamine enriched enteral nutrition. Author(s): Demirag K, Uyar M, Gulbahar O, Kocabas S, Delen Akcay Y, Moral AR. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 August; 22(S1): S50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14683937&dopt=Abstract
•
Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants. Author(s): Poindexter BB, Ehrenkranz RA, Stoll BJ, Koch MA, Wright LL, Oh W, Papile LA, Bauer CR, Carlo WA, Donovan EF, Fanaroff AA, Korones SB, Laptook AR, Shankaran S, Stevenson DK, Tyson JE, Lemons JA; National Institute of Child Health and Human Development Neonatal Research Network.
142
Glutamine
Source: The American Journal of Clinical Nutrition. 2003 March; 77(3): 737-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12600870&dopt=Abstract •
Effects of diazepam on neutrophil (PMN) free amino acid profiles and immune functions in vitro. Metabolical and immunological consequences of L-alanyl-Lglutamine supplementation. Author(s): Muhling J, Sablotzki A, Fuchs M, Krull M, Dehne MG, Weiss S, Gonter J, Quandt D, Hempelmann G. Source: The Journal of Nutritional Biochemistry. 2001 January; 12(1): 46-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11179861&dopt=Abstract
•
Effects of effervescent creatine, ribose, and glutamine supplementation on muscular strength, muscular endurance, and body composition. Author(s): Falk DJ, Heelan KA, Thyfault JP, Koch AJ. Source: Journal of Strength and Conditioning Research / National Strength & Conditioning Association. 2003 November; 17(4): 810-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14636104&dopt=Abstract
•
Effects of glutamine on head and neck squamous cell carcinoma. Author(s): Erickson R, Ross D, Medina J. Source: Otolaryngology and Head and Neck Surgery. 1999 October; 121(4): 348-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10504586&dopt=Abstract
•
Effects of glutamine supplementation of an amino acid-based purified diet on intestinal mucosal integrity in cats with methotrexate-induced enteritis. Author(s): Marks SL, Cook AK, Reader R, Kass PH, Theon AP, Greve C, Rogers QR. Source: Am J Vet Res. 1999 June; 60(6): 755-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10376908&dopt=Abstract
•
Effects of glutamine supplementation on circulating lymphocytes after bone marrow transplantation: a pilot study. Author(s): Ziegler TR, Bye RL, Persinger RL, Young LS, Antin JH, Wilmore DW. Source: The American Journal of the Medical Sciences. 1998 January; 315(1): 4-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9427568&dopt=Abstract
•
Effects of glutamine supplementation on innate immune response in rats with gutderived sepsis. Author(s): Yeh SL, Lai YN, Shang HF, Lin MT, Chen WJ. Source: The British Journal of Nutrition. 2004 March; 91(3): 423-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=15005828&dopt=Abstract
•
Effects of glutamine supplementation, GH, and IGF-I on glutamine metabolism in critically ill patients.
Alternative Medicine 143
Author(s): Jackson NC, Carroll PV, Russell-Jones DL, Sonksen PH, Treacher DF, Umpleby AM. Source: American Journal of Physiology. Endocrinology and Metabolism. 2000 February; 278(2): E226-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10662706&dopt=Abstract •
Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. Author(s): Yoshida S, Matsui M, Shirouzu Y, Fujita H, Yamana H, Shirouzu K. Source: Annals of Surgery. 1998 April; 227(4): 485-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9563534&dopt=Abstract
•
Effects of growth hormone (rhGH) and glutamine supplemented parenteral nutrition on intestinal adaptation in short bowel rats. Author(s): Gu Y, Wu ZH, Xie JX, Jin DY, Zhuo HC. Source: Clinical Nutrition (Edinburgh, Lothian). 2001 April; 20(2): 159-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11327744&dopt=Abstract
•
Effects of n-3 fatty acid, fructose-1,6-diphosphate and glutamine on mucosal cell proliferation and apoptosis of small bowel graft after transplantation in rats. Author(s): Wu XT, Li JS, Zhao XF, Li N, Ma YK, Zhuang W, Zhou Y, Yang G. Source: World Journal of Gastroenterology : Wjg. 2003 June; 9(6): 1323-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12800249&dopt=Abstract
•
Effects of oral arginine and glutamine on radiation-induced injury in the rat. Author(s): Hwang JM, Chan DC, Chang TM, Tsao TY, Tsou SS, Lu RH, Tsai LM. Source: The Journal of Surgical Research. 2003 February; 109(2): 149-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12643857&dopt=Abstract
•
Effects of oral supplement of L-glutamine on diverted colon wall. Author(s): Paulo FL. Source: Journal of Cellular and Molecular Medicine. 2002 July-September; 6(3): 377-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12417053&dopt=Abstract
•
Effects of parenteral alanine-glutamine supplementation on the rat nutritional condition. Author(s): Ortiz de Urbina JJ, Jorquera F, Villares C, Culebras J, Gonzalez P, GonzalezGallego J, Tunon MJ. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 August; 22(S1): S31-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14683865&dopt=Abstract
•
Effects on skeletal muscle of intravenous glutamine supplementation to ICU patients. Author(s): Tjader I, Rooyackers O, Forsberg AM, Vesali RF, Garlick PJ, Wernerman J.
144
Glutamine
Source: Intensive Care Medicine. 2004 February; 30(2): 266-75. Epub 2004 January 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14722645&dopt=Abstract •
Enteral alanyl-glutamine supplement promotes intestinal adaptation in rats. Author(s): Satoh J, Tsujikawa T, Fujiyama Y, Banba T. Source: International Journal of Molecular Medicine. 2003 October; 12(4): 615-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12964044&dopt=Abstract
•
Enteral glutamine supplementation and dexamethasone attenuate the local intestinal damage in rats with experimental necrotizing enterocolitis. Author(s): Dilsiz A, Ciftci I, Aktan TM, Gurbilek M, Karagozoglu E. Source: Pediatric Surgery International. 2003 October; 19(8): 578-82. Epub 2003 October 11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14556027&dopt=Abstract
•
Enteral glutamine supplementation and morbidity in low birth weight infants. Author(s): Vaughn P, Thomas P, Clark R, Neu J. Source: The Journal of Pediatrics. 2003 June; 142(6): 662-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12838195&dopt=Abstract
•
Enteral glutamine supplementation for the very low birthweight infant: plasma amino acid concentrations. Author(s): Roig JC, Meetze WH, Auestad N, Jasionowski T, Veerman M, McMurray CA, Neu J. Source: The Journal of Nutrition. 1996 April; 126(4 Suppl): 1115S-20S. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8642443&dopt=Abstract
•
Enteral glutamine supplementation for very low birth weight infants decreases morbidity. Author(s): Neu J, Roig JC, Meetze WH, Veerman M, Carter C, Millsaps M, Bowling D, Dallas MJ, Sleasman J, Knight T, Auestad N. Source: The Journal of Pediatrics. 1997 November; 131(5): 691-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9403648&dopt=Abstract
•
Enteral glutamine supplementation for very-low-birth-weight infants decreases hospital costs. Author(s): Dallas MJ, Bowling D, Roig JC, Auestad N, Neu J. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1998 November-December; 22(6): 352-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9829607&dopt=Abstract
Alternative Medicine 145
•
Expression of glial fibrillary acidic protein (GFAP), glutamine synthetase (GS), and Bcl-2 protooncogene protein by Muller (glial) cells in retinal light damage of rats. Author(s): Grosche J, Hartig W, Reichenbach A. Source: Neuroscience Letters. 1995 February 9; 185(2): 119-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7746501&dopt=Abstract
•
Functional importance of Asp56 from the alpha-polypeptide of Phaseolus vulgaris glutamine synthetase. An essential residue for transferase but not for biosynthetic enzyme activity. Author(s): Clemente MT, Marquez AJ. Source: European Journal of Biochemistry / Febs. 1999 September; 264(2): 453-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10491091&dopt=Abstract
•
Glucocorticoids play an important role in mediating the enhanced metabolism of arginine and glutamine in enterocytes of postweaning pigs. Author(s): Flynn NE, Wu G. Source: The Journal of Nutrition. 1997 May; 127(5): 732-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9164994&dopt=Abstract
•
Glucose, galactose, and glutamine metabolism in pig isolated enterocytes during development. Author(s): Darcy-Vrillon B, Posho L, Morel MT, Bernard F, Blachier F, Meslin JC, Duee PH. Source: Pediatric Research. 1994 August; 36(2): 175-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7970931&dopt=Abstract
•
Glutamate in enteral nutrition: can glutamate replace glutamine in supplementation to enteral nutrition in burned rats? Author(s): Hasebe M, Suzuki H, Mori E, Furukawa J, Kobayashi K, Ueda Y. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1999 September-October; 23(5 Suppl): S78-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10483902&dopt=Abstract
•
Glutamine alimentation in catabolic state. Author(s): Boelens PG, Nijveldt RJ, Houdijk AP, Meijer S, van Leeuwen PA. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2569S-77S; Discussion 2590S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533315&dopt=Abstract
•
Glutamine and arginine: immunonutrients for improved health. Author(s): Field CJ, Johnson I, Pratt VC.
146
Glutamine
Source: Medicine and Science in Sports and Exercise. 2000 July; 32(7 Suppl): S377-88. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10910294&dopt=Abstract •
Glutamine and cancer. Author(s): Medina MA. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2539S-42S; Discussion 2550S-1S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533309&dopt=Abstract
•
Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Author(s): Goringe AP, Brown S, O'Callaghan U, Rees J, Jebb S, Elia M, Poynton CH. Source: Bone Marrow Transplantation. 1998 April; 21(8): 829-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9603409&dopt=Abstract
•
Glutamine and wound healing. Author(s): Collins N. Source: Advances in Skin & Wound Care. 2002 September-October; 15(5): 233-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12368714&dopt=Abstract
•
Glutamine effects on permeability and ATP content of jejunal mucosa in starved rats. Author(s): Yang H, Soderholm J, Larsson J, Permert J, Olaison G, Lindgren J, Wiren M. Source: Clinical Nutrition (Edinburgh, Lothian). 1999 October; 18(5): 301-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10601538&dopt=Abstract
•
Glutamine for irinotecan diarrhea. Author(s): Savarese D, Al-Zoubi A, Boucher J. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2000 January; 18(2): 450-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10637264&dopt=Abstract
•
Glutamine for the gut: mystical properties or an ordinary amino acid? Author(s): Buchman AL. Source: Current Gastroenterology Reports. 1999 October; 1(5): 417-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10980981&dopt=Abstract
•
Glutamine in pediatrics: where next? Author(s): Ball PA, Hardy G. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 June; 18(6): 451-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044814&dopt=Abstract
Alternative Medicine 147
•
Glutamine metabolism stimulates intestinal cell MAPKs by a cAMP-inhibitable, Rafindependent mechanism. Author(s): Rhoads JM, Argenzio RA, Chen W, Graves LM, Licato LL, Blikslager AT, Smith J, Gatzy J, Brenner DA. Source: Gastroenterology. 2000 January; 118(1): 90-100. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10611157&dopt=Abstract
•
Glutamine parenteral supplementation in stem cell transplant. Author(s): Piccirillo N, De Matteis S, Sora F, Laurenti L, Chiusolo P, Leone G, Sica S. Source: Bone Marrow Transplantation. 2004 February; 33(4): 455; Author Reply 457. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14676779&dopt=Abstract
•
Glutamine supplementation and deprivation: effect on artificially reared rat small intestinal morphology. Author(s): Potsic B, Holliday N, Lewis P, Samuelson D, DeMarco V, Neu J. Source: Pediatric Research. 2002 September; 52(3): 430-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12193680&dopt=Abstract
•
Glutamine supplementation and GH/IGF-I treatment in critically ill patients: effects on glutamine metabolism and protein balance. Author(s): Umpleby AM, Carroll PV, Russell-Jones DL, Treacher DF, Jackson NC. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 February; 18(2): 127-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844642&dopt=Abstract
•
Glutamine supplementation and intestinal permeability in Crohn's disease. Author(s): Akobeng AK, Miller V, Thomas AG, Richmond K. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2000 May-June; 24(3): 196. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10850950&dopt=Abstract
•
Glutamine supplementation does not prevent bacterial translocation after non-lethal haemorrhage in rats. Author(s): Bark T, Katouli M, Ljungquist O, Mollby R, Svenberg T. Source: The European Journal of Surgery = Acta Chirurgica. 1995 January; 161(1): 3-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7727603&dopt=Abstract
•
Glutamine supplementation enhances mucosal immunity in rats with Gut-Derived sepsis. Author(s): Lai YN, Yeh SL, Lin MT, Shang HF, Yeh CL, Chen WJ. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2004 March; 20(3): 286-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14990270&dopt=Abstract
148
Glutamine
•
Glutamine supplementation fails to affect muscle protein kinetics in critically ill patients. Author(s): Gore DC, Wolfe RR. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2002 November-December; 26(6): 342-9; Discussion 349-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405645&dopt=Abstract
•
Glutamine supplementation for low-birth-weight and very low-birth-weight infants. Author(s): Wu PY. Source: Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998 March-April; 39(2): 7881. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9599893&dopt=Abstract
•
Glutamine supplementation for preventing morbidity in preterm infants. Author(s): Tubman TR, Thompson SW. Source: Cochrane Database Syst Rev. 2000; (2): Cd001457. Review. Update In: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10796267&dopt=Abstract
•
Glutamine supplementation for prevention of morbidity in preterm infants. Author(s): Tubman TR, Thompson SW. Source: Cochrane Database Syst Rev. 2001; (4): Cd001457. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11687112&dopt=Abstract
•
Glutamine supplementation further enhances exercise-induced plasma IL-6. Author(s): Hiscock N, Petersen EW, Krzywkowski K, Boza J, Halkjaer-Kristensen J, Pedersen BK. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2003 July; 95(1): 145-8. Epub 2003 February 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12611772&dopt=Abstract
•
Glutamine supplementation in artificial nutritional support. Author(s): Powell-Tuck J. Source: Lancet. 1997 August 23; 350(9077): 534. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9284773&dopt=Abstract
•
Glutamine supplementation in bone marrow transplantation. Author(s): Ziegler TR. Source: The British Journal of Nutrition. 2002 January; 87 Suppl 1: S9-15. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11895159&dopt=Abstract
•
Glutamine supplementation in cancer patients transplantation and high dose chemotherapy. Author(s): Ziegler TR.
receiving
bone
marrow
Alternative Medicine 149
Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2578S-84S; Discussion 2590S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533316&dopt=Abstract •
Glutamine supplementation in cancer patients receiving chemotherapy: a doubleblind randomized study. Author(s): Bozzetti F, Biganzoli L, Gavazzi C, Cappuzzo F, Carnaghi C, Buzzoni R, Dibartolomeo M, Baietta E. Source: Nutrition (Burbank, Los Angeles County, Calif.). 1997 July-August; 13(7-8): 74851. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9263281&dopt=Abstract
•
Glutamine supplementation in cancer patients. Author(s): Yoshida S, Kaibara A, Ishibashi N, Shirouzu K. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2001 September; 17(9): 766-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11527675&dopt=Abstract
•
Glutamine supplementation in catabolic illness. Author(s): Ziegler TR. Source: The American Journal of Clinical Nutrition. 1996 October; 64(4): 645-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8839515&dopt=Abstract
•
Glutamine supplementation in catabolic patients. Author(s): Sacks GS. Source: The Annals of Pharmacotherapy. 1999 March; 33(3): 348-54. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10200861&dopt=Abstract
•
Glutamine supplementation in critically ill and elective surgical patients: does the evidence warrant its use? Author(s): Miskovitz P. Source: Critical Care Medicine. 2002 September; 30(9): 2152-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352061&dopt=Abstract
•
Glutamine supplementation in low-birth-weight infants: mechanisms of action. Author(s): Neu J, DeMarco V, Weiss M. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1999 September-October; 23(5 Suppl): S49-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10483895&dopt=Abstract
•
Glutamine supplementation in serious illness: a systematic review of the evidence. Author(s): Novak F, Heyland DK, Avenell A, Drover JW, Su X.
150
Glutamine
Source: Critical Care Medicine. 2002 September; 30(9): 2022-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352035&dopt=Abstract •
Glutamine supplementation in vitro and in vivo, in exercise and in immunodepression. Author(s): Castell L. Source: Sports Medicine (Auckland, N.Z.). 2003; 33(5): 323-45. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12696982&dopt=Abstract
•
Glutamine supplementation is safe in home parenteral nutrition (HPN). Author(s): Culkin A, Gabe SM, Forbes A, Chadwick C. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 August; 22(S1): S89. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14684083&dopt=Abstract
•
Glutamine supplementation maintains intramuscular glutamine concentrations and normalizes lymphocyte function in infected early weaned pigs. Author(s): Yoo SS, Field CJ, McBurney MI. Source: The Journal of Nutrition. 1997 November; 127(11): 2253-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9349855&dopt=Abstract
•
Glutamine supplementation of enteral nutrition: impact on whole body protein kinetics and glucose metabolism in critically ill patients. Author(s): Long CL, Nelson KM, DiRienzo DB, Weis JK, Stahl RD, Broussard TD, Theus WL, Clark JA, Pinson TW, Geiger JW, et al. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1995 November-December; 19(6): 470-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8748361&dopt=Abstract
•
Glutamine supplementation prevents the decrease of mitogen response after a treadmill exercise in rats. Author(s): Moriguchi S, Miwa H, Kishino Y. Source: J Nutr Sci Vitaminol (Tokyo). 1995 February; 41(1): 115-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7616318&dopt=Abstract
•
Glutamine supplementation promotes anaplerosis but not oxidative energy delivery in human skeletal muscle. Author(s): Bruce M, Constantin-Teodosiu D, Greenhaff PL, Boobis LH, Williams C, Bowtell JL. Source: American Journal of Physiology. Endocrinology and Metabolism. 2001 April; 280(4): E669-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11254475&dopt=Abstract
Alternative Medicine 151
•
Glutamine supplementation. Heal the gut, help the patient. Author(s): Savy GK. Source: Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society. 2002 January-February; 25(1): 65-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11840007&dopt=Abstract
•
Glutamine supplements in premature infants: why and how. Author(s): Neu J. Source: Journal of Pediatric Gastroenterology and Nutrition. 2003 November; 37(5): 5335. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14581791&dopt=Abstract
•
Glutamine synthetase activity in Solanaceous cell suspensions accumulating alkaloids or not. 13C NMR and enzymatic assay. Author(s): Mesnard F, Marty D, Gillet-Manceau F, Fliniaux MA, Monti JP. Source: Comptes Rendus De L'academie Des Sciences. Serie Iii, Sciences De La Vie. 1999 September; 322(9): 743-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10547716&dopt=Abstract
•
Glutamine synthetase from N2-fixing cyanobacterium Nostoc muscorum-purification, biochemical and immunological characteristics. Author(s): Srivastava R, Amla DV. Source: Indian J Exp Biol. 1997 October; 35(10): 1098-107. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9475046&dopt=Abstract
•
Glutamine to intensive care unit patients. Author(s): Wernerman J. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2003 July-August; 27(4): 302-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12903897&dopt=Abstract
•
Glutamine transport in rat brain synaptic and non-synaptic mitochondria. Author(s): Roberg B, Torgner IA, Kvamme E. Source: Neurochemical Research. 1999 March; 24(3): 383-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10215512&dopt=Abstract
•
Glutamine treatment of paclitaxel-induced myalgias and arthralgias. Author(s): Savarese D, Boucher J, Corey B. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 December; 16(12): 3918-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9850043&dopt=Abstract
152
Glutamine
•
Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. Author(s): Cordoba J, Gottstein J, Blei AT. Source: Hepatology (Baltimore, Md.). 1996 October; 24(4): 919-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8855198&dopt=Abstract
•
Glutamine. Author(s): Heys SD, Ashkanani F. Source: The British Journal of Surgery. 1999 March; 86(3): 289-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10201766&dopt=Abstract
•
Glutamine: a potentially useful supplement for athletes. Author(s): Antonio J, Street C. Source: Canadian Journal of Applied Physiology = Revue Canadienne De Physiologie Appliquee. 1999 February; 24(1): 1-14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9916176&dopt=Abstract
•
Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Author(s): Shabert JK, Winslow C, Lacey JM, Wilmore DW. Source: Nutrition (Burbank, Los Angeles County, Calif.). 1999 November-December; 15(11-12): 860-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10575661&dopt=Abstract
•
Glutamine-enhanced nutrition in the critically ill patient. Author(s): Andrews F, Griffiths R. Source: Hosp Med. 2002 March; 63(3): 144-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11933816&dopt=Abstract
•
Glutamine-supplemented tube feedings versus total parenteral nutrition in children receiving intensive chemotherapy. Author(s): Ford C, Whitlock JA, Pietsch JB. Source: Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses. 1997 April; 14(2): 68-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9144976&dopt=Abstract
•
Glutathione stimulates A549 cell proliferation in glutamine-deficient culture: the effect of glutamate supplementation. Author(s): Kang YJ, Feng Y, Hatcher EL. Source: Journal of Cellular Physiology. 1994 December; 161(3): 589-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7962140&dopt=Abstract
Alternative Medicine 153
•
Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. Author(s): Byrne TA, Morrissey TB, Nattakom TV, Ziegler TR, Wilmore DW. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1995 July-August; 19(4): 296302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8523629&dopt=Abstract
•
Gut glutamine metabolism at different stages of sepsis in rats. Author(s): Nose K, Wasa M, Okada A. Source: Surgery Today. 2002; 32(8): 695-700. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12181719&dopt=Abstract
•
Identification of several soybean cytosolic glutamine synthetase transcripts highly or specifically expressed in nodules: expression studies using one of the corresponding genes in transgenic Lotus corniculatus. Author(s): Marsolier MC, Debrosses G, Hirel B. Source: Plant Molecular Biology. 1995 January; 27(1): 1-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7865779&dopt=Abstract
•
Immunosuppression in undernourished rats: the effect of glutamine supplementation. Author(s): Cunha WD, Friedler G, Vaisberg M, Egami MI, Costa Rosa LF. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 October; 22(5): 453-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14512032&dopt=Abstract
•
Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteers. Author(s): Valencia E, Marin A, Hardy G. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 May; 18(5): 367-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11985937&dopt=Abstract
•
Increased circulating B and T lymphocyte in burn patients given enteral glutamine supplement. Author(s): Garrel DR, Bernier J. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 August; 22(S1): S38. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14683893&dopt=Abstract
•
Influence of divalent cations on the catalytic properties and secondary structure of unadenylylated glutamine synthetase from Azospirillum brasilense. Author(s): Antonyuk LP, Smirnova VE, Kamnev AA, Serebrennikova OB, Vanoni MA, Zanetti G, Kudelina IA, Sokolov OI, Ignatov VV.
154
Glutamine
Source: Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine. 2001 March; 14(1): 13-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11368271&dopt=Abstract •
Involvement of glutamine, arginine, and polyamines in the action of ornithine alphaketoglutarate on macrophage functions in stressed rats. Author(s): Moinard C, Caldefie F, Walrand S, Felgines C, Vasson MP, Cynober L. Source: Journal of Leukocyte Biology. 2000 June; 67(6): 834-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10857856&dopt=Abstract
•
L-glutamine supplementation improves nelfinavir-associated diarrhea in HIVinfected individuals. Author(s): Huffman FG, Walgren ME. Source: Hiv Clinical Trials. 2003 September-October; 4(5): 324-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14583848&dopt=Abstract
•
L-glutamine supplementation in home total parenteral nutrition patients: stability, safety, and effects on intestinal absorption. Author(s): Hornsby-Lewis L, Shike M, Brown P, Klang M, Pearlstone D, Brennan MF. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1994 May-June; 18(3): 268-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8065004&dopt=Abstract
•
L-glutamine supplementation of a high fat diet reduces body weight and attenuates hyperglycemia and hyperinsulinemia in C57BL/6J mice. Author(s): Opara EC, Petro A, Tevrizian A, Feinglos MN, Surwit RS. Source: The Journal of Nutrition. 1996 January; 126(1): 273-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8558312&dopt=Abstract
•
Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease: effect of enteral nutritional support and glutamine supplementation. Author(s): Akobeng AI, Clayton PE, Miller V, Hall CM, Thomas AG. Source: Scandinavian Journal of Gastroenterology. 2002 December; 37(12): 1422-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12523592&dopt=Abstract
•
Luminal glutamine perfusion alters endotoxin-related changes in ileal permeability of the piglet. Author(s): Dugan ME, McBurney MI. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1995 January-February; 19(1): 83-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7658607&dopt=Abstract
•
Mechanisms of glutamine transport in rat adipocytes and acute regulation by cell swelling.
Alternative Medicine 155
Author(s): Ritchie JW, Baird FE, Christie GR, Stewart A, Low SY, Hundal HS, Taylor PM. Source: Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 2001; 11(5): 259-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11684815&dopt=Abstract •
Metabolic and immune effects of dietary arginine, glutamine and omega-3 fatty acids supplementation in immunocompromised patients. Author(s): Chuntrasakul C, Siltharm S, Sarasombath S, Sittapairochana C, Leowattana W, Chockvivatanavanit S, Bunnak A. Source: J Med Assoc Thai. 1998 May; 81(5): 334-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9623033&dopt=Abstract
•
Metabolic regulation of the gene encoding glutamine-dependent asparagine synthetase in Arabidopsis thaliana. Author(s): Lam HM, Peng SS, Coruzzi GM. Source: Plant Physiology. 1994 December; 106(4): 1347-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7846154&dopt=Abstract
•
Metabolic response of muscle to alanine, glutamine, and valine supplementation during severe illness. Author(s): Gore DC, Wolfe RR. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2003 September-October; 27(5): 307-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12971729&dopt=Abstract
•
NAC, glutamine, and alpha lipoic acid. Interview by John S. James. Author(s): Lands L. Source: Aids Treat News. 1997 April 4; (No 268): 2-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11364196&dopt=Abstract
•
Neither glutamine nor arginine supplementation of diets increase glutamine body stores in healthy growing rats. Author(s): Boza JJ, Moennoz D, Jarret AR, Vuichoud J, Garcia-Rodenas C, Finot PA, Ballevre O. Source: Clinical Nutrition (Edinburgh, Lothian). 2000 October; 19(5): 319-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11031069&dopt=Abstract
•
Nitrogen metabolism in actinorhizal nodules of Alnus glutinosa: expression of glutamine synthetase and acetylornithine transaminase. Author(s): Guan C, Ribeiro A, Akkermans AD, Jing Y, van Kammen A, Bisseling T, Pawlowski K.
156
Glutamine
Source: Plant Molecular Biology. 1996 December; 32(6): 1177-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9002618&dopt=Abstract •
No differences in mucosal adaptive growth one week after intestinal resection in rats given enteral glutamine supplementation or deprived of glutamine. Author(s): Wiren ME, Permert J, Skullman SP, Wang F, Larsson J. Source: The European Journal of Surgery = Acta Chirurgica. 1996 June; 162(6): 489-98. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8817227&dopt=Abstract
•
No effect of bolus glutamine supplementation on the postresectional adaptation of small bowel mucosa in rats receiving chow ad libitum. Author(s): Yang H, Larsson J, Permert J, Braaf Y, Wiren M. Source: Digestive Surgery. 2000; 17(3): 256-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10867459&dopt=Abstract
•
Nutrients and HIV: part three - N-acetylcysteine, alpha-lipoic acid, L-glutamine, and L-carnitine. Author(s): Patrick L. Source: Alternative Medicine Review : a Journal of Clinical Therapeutic. 2000 August; 5(4): 290-305. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10956377&dopt=Abstract
•
Nutritional benefits of enteral alanyl-glutamine supplementation on rat small intestinal damage induced by cyclophosphamide. Author(s): Satoh J, Tsujikawa T, Fujiyama Y, Bamba T. Source: Journal of Gastroenterology and Hepatology. 2003 June; 18(6): 719-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12753156&dopt=Abstract
•
Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, doubleblind, placebo-controlled study. Author(s): Clark RH, Feleke G, Din M, Yasmin T, Singh G, Khan FA, Rathmacher JA. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2000 May-June; 24(3): 133-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10850936&dopt=Abstract
•
Oral glutamine (AES-14) supplementation inhibits PI-3k/Akt signaling in experimental breast cancer. Author(s): Todorova VK, Harms SA, Luo S, Kaufmann Y, Babb KB, Klimberg VS. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2003 November-December; 27(6): 404-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14621121&dopt=Abstract
Alternative Medicine 157
•
Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Author(s): Cockerham MB, Weinberger BB, Lerchie SB. Source: The Annals of Pharmacotherapy. 2000 March; 34(3): 300-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10917373&dopt=Abstract
•
Oral glutamine supplements in autologous hematopoietic transplant: impact on gastrointestinal toxicity and plasma protein levels. Author(s): Canovas G, Leon-Sanz M, Gomez P, Valero MA, Gomis P, La Huerta JJ. Source: Haematologica. 2000 November; 85(11): 1229-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11064482&dopt=Abstract
•
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. Author(s): Skubitz KM, Anderson PM. Source: The Journal of Laboratory and Clinical Medicine. 1996 February; 127(2): 223-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8636652&dopt=Abstract
•
Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Author(s): Niihara Y, Zerez CR, Akiyama DS, Tanaka KR. Source: American Journal of Hematology. 1998 June; 58(2): 117-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9625578&dopt=Abstract
•
Organization and expression of genes in the genomic region surrounding the glutamine synthetase gene Gln1 from Lotus japonicus. Author(s): Thykjaer T, Danielsen D, She Q, Stougaard J. Source: Molecular & General Genetics : Mgg. 1997 August; 255(6): 628-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9323367&dopt=Abstract
•
Outcome of critically ill patients after supplementation with glutamine. Author(s): Griffiths RD. Source: Nutrition (Burbank, Los Angeles County, Calif.). 1997 July-August; 13(7-8): 7524. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9263282&dopt=Abstract
•
Overexpression of the complementary DNA for human glutamine:fructose-6phosphate amidotransferase in mesangial cells enhances glucose-induced fibronectin synthesis and transcription factor cyclic adenosine monophosphate-responsive element binding phosphorylation. Author(s): Singh LP, Alexander M, Greene K, Crook ED.
158
Glutamine
Source: Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research. 2003 February; 51(1): 32-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12580319&dopt=Abstract •
Oxidative inactivation of glutamine synthetase from the cyanobacterium Anabaena variabilis. Author(s): Martin G, Haehnel W, Boger P. Source: Journal of Bacteriology. 1997 February; 179(3): 730-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9006027&dopt=Abstract
•
Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapyinduced toxicity. Author(s): van Zaanen HC, van der Lelie H, Timmer JG, Furst P, Sauerwein HP. Source: Cancer. 1994 November 15; 74(10): 2879-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7954251&dopt=Abstract
•
Peroxynitrite-mediated nitration of tyrosine residues in Escherichia coli glutamine synthetase mimics adenylylation: relevance to signal transduction. Author(s): Berlett BS, Friguet B, Yim MB, Chock PB, Stadtman ER. Source: Proceedings of the National Academy of Sciences of the United States of America. 1996 March 5; 93(5): 1776-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8700834&dopt=Abstract
•
Pilot study with a glutamine-supplemented enteral formula in critically ill infants. Author(s): Barbosa E, Moreira EA, Goes JE, Faintuch J. Source: Revista Do Hospital Das Clinicas. 1999 January-February; 54(1): 21-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10488597&dopt=Abstract
•
Plasma amino acid levels in children with sickle cell disease receiving an oral glutamine supplement. Author(s): Storm MC, Helms RA, Williams R, Olivi S, Li C, Wang WC. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 August; 22(S1): S73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14684022&dopt=Abstract
•
Plasma taurine concentrations increase after enteral glutamine supplementation in trauma patients and stressed rats. Author(s): Boelens PG, Houdijk AP, de Thouars HN, Teerlink T, van Engeland MI, Haarman HJ, van Leeuwen PA. Source: The American Journal of Clinical Nutrition. 2003 January; 77(1): 250-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12499349&dopt=Abstract
•
Prevention of chemotherapy and radiation toxicity with glutamine. Author(s): Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B.
Alternative Medicine 159
Source: Cancer Treatment Reviews. 2003 December; 29(6): 501-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14585260&dopt=Abstract •
Prevention of muscle function impairment by glutamine supplementation during systemic inflammation. Author(s): Maglara A, McArdle A, Griffiths RD, Jackson MJ. Source: Clinical Nutrition (Edinburgh, Lothian). 2003 August; 22(S1): S32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14683871&dopt=Abstract
•
Prolonged dietary treatment with conjugated linoleic acid stimulates porcine muscle peroxisome proliferator activated receptor gamma and glutamine-fructose aminotransferase gene expression in vivo. Author(s): Meadus WJ, MacInnis R, Dugan ME. Source: Journal of Molecular Endocrinology. 2002 April; 28(2): 79-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932205&dopt=Abstract
•
Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Author(s): Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S. Source: Gut. 1997 October; 41(4): 487-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9391247&dopt=Abstract
•
Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract. Author(s): Hazeki N, Nakamura K, Goto J, Kanazawa I. Source: Biochemical and Biophysical Research Communications. 1999 March 16; 256(2): 361-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10079189&dopt=Abstract
•
Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Author(s): Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Source: European Journal of Cancer (Oxford, England : 1990). 1999 February; 35(2): 2027. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10448260&dopt=Abstract
•
Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Author(s): Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C.
160
Glutamine
Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2001 May; 7(5): 1192-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11350883&dopt=Abstract •
Regulation of glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase. Author(s): Zhou J, Huynh QK, Hoffman RT, Crook ED, Daniels MC, Gulve EA, McClain DA. Source: Diabetes. 1998 December; 47(12): 1836-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9836513&dopt=Abstract
•
Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Author(s): May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Source: American Journal of Surgery. 2002 April; 183(4): 471-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11975938&dopt=Abstract
•
Role of L-glutamine in critical illness: new insights. Author(s): Kelly D, Wischmeyer PE. Source: Current Opinion in Clinical Nutrition and Metabolic Care. 2003 March; 6(2): 21722. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12589192&dopt=Abstract
•
Site-directed mutagenesis of Glu-297 from the alpha-polypeptide of Phaseolus vulgaris glutamine synthetase alters kinetic and structural properties and confers resistance to L-methionine sulfoximine. Author(s): Clemente MT, Marquez AJ. Source: Plant Molecular Biology. 1999 July; 40(5): 835-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10487218&dopt=Abstract
•
Some aspects of the acute phase response after a marathon race, and the effects of glutamine supplementation. Author(s): Castell LM, Poortmans JR, Leclercq R, Brasseur M, Duchateau J, Newsholme EA. Source: European Journal of Applied Physiology and Occupational Physiology. 1997; 75(1): 47-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9007457&dopt=Abstract
•
Special feature for the Olympics: effects of exercise on the immune system: modification of immune responses to exercise by carbohydrate, glutamine and antioxidant supplements. Author(s): Gleeson M, Bishop NC.
Alternative Medicine 161
Source: Immunology and Cell Biology. 2000 October; 78(5): 554-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11050539&dopt=Abstract •
Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Author(s): Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, Kozak T. Source: Bone Marrow Transplantation. 2002 December; 30(12): 953-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12476290&dopt=Abstract
•
The effect of enteral glutamine deprivation and supplementation on the structure of rat small-intestine mucosa during a systemic injury response. Author(s): Wusteman M, Tate H, Weaver L, Austin S, Neale G, Elia M. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 1995 January-February; 19(1): 22-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7658595&dopt=Abstract
•
The effect of glutamine supplementation in patients following elective surgery and accidental injury. Author(s): Wilmore DW. Source: The Journal of Nutrition. 2001 September; 131(9 Suppl): 2543S-9S; Discussion 2550S-1S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533310&dopt=Abstract
•
The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. Author(s): Zhou YP, Jiang ZM, Sun YH, Wang XR, Ma EL, Wilmore D. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2003 July-August; 27(4): 241-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12903886&dopt=Abstract
•
The effects of 8 weeks of creatine monohydrate and glutamine supplementation on body composition and performance measures. Author(s): Lehmkuhl M, Malone M, Justice B, Trone G, Pistilli E, Vinci D, Haff EE, Kilgore JL, Haff GG. Source: Journal of Strength and Conditioning Research / National Strength & Conditioning Association. 2003 August; 17(3): 425-38. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12930166&dopt=Abstract
•
The effects of glutamine-supplemented diet on the intestinal mucosa of the malnourished growing rat. Author(s): Tannuri U, Carrazza FR, Iriya K.
162
Glutamine
Source: Revista Do Hospital Das Clinicas. 2000 May-June; 55(3): 87-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10983011&dopt=Abstract •
The effects of high-dose glutamine ingestion on weightlifting performance. Author(s): Antonio J, Sanders MS, Kalman D, Woodgate D, Street C. Source: Journal of Strength and Conditioning Research / National Strength & Conditioning Association. 2002 February; 16(1): 157-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11834123&dopt=Abstract
•
The effects of oral glutamine supplementation on athletes after prolonged, exhaustive exercise. Author(s): Castell LM, Newsholme EA. Source: Nutrition (Burbank, Los Angeles County, Calif.). 1997 July-August; 13(7-8): 73842. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9263279&dopt=Abstract
•
The role of dietary supplementation with L-glutamine in inflammatory mediator release and intestinal injury in hypoxia/reoxygenation-induced experimental necrotizing enterocolitis. Author(s): Akisu M, Baka M, Huseyinov A, Kultursay N. Source: Annals of Nutrition & Metabolism. 2003; 47(6): 262-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14520021&dopt=Abstract
•
The spontaneous induction of glutamine synthetase in pig hepatocytes cocultured with RL-ET-14 cells is completely inhibited by trijodothyronine and okadaic acid. Author(s): Gebhardt R, Schuler M, Schorner D. Source: Biochemical and Biophysical Research Communications. 1998 May 29; 246(3): 895-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9618308&dopt=Abstract
•
Therapeutic considerations of L-glutamine: a review of the literature. Author(s): Miller AL. Source: Alternative Medicine Review : a Journal of Clinical Therapeutic. 1999 August; 4(4): 239-48. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10468648&dopt=Abstract
•
Total parenteral nutrition supplementation with glutamine improves survival after gut ischemia/reperfusion. Author(s): Ikeda S, Zarzaur BL, Johnson CD, Fukatsu K, Kudsk KA. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2002 May-June; 26(3): 169-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12005457&dopt=Abstract
Alternative Medicine 163
•
TPN decreases IL-4 and IL-10 mRNA expression in lipopolysaccharide stimulated intestinal lamina propria cells but glutamine supplementation preserves the expression. Author(s): Fukatsu K, Kudsk KA, Zarzaur BL, Wu Y, Hanna MK, DeWitt RC. Source: Shock (Augusta, Ga.). 2001 April; 15(4): 318-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11303733&dopt=Abstract
•
Where is the glutamine? Intradialytic supplementation may not solve all issues in amino acid balance. Author(s): Solomons NW, Stehle P, Furst P. Source: The American Journal of Clinical Nutrition. 2000 November; 72(5): 1236-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11063458&dopt=Abstract
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com®: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMD®Health: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to glutamine; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Abdominal Wall Inflammation Source: Integrative Medicine Communications; www.drkoop.com
164
Glutamine
AIDS and HIV Source: Integrative Medicine Communications; www.drkoop.com Alcohol Withdrawal Source: Healthnotes, Inc.; www.healthnotes.com Alcoholism Source: Integrative Medicine Communications; www.drkoop.com Arthritis Source: Integrative Medicine Communications; www.drkoop.com Athletic Performance Source: Healthnotes, Inc.; www.healthnotes.com Attention Deficit Disorder Source: Prima Communications, Inc.www.personalhealthzone.com Autoimmune Conditions Source: Integrative Medicine Communications; www.drkoop.com Bone Cancer Source: Integrative Medicine Communications; www.drkoop.com Burns Source: Integrative Medicine Communications; www.drkoop.com Colorectal Cancer Source: Integrative Medicine Communications; www.drkoop.com Connective Tissue Diseases Source: Integrative Medicine Communications; www.drkoop.com Crohn's Disease Source: Integrative Medicine Communications; www.drkoop.com Diarrhea Source: Integrative Medicine Communications; www.drkoop.com Digestive Disorders Source: Integrative Medicine Communications; www.drkoop.com Diverticular Disease Source: Integrative Medicine Communications; www.drkoop.com Fatigue Source: Integrative Medicine Communications; www.drkoop.com Food Cravings Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 165
Gastritis Source: Healthnotes, Inc.; www.healthnotes.com Growth and Development Source: Integrative Medicine Communications; www.drkoop.com HIV and AIDS Source: Integrative Medicine Communications; www.drkoop.com HIV and AIDS Support Source: Healthnotes, Inc.; www.healthnotes.com Immune Function Source: Healthnotes, Inc.; www.healthnotes.com Impotence Source: Integrative Medicine Communications; www.drkoop.com Infection Source: Healthnotes, Inc.; www.healthnotes.com Irritable Bowel Syndrome Source: Integrative Medicine Communications; www.drkoop.com Irritable Bowel Syndrome Alternative names: Spastic Colon Source: Prima Communications, Inc.www.personalhealthzone.com Muscle Wasting Source: Integrative Medicine Communications; www.drkoop.com Obesity Source: Integrative Medicine Communications; www.drkoop.com Pancreatitis Source: Integrative Medicine Communications; www.drkoop.com Peptic Ulcer Source: Healthnotes, Inc.; www.healthnotes.com Peptic Ulcer Source: Integrative Medicine Communications; www.drkoop.com Peritonitis Source: Integrative Medicine Communications; www.drkoop.com Proctitis Source: Integrative Medicine Communications; www.drkoop.com Psychological Conditions and Disorders Source: Integrative Medicine Communications; www.drkoop.com
166
Glutamine
Radiation Damage Source: Integrative Medicine Communications; www.drkoop.com Rectal Inflammation Source: Integrative Medicine Communications; www.drkoop.com Schizophrenia Source: Integrative Medicine Communications; www.drkoop.com Seizure Disorders Source: Integrative Medicine Communications; www.drkoop.com Sexual Dysfunction Source: Integrative Medicine Communications; www.drkoop.com Shock Source: Integrative Medicine Communications; www.drkoop.com Stress Source: Integrative Medicine Communications; www.drkoop.com Ulcers Source: Prima Communications, Inc.www.personalhealthzone.com Wounds Source: Integrative Medicine Communications; www.drkoop.com •
Herbs and Supplements Amino Acids Overview Source: Healthnotes, Inc.; www.healthnotes.com Arginine Source: Healthnotes, Inc.; www.healthnotes.com Carbamazepine Alternative names: Atretol, Carbatrol, Epitol, Tegretol, Tegretol XR Source: Prima Communications, Inc.www.personalhealthzone.com Chemotherapy Source: Healthnotes, Inc.; www.healthnotes.com Cyclophosphamide Source: Healthnotes, Inc.; www.healthnotes.com Docetaxel Source: Healthnotes, Inc.; www.healthnotes.com Fluorouracil Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 167
GABA (Gamma-Amino Butyric Acid) Source: Healthnotes, Inc.; www.healthnotes.com Glutamic Acid Source: Healthnotes, Inc.; www.healthnotes.com Glutamine Source: Healthnotes, Inc.; www.healthnotes.com Glutamine Source: Integrative Medicine Communications; www.drkoop.com Glutamine Source: Prima Communications, Inc.www.personalhealthzone.com Glutamine Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10030,00.html Glutathione Source: Healthnotes, Inc.; www.healthnotes.com Methotrexate Source: Healthnotes, Inc.; www.healthnotes.com Ornithine Alpha-Ketoglutarate Source: Healthnotes, Inc.; www.healthnotes.com Ornithine Alpha-Ketoglutarate Source: Prima Communications, Inc.www.personalhealthzone.com Paclitaxel Source: Healthnotes, Inc.; www.healthnotes.com Passiflora Alternative names: Passion Flower; Passiflora alata L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Phenobarbital Alternative names: Bellatal, Solfoton Source: Prima Communications, Inc.www.personalhealthzone.com Phenylalanine Source: Prima Communications, Inc.www.personalhealthzone.com Primidone Alternative names: Mysoline Source: Prima Communications, Inc.www.personalhealthzone.com Proteolytic Enzymes Source: Prima Communications, Inc.www.personalhealthzone.com
168
Glutamine
Tyrosine Source: Prima Communications, Inc.www.personalhealthzone.com Valproic Acid Source: Prima Communications, Inc.www.personalhealthzone.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
169
CHAPTER 4. DISSERTATIONS ON GLUTAMINE Overview In this chapter, we will give you a bibliography on recent dissertations relating to glutamine. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “glutamine” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on glutamine, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Glutamine ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to glutamine. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
Changes in the Amino Acid Content of Nerve Endings (Synaptosomes) Induced by Drugs That Alter the Metabolism of Gaba, Glutamate, Aspartate, and Glutamine by Geddes, James W; PhD from The University of Saskatchewan (Canada), 1984 http://wwwlib.umi.com/dissertations/fullcit/NK65349
•
Effects of Dietary Glutamine on Sow and Litter Performance and Nursery Pig Performance and Intestine Growth by Kitt, Steven James; PhD from The University of Nebraska - Lincoln, 2003, 138 pages http://wwwlib.umi.com/dissertations/fullcit/3092564
•
Effects of the Polyglutamine Neurodegenerative Protein Ataxin-3 on Transcriptional Regulation and the Ubiquitin-Proteasome Pathway by Li, Fusheng; PhD from University of Pennsylvania, 2003, 156 pages http://wwwlib.umi.com/dissertations/fullcit/3095910
•
Enzymes of Glutamine Metabolism in Rat: Subcellular Localization of Glutaminases in Liver and Kidney Cortex and Characterization of Gamma-glutamyl Transferring
170
Glutamine
Activities in Rat Kidney Cortex by Kalra, Jawahar; PhD from Memorial University of Newfoundland (Canada), 1976 http://wwwlib.umi.com/dissertations/fullcit/NK31417 •
Expression of Glutamine Synthetase in Early Life Stages of Rainbow Trout (Oncorhynchus mykiss) by Essex-Fraser, Phyllis Ann; MSC from University of Guelph (Canada), 2003, 99 pages http://wwwlib.umi.com/dissertations/fullcit/MQ76067
•
Glutamine and Asparagine Metabolism in Developing Endosperm of Corn by Misra, Santosh; PhD from McMaster University (Canada), 1983 http://wwwlib.umi.com/dissertations/fullcit/NK65450
•
Interaction between Neurons and Astrocytes in Glutamate and Glutamine Metabolism by Yu, Albert Cheung-Hoi; PhD from The University of Saskatchewan (Canada), 1984 http://wwwlib.umi.com/dissertations/fullcit/NK65328
•
L-glutamine Modulation of Macromolecular Metabolism and Gene Expression during Differentiation and Sporulation in a Water Mould Achlya Klebsiana by Braithwaite, Cleantis Esewanu; PhD from The University of Manitoba (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL37126
•
Nuclear Localization of Polyglutamine Expressed in an Ectopic Context Correlates with Onset of Abnormalities in the Mouse by Jackson, Walker Scot; PhD from The University of Alabama at Birmingham, 2003, 127 pages http://wwwlib.umi.com/dissertations/fullcit/3101518
•
On the Involvement of a Novel Proteolytic System in L-glutamine Control of Polyphosphate and Nucleic Acid Metabolism under Gyperthermic Conditions in Mammalian Cells Transformed by HA-RAS Oncogene, Sv40 Virus and 9,10-dimethyl1,2-benzanthracene by Deffie, Abdulai Mohamed; PhD from The University of Manitoba (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL37184
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
171
CHAPTER 5. CLINICAL TRIALS AND GLUTAMINE Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning glutamine.
Recent Trials on Glutamine The following is a list of recent trials dedicated to glutamine.8 Further information on a trial is available at the Web site indicated. •
L-glutamine Therapy for Sickle Cell Anemia Condition(s): Anemia, Sickle Cell; Thalassemia Study Status: This study is currently recruiting patients. Sponsor(s): FDA Office of Orphan Products Development Purpose - Excerpt: This is a study to determine the efficacy of L-glutamine as therapy for sickle cell anemia and sickle O-thalassemia. Phase(s): Phase II; Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00029887
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions.
8
These are listed at www.ClinicalTrials.gov.
172
Glutamine
The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “glutamine” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
173
CHAPTER 6. PATENTS ON GLUTAMINE Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.9 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “glutamine” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on glutamine, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Glutamine By performing a patent search focusing on glutamine, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 9Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
174
Glutamine
example of the type of information that you can expect to obtain from a patent search on glutamine: •
Antibiotic peptides from bovine milk Inventor(s): Adermann; Knut (Hannover, DE), Forssmann; Wolf-Georg (Hannover, DE), Magert; Hans-Jurgen (Hannover, DE), Raida; Manfred (Heidelberg, DE), Zucht; HansDieter (Hannover, DE) Assignee(s): Haemopep Pharma Gmbh (hannover, De) Patent Number: 6,579,849 Date filed: September 24, 1998 Abstract: A peptide having the amino acid sequenceH.sub.2 N--X.sub.1 --R--X.sub.3 -X.sub.2 --COOH (formula I)whereinX.sub.1 is either zero orX.sub.1 and/or X.sub.2 are a residue representing at least five amino acid residues (symbolized in the one letter amino acid code), preferably naturally occurring amino acids,with the proviso thatX.sub.1 and/or X.sub.2 contain at least one basic amino acid residue immediately followed by a hydrophobic amino acid residue andX.sub.1 and/or X.sub.2 contain at least one glutamine residue. Excerpt(s): The present invention is concerned with peptides having the amino acid according to claim 1, fragments of the peptides obtainable by proteolytic cleavage, a medicament comprising a peptide of the invention, a process for the manufacturing of peptides of the invention, a method of treating by ad-ministering a peptide of the invention as well as methods of using the peptides of the invention. Antimicrobial peptides are small peptide compounds which are capable to decrease the incidence of disease and could serve as modulators of a naturally occurring bacterial flora (Ganz T. et al., 1992, Med. Microbiol. Immunol. 181, 99-105; Eisenhauer P. B. et al., 1992, Infect. Immun. 60, 3556-3565; Oulette A. J. et al., 1992, FEBS Lett. 304, 146-148; Jones D. E. and Bevins C. L., 1993, FEBS Lett. 315, 187-192; Selstedt M. E. et al. (1992) J. Cell. Biol. 118, 929-936). The fact that milk could influence micro-organisms is also well established (Wharton B. A. et al, 1994, Acta Paediatr. Jpn. 36, 579-584). Present factors thought to be responsible are lactoferrin (Bullen J. J. et al., 1972, Brit. J. Med. 1, 69-72; Baggiolini M. et al, 1970, J. Exp. Med. 13, 559-570), lysozyme (Fleming A., 1922, Proc. Roy. Soc., London, 93, 306-317, Jolles J. and Jolles P., 1968, Bull. Soc. Chim. Biol., Paris, 50, 2543-2551), lactoperoxidase (Cals M. M. et al., 1991, Eur. J. Biochem. 198, 733-739, Bullen J. J. et al., 1972, Brit. J. Med. 1, 69-72). Milk is a rich source of peptides mainly derived from proteolytic cleavage of proteins. Beyond a nutritive value several biological effects were described like immunomodulation, antithrombotic activities, opioid action or inhibition or mineral carriage (Meisel H. et al., 1989, Z. Ernahrungswiss. 28, 267-278; Fiat A. M. and Jolles P., 1989, Mol. Cell. Biochem. 87, 5-30; Fiat A. M. et al., 1993, J. Dairy. Sci. 76, 301310). Web site: http://www.delphion.com/details?pn=US06579849__
Patents 175
•
Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes Inventor(s): Guerrant; Richard L. (Charlottesville, VA), Timko; Michael P. (Charlottesville, VA) Assignee(s): University of Virginia Patent Foundation (charlottesville, Va) Patent Number: 6,649,746 Date filed: May 2, 2000 Abstract: The invention provides a bioproduction of glutamine rich peptides. These peptides are used for rehydration and nutrition therapy in patients and for enhanced nutrition in animals. The peptides may be used as individual peptides or combined with other peptides in oligopeptides or proteins. Compositions of glutamine rich peptides and nucleic acid sequences for producing such peptides, as well as methods of production and use, are described. Excerpt(s): The present invention relates to stable glutamine derivatives and their use in rehydration and nutrition therapy and for enhanced nutrition in animals. More particularly the present invention is directed to the bioproduction of polypeptides comprising glutamine or glutamine rich regions and use of these polypeptides for rehydration and nutrition therapy and enhanced nutrition in animals. Glutamine is an amino acid which cotransports Na.sup.+ across the enterocyte brush border membrane. It is known to be the major bowel nutrient and energy source and has been used in intravenous solutions to improve nitrogen balance, inhibit protein breakdown, stimulate the growth of epithelial cells, and reduce intestinal villous atrophy. In addition, various researchers have shown that glutamine stimulates the absorption of sodium and chloride and have used glutamine in oral rehydration solutions to reduce cholera diarrhea. Viral enteritis is a leading cause of diarrhea in infants and toddlers less than two years old. Each year in the United States, about 22,000 infants are hospitalized for treatment of rotavirus-induced dehydration. In a majority of the cases, diarrheal disease morbidity and mortality is due to dehydration. The primary effect seen is the loss of fluid and electrolytes in diarrheal stools. An immediate effect in treatment of dehydration can be achieved by early oral administration of sugar (glucose) and electrolyte solution and continued feeding. However, conventional therapy by administration of oral rehydration formulations does not reduce stool volume or the duration of diarrhea. Thus, modifications of the oral rehydration therapy are needed to actually reduce stool volumes or speed the recovery of normal mucosal function, which in term will substantially enhance the acceptability and effectiveness of such therapy. The effects of organic compounds of salt and water absorption were first applied successfully to the treatment of patients with chloera and thereafter it was shown experimentally that the salt substrate cotransport was substantially intact in cholera patients and that oral therapy with sodium, chloride, potassium, biocarbonate and glucose in the same solution will restore and maintain normal blood volume and electrolyte concentrations, organic molecules such as D-hexoses, neutral amino acids, dipeptides and tripeptides of neutral amino acids, and water soluble vitamins can also enhance sodium absorption, following by water absorption in the small intestines. The present inventors have previously shown the efficacy of glutamine in intestinal sodium absorption. (Lima et al., Brazilian J. Med. Biol Res., 25; 637-640, (1992)). However, the greatest limitations to the oral use of glutamine is its instability and tendency to degrade in water and acid, conditions which are found in the stomach. Web site: http://www.delphion.com/details?pn=US06649746__
176
•
Glutamine
Biologically active phytogenous proteoglycan and a method of making thereof Inventor(s): Chekanovskaya; Ludmila (ul, Tallinskaya, D 5, Korp. 2, Kv. 47, Moscow 12345, RU) Assignee(s): None Reported Patent Number: 6,274,146 Date filed: April 17, 2000 Abstract: A biologically active phytogenous proteoglycan not having hemagglutinating activity via water solution obtained by disintegration of divisible plant cells from young potato plants, Solanum tuberosum of the Family Solanaceae, fractionated and concentrated to obtain a dry substance with a molecular mass of 8.0.times.10.sup.5 2.5.times.10.sup.6 D and the mass percentages of the following elements: nitrogen 1.122.48%, carbon 39.93-44.42%, hydrogen 5.15-7.21%; the remaining is an ash component, which includes a polysaccharide chain consisting of residues of neutral sugars in the amount of 34.0-85.3% and in the following mass percentages: glucose 26.4-33.1%, galacturonic acid 19.0-25.1%, arabinose 1.7-4.4%, uronic acids 12.0-18.0%, rhamnose 1.210.0%, xylose 0.1-3.0%, mannose 0.1-5.0%, galactose 2.5-27.0%; and up to 15 ng of pro that consists of amino acids residues in the following quantities based on ng per 0.1 mg of proteoglycan: asparagine 126.0-146.0 ng, serine 139.0-159.0 ng, glutamine 263.0-283.0 ng, glycine 117.0-131.0 ng, alanine 80.0-100.0 ng, valine 76.0-96.0 ng, leucine 85.0-105.0 ng, lysine 62.0-85.0 ng, arginine 42.0-62.0 ng; and trace amounts of cysteine, isoleucine, histidine, phenylalanine, tyrosine, and threonine. Excerpt(s): The invention refers to biologically active substances and, in particular, to phytogenous proteoglycans applied in medicine, pharmacology, veterinary medicine, and biology as a component of medicinal products. Bioactive polysaccharide.gamma.PL (gamma-plant) is also known, which is extracted from plant cells, for example from corn, potato, marine fungus, etc. With the molecular mass equal to 2.times.10.sup.6.+.9.times.10.sup.5 D and element composition (mass %) as follows: nitrogen 1.7-1.98; carbon 40.12-40.39; hydrogen 5.81-6.07; the remainder is the ash component which includes the polysaccharide chain consisting of (mass %) neutral carbohydrate residues (35.0-41.0), glucose (27.0-33.0), galacturonic acid (19.0-25.0), arabinose (1.7-2.3), uronic acids (12.0-18.0) and protein (no less than 0.5) that consists of amino acids residues in the following quantities (per 0.1 g of.crclbar.-pl): asparagin 126.0-146.0, serine 139.0-159.0, glutamine 263.0-283.0, glycine 117.0-131.0, alanine 80.0-100.0, valine 76.0-96.0, leucine 85.0-105.0, lysine 65.0-85.0, arginine 42.0-62.0; in trace quantities are: cystein, isoleucine, histidine, phenylalanine, tyrosine, threonine. As an anti-infective agent gPL was studied during treatment of viral and bacterial infections in laboratory and agricultural animals. With experimental infection of mice by viruses of simple herpes such as 1 and 2 types on the model of herpetic meningocephalitis at application of a dose 10LD.sub.50 gPL protective effect reached 60%. Comparatively narrow range of anti-infective activity as well as an occurrences of local inflammatory reactions while subcutaneous injections are gPL applications shortcomings. It is therefore an object of the present invention to eliminate the shortcomings mentioned above by creation of a new substance having a broad spectrum of anti-infectious activities and free from side effects. Web site: http://www.delphion.com/details?pn=US06274146__
Patents 177
•
Compositions of matter containing L-glutamine and pyridoxal-alpha-ketoglutarate Inventor(s): Jaffe; Russell (10430 Hunter View, Vienna, VA 22181) Assignee(s): None Reported Patent Number: 6,545,044 Date filed: May 30, 2001 Abstract: Compositions having synergistic effects which make it possible to obtain full beneficial effects of L-glutamine while avoiding the toxic effects that may accompany administration of L-glutamine. This benefit is attained by administration of L-glutamine in conjunction with pyridoxal-alpha-ketoglutarate (PAK). Compositions containing PAK:L-glutamine at a ratio (w/w) of from 1:1 to 1:10 are effective for providing beneficial effects of L-glutamine at nontoxic levels. Excerpt(s): This invention relates to use of beneficial synergistic administration of Lglutamine in conjunction with pyridoxal-alpha-ketoglutarate (PAK) to stimulate repair of tissues dependent on high turnover of cells. The use of L-glutamine, a basic amino acid, to provide an energy source for cells having a rapid turnover, such as cells of the mucosa of the intestine, has been known. Patients in need of significant stimulation of growth and repair of intestinal mucosa include those who have undergone surgical resection of the intestine and those suffering from chronic diseases as enteropathy (atrophy of the intestine) and persistent inflammatory bowel syndrome (IBS). Furthermore, certain infectious diseases and treatment modalities such as administration of antibodies can cause severe damage to the gastrointestinal mucosa. However, large amounts of L-glutamine are needed to achieve clinical results. Concerns have been raised about the high dosages. The build-up of L-glutamine (derived from energy-producing deamination of L-glutamine), which can act as an ex